2009
欧州リウマチ学会賞

2008
日本リウマチ学会賞
Japan

2003
日本骨代謝学会学術賞
Japan

1999
第20回日本炎症学会奨励賞
Japan

1994
日本骨代謝学会奨励賞
Japan

1989
第3回福岡県医師会長賞
Japan

1988
第6回産業医科大学学会会長賞
Japan

IgG4 関連疾患の治療
田中 良哉
アレルギーリウマチ性疾患, May 2026, Reviewed

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.
Hidenori Sakai; Koshiro Sonomoto; Shingo Nakayamada; Masanobu Ueno; Atsushi Nagayasu; Takafumi Aritomi; Hiroaki Tanaka; Satoshi Kubo; Ippei Miyagawa; Yasuyuki Todoroki; Yurie Satoh-Kanda; Yuya Fujita; Ryuichiro Kanda; Yoshiya Tanaka
RMD open, Feb. 2026

Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.
Koji Suzuki; Hideto Kameda; Kei Ikeda; Tomonori Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi; Yuko Kaneko
Rheumatology (Oxford, England), Feb. 2026

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.
Koshiro Sonomoto; Shingo Nakayamada; Hidenori Sakai; Masanobu Ueno; Hiroaki Tanaka; Atsushi Nagayasu; Takafumi Aritomi; Makoto Okawara; Akinori Nakata; Yoshiya Tanaka
RMD open, Jan. 2026

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.
Masanobu Ueno; Koshiro Sonomoto; Hiroaki Tanaka; Atsushi Nagayasu; Takafumi Aritomi; Ippei Miyagawa; Satoshi Kubo; Yusuke Miyazaki; Yasuyuki Todoroki; Yurie Satoh-Kanda; Yuya Fujita; Hidenori Sakai; Shingo Nakayamada; Yoshiya Tanaka
RMD open, Jan. 2026

Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.
Koji Suzuki; Hideto Kameda; Kei Ikeda; Tomonori Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi; Yuko Kaneko
Rheumatology (Oxford, England), Jan. 2026

A Multicentre, Prospective Registry of Patients with Systemic Sclerosis in Japan: Baseline Patient Characteristics.
Masataka Kuwana; Shinji Watanabe; Tohru Takeuchi; Yuko Kaneko; Yasushi Kawaguchi; Yoshiya Tanaka; Yukie Yamaguchi; Hiroaki Dobashi; Yusho Ishii; Hiroaki Niiro; Masanari Kodera; Hidekata Yasuoka; Tatsuya Atsumi; Hiroki Takahashi; Naoki Iwamoto; Yu Matsueda; Yohei Isomura; Yasuhiro Kondoh
Modern rheumatology, Nov. 2025

Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.
Koji Suzuki; Hideto Kameda; Kei Ikeda; Tomonori Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi; Yuko Kaneko
Rheumatology (Oxford, England), Nov. 2025

The Diagnostic Value of Contrast-Enhanced Vessel Wall MRI for Diagnosing Neuropsychiatric Systemic Lupus Erythematosus.
Satoru Ide; Yuya Fujita; Yu Murakami; Koichiro Futatsuya; Yuta Yoshimatsu; Jun Tsukamoto; Haruka Oku; Toshihiro Sakamoto; Yoshiya Tanaka; Takatoshi Aoki
Journal of magnetic resonance imaging : JMRI, Oct. 2025

機械学習を用いたスコアリングシステムによるDifficult to treat RA(D2T RA)進展予測 FIRST registry
上野 匡庸; 園本 格士朗; 田中 宏明; 永安 敦; 有冨 貴史; 宮川 一平; 久保 智史; 宮崎 佑介; 轟 泰幸; 神田 友梨恵; 藤田 悠哉; 酒井 秀典; 中山田 真吾; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチにおけるb/tsDMARDs導入前CTの潜在性結核感染症検出と結核発症予防への有効性 FIRST registry
船田 将史; 宮崎 佑介; 中山田 真吾; 久保 智史; 園本 格士朗; 宮川 一平; 神田 友梨恵; 田中 宏明; 轟 泰幸; 上野 匡庸; 永安 敦; 有冨 貴史; 藤田 悠哉; 酒井 秀典; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチに伴う間質性肺疾患における治療マネジメント FIRST registryより
神田 龍一郎; 宮崎 佑介; 中山田 真吾; 久保 智史; 園本 格士朗; 宮川 一平; 山口 絢子; 神田 友梨恵; 田中 宏明; 轟 泰幸; 上野 匡庸; 永安 敦; 藤田 悠哉; 有冨 貴史; 田中 良哉
九州リウマチ, Sep. 2025

関節リウマチにおける生物学的/分子標的合成抗リウマチ薬開始後長期の骨密度の変化 FIRSTレジストリより
有冨 貴史; 園本 格士朗; 中山田 真吾; 田中 宏明; 久保 智史; 宮川 一平; 山口 絢子; 大久保 直紀; 上野 匡庸; 田中 良哉
九州リウマチ, Sep. 2025

Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study.
Koichiro Ohmura; Hayato Shimizu; Yoshiya Tanaka; Keiju Hiromura; Hiroki Hayashi; Kazuro Kamada; Kentaro Minowa; Yutaka Kawahito; Akiho Iwashita; Shinya Kaname; Shinsuke Yasuda; Kazuoto Hiramoto; Shoichi Maruyama; Nobuyuki Yajima; Yasunori Iwata; Isao Matsumoto; Takahisa Gono; Hiroko Sato; Satoshi Kubo; Singo Nakayamada; Hidekazu Ikeuchi; Yukio Yuzawa; Michihito Kono; Naoto Tamura; Takahiro Seno; Takashi Kida; Aki Sakashita; Akira Onishi; Akio Morinobu; Takahisa Kawakami; Tadashi Hosoya; Taiki Yamaguchi; Yuko Kaneko; Hironari Hanaoka; Sawako Kato; Kayaho Maeda; Shiori Nakagawa; Yuya Kondo; Masataka Kuwana; Tomonori Ishii; Shuji Sumitomo; Chisato Miyakoshi; Tatsuya Atsumi
Rheumatology (Oxford, England), Sep. 2025

Clinical profile of IgG4-related disease in Japan based on the rare disease data registry.
Motohisa Yamamoto; Masatoshi Kanda; Ichiro Mizushima; Atsushi Kanno; Takeji Umemura; Tsukasa Ikeura; Yuzo Kodama; Hiroaki Dobashi; Yoshiya Tanaka; Atsushi Masamune; Masafumi Moriyama; Takako Saeki; Shoko Matsui; Tomoki Origuchi; Yasufumi Masaki; Masanori Asada; Hisanori Umehara; Hiroshi Seno; Itaru Naitoh; Satoshi Yamamoto; Eisuke Iwasaki; Kensuke Kubota; Shiroh Tanoue; Takayoshi Nishino; Hiroto Tsuboi; Yasushi Matsumoto; Hiroyuki Isayama; Hiroshi Goto; Kenji Notohara; Kazushige Uchida; Ken Kawabe; Kazunori Yamada; Satomi Kasashima; Masayuki Takahira; Yasuharu Sato; Izumi Kawachi; Izumi Yamaguchi; Kazuichi Okazaki; Seiji Nakamura; Fumihiko Matsuda; Hideki Ishikawa; Mitsuhiro Kawano
Immunological medicine, Sep. 2025

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.
Satoshi Kubo; Yusuke Miyazaki; Hiroaki Tanaka; Yuya Fujita; Hidenori Sakai; Masanobu Ueno; Yasuyuki Todoroki; Yurie Satoh-Kanda; Ippei Miyagawa; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology (Oxford, England), Sep. 2025

Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study.
Katsuhide Kusaka; Satoshi Kubo; Shingo Nakayamada; Ippei Miyagawa; Yusuke Miyazaki; Yurie Kanda; Yasuyuki Todoroki; Masanobu Ueno; Ryuichiro Kanda; Koshi Setoyama; Masaharu Kataoka; Yoshiya Tanaka
Arthritis research & therapy, Aug. 2025

Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism.
Kenichi Tanaka; Yosuke Okada; Kenji Koikawa; Fumi Uemura; Maiko Sumikawa; Keiichi Torimoto; Yoshiya Tanaka
Endocrine journal, Aug. 2025

日本人全身性エリテマトーデス(SLE)患者の末梢血単球における1型インターフェロン遺伝子シグネチャー(IFNGS)と血中1型IFN活性の乖離に関する前向き多施設共同研究
上月 友寛; 村上 孝作; 谷口 智憲; 隅川 舞子; 宇賀 均; 大村 浩一郎; 田中 良哉; 森信 暁雄; 茶本 健司
日本臨床免疫学会総会プログラム・抄録集, Aug. 2025

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Atsushi Nagayasu; Yusuke Miyazaki; Koshiro Sonomoto; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Hiroaki Tanaka; Yasuyuki Todoroki; Masanobu Ueno; Takafumi Aritomi; Yuya Fujita; Hidenori Sakai; Katsunori Suzuki; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Aug. 2025

Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial.
Yusuke Miyazaki; Nobuko Horiuchi; Shunsuke Okamoto; Rumiko Matsumoto; Tsutomu Takeuchi; Yoshiya Tanaka
RMD open, Jun. 2025

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry.
Hiroki Kobayashi; Yusuke Miyazaki; Shingo Nakayamada; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Yoshino Inoue; Yasuyuki Todoroki; Hiroko Miyata; Hiroaki Tanaka; Yoshihisa Fujino; Shintaro Hirata; Yoshiya Tanaka
Rheumatology (Oxford, England), May 2025

Anti-annexin A4 antibody as a biomarker for desquamative interstitial pneumonia.
Noriho Sakamoto; Minoru Satoh; Kaname Ohyama; Nozomi Aibara; Yasuhiko Yamano; Yasuhiro Kondoh; Shimpei Morimoto; Mari Yamasue; Kosaku Komiya; Yoshiaki Kinoshita; Hiroshi Ishii; Masaki Fujita; Shigehisa Yanagi; Toshimasa Shimizu; Kiyoyasu Fukushima; Yoshiko Akiyama; Ritsuko Murakami; Takatomo Tokito; Daisuke Okuno; Mutsumi Ozasa; Hirokazu Yura; Takashi Kido; Hiroshi Ishimoto; Hirokazu Taniguchi; Naoki Iwanaga; Shinnosuke Takemoto; Takahiro Takazono; Susumu Fukahori; Yasushi Obase; Yuji Ishimatsu; Tomoya Nishino; Shin Tanaka; Yoshiya Tanaka; Junya Fukuoka; Atsushi Kawakami; Hiroshi Mukae
Journal of autoimmunity, May 2025

Clinical Characteristics and Treatment Outcomes of Patients With Newly Diagnosed Takayasu Arteritis in Japan During the First 2 Years of Treatment - A Nationwide Retrospective Cohort Study.
Haruhito A Uchida; Yoshikazu Nakaoka; Takahiko Sugihara; Hajime Yoshifuji; Yasuhiro Maejima; Yoshiko Watanabe; Hiroko Nagafuchi; Takahiro Okazaki; Yoshinori Komagata; Yoshiya Tanaka; Eisuke Amiya; Tatsuya Atsumi; Kazuo Tanemoto; Tsutomu Takeuchi; Taio Naniwa; Atsushi Komatsuda; Hiroaki Dobashi; Koichi Amano; Noriyoshi Ogawa; Yohko Murakawa; Hitoshi Hasegawa; Taichi Hayashi; Yoshihiro Arimura; Mitsuaki Isobe; Masayoshi Harigai
Circulation journal : official journal of the Japanese Circulation Society, Apr. 2025

Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus.
Akina Ishii; Shingo Nakayamada; Naoaki Ohkubo; Yusuke Miyazaki; Shigeru Iwata; Junpei Annan; Naohiro Hashimoto; Kei Sakata; Yoshiya Tanaka
Clinical and experimental rheumatology, Apr. 2025

Critical roles of IL-6 signaling in myoblast differentiation of human adipose-derived mesenchymal stem cells.
Takashi Otsuka; Kaoru Yamagata; Mai-Phuong Nguyen; Uyen Thi Ngo; Hidenori Sakai; Gulzhan Trimova; Junpei Anan; Yosuke Okada; Shingo Nakayamada; Yoshiya Tanaka
Inflammation and regeneration, Apr. 2025

Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study.
Yoshiya Tanaka; Tatsuya Atsumi; Masato Okada; Tomoya Miyamura; Tomonori Ishii; Susumu Nishiyama; Ryutaro Matsumura; Yosuke Morishima; Yoshiyuki Yamaguchi; Gabriel Abreu; Catharina Lindholm; Eric F Morand; Tsutomu Takeuchi
Modern rheumatology, Apr. 2025

Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial.
Yoshiya Tanaka; Tatsuya Atsumi; Masato Okada; Tomoya Miyamura; Tomonori Ishii; Susumu Nishiyama; Ryutaro Matsumura; Nobuya Hayashi; Takahiro Matsumoto; Toshiki Yabe-Wada; Yoshiyuki Yamaguchi; Gabriel Abreu; Catharina Lindholm; Tsutomu Takeuchi
Modern rheumatology, Apr. 2025

The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis.
Masatoshi Kanda; Ken Nagahata; Masafumi Moriyama; Ken-Ichi Takano; Ryuta Kamekura; Hajime Yoshifuji; Hiroto Tsuboi; Motohisa Yamamoto; Hisanori Umehara; Masataka Umeda; Mizuki Sakamoto; Takashi Maehara; Yoshino Inoue; Satoshi Kubo; Tetsuo Himi; Tomoki Origuchi; Yasufumi Masaki; Tsuneyo Mimori; Hiroaki Dobashi; Yoshiya Tanaka; Seiji Nakamura; Hiroki Takahashi
Modern rheumatology, Apr. 2025

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Hidenori Sakai; Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kentaro Hanami; Shunsuke Fukuyo; Ayako Yamaguchi; Ippei Miyagawa; Masanobu Ueno; Hiroaki Tanaka; Yasuyuki Todoroki; Naoaki Ohkubo; Masashi Funada; Satsuki Matsunaga; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Ryuichiro Kanda; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yurie Satoh-Kanda; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Yuya Fujita; Takafumi Aritomi; Katsuhide Kusaka; Hidenori Sakai; Satsuki Matsunaga; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Apr. 2025

RA治療の進歩と課題 FIRSTレジストリ20年の歴史より
園本 格士朗; 永安 敦; 田中 宏明; 有冨 貴史; 上野 匡庸; 中山田 真吾; 田中 良哉
九州リウマチ, Mar. 2025

非典型的な画像所見を呈した再発性多発軟骨炎の1例
治 和樹; 中山田 真吾; 宮川 一平; 有冨 貴史; 久保 智史; 神田 友梨恵; 轟 泰幸; 上野 匡庸; 吉松 克真; 定直 日菜; 田中 文啓; 田中 良哉
九州リウマチ, Mar. 2025

妊娠・出産・移行医療 全身性エリテマトーデス母体から出生した児の精神発達評価(中間報告)
宮前 多佳子; 金子 詩子; 谷 諭美; 宮川 英子; 樋口 秋津; 岩田 恭宜; 奥 健志; 金子 佳代子; 佐田 憲映; 藤尾 圭志; 松下 雅和; 田中 良哉; 一瀬 邦弘; 村島 温子; 中島 亜矢子
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2025

若年全身性エリテマトーデス患者における睡眠健康状態と精神神経症状との関連性 PLEASURE-Jコホートを用いた検討
吉村 大; 藤枝 雄一郎; 久田 諒; 河野 通仁; 磯島 咲子; 一瀬 邦弘; 岩田 恭宜; 奥 健志; 金子 佳代子; 佐田 憲映; 田中 良哉; 藤尾 圭志; 松下 雅和; 宮前 多佳子; 村島 温子; 中島 亜矢子; 渥美 達也
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2025

我が国の若年全身性エリテマトーデス患者の現状と妊娠転帰を含む長期・短期予後に関する前向きコホート研究(PLEASURE-J研究)の現状と展望
宮川 英子; 金子 佳代子; 磯島 咲子; 一瀬 邦弘; 岩田 恭宜; 奥 健志; 佐田 憲映; 樋口 秋津; 藤尾 圭志; 松下 雅和; 宮前 多佳子; 村島 温子; 田中 良哉; 中島 亜矢子
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2025

成人発症スティル病とベーチェット病 全国ベーチェット病レジストリ登録患者の疾患活動性指標BDCAFと予後不良病型との関連解析
飯塚 友紀; 桐野 洋平; 平原 理紗; 副島 裕太郎; 菊地 弘敏; 土橋 浩章; 岳野 光洋; 桑名 正隆; 川上 純; 山岡 邦宏; 東野 俊洋; 田中 良哉; 宮川 一平; 永渕 裕子; 池田 高治; 渥美 達也; 藤枝 雄一郎; 小林 大介; 山本 託矢; 中島 秀明
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2025

全身性硬化症とその合併症に関する新たな知見 日本における全身性硬化症患者の多施設前向き観察レジストリ ベースライン特性
桑名 正隆; 渡邊 晋二; 磯村 洋平; 武内 徹; 金子 祐子; 川口 鎮司; 田中 良哉; 山口 由衣; 土橋 浩章; 石井 悠翔; 新納 宏昭; 小寺 雅也; 安岡 秀剛; 渥美 達也; 高橋 裕樹; 岩本 直樹; 松枝 佑; 近藤 康博; 田村 雄一
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2025

Association of Glycaemia Risk Index With Indices of Atherosclerosis: A Cross-Sectional Study.
Keiichi Torimoto; Yosuke Okada; Tomoya Mita; Kenichi Tanaka; Fumiya Sato; Naoto Katakami; Hidenori Yoshii; Keiko Nishida; Yoshiya Tanaka; Ryota Ishii; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada
Journal of diabetes, Mar. 2025

A case of newly onset rheumatoid arthritis successfully treated with methotrexate under the anti-retrovirus therapy against HIV infection.
Ippei Miyagawa; Shingo Nakayamada; Kazuyoshi Saito; Shoichi Shimizu; Kentaro Hanami; Masanobu Ueno; Yoshiya Tanaka
Modern rheumatology case reports, Feb. 2025

Performance of the modified 2022 ACR/EULAR giant cell arteritis classification criteria without age restriction for discriminating from Takayasu arteritis
Takahiko Sugihara; Masayoshi Harigai; Haruhito A. Uchida; Hajime Yoshifuji; Yasuhiro Maejima; Jun Ishizaki; Yoshiko Watanabe; Hiroaki Dobashi; Yoshinori Komagata; Naoto Tamura; Yoshikazu Nakaoka; Yoshiya Tanaka; Tsutomu Takeuchi; Taio Naniwa; Hiroko Nagafuchi; Takahiro Okazaki; Tetsuya Horita; Tatsuya Atsumi; Yoshihiro Arimura; Mitsuaki Isobe; Kazuo Tanemoto; Noriyoshi Ogawa; Yohko Murakawa; Shunsuke Furuta; Hitoshi Hasegawa; Yasuhiro Katsumata; Eisuke Amiya; Hiroshi Akazawa; Issei Komuro; Koichi Amano; Atsushi Kawakami; Shigeto Kobayashi; Takashi Wada; Eri Muso; Atsushi Komatsuda; Satoshi Ito; Noriyuki Homma; Taichi Hayashi; Shinichi Takeda; Takashi Wada
Arthritis Research & Therapy, Jan. 2025

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yurie Satoh-Kanda; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
RMD open, Jan. 2025

Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study.
Yoshiya Tanaka; Yusuke Miyazaki; Shintaro Hirata; Katsuhide Kusaka; Shunpei Kosaka; Keisuke Nakatsuka; Kazuyoshi Saito; Shigeru Iwata; Yoshiyuki Yamaguchi; Toshiki Yabe-Wada; Masakazu Fujiwara; Yoshifumi Arita; Mitsuru Hoshino; Naoko Ozaki; Kunihiro Yamaoka; Shingo Nakayamada
Lupus science & medicine, Jan. 2025

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.
Masanobu Ueno; Shigeru Iwata; Kaoru Yamagata; Yasuyuki Todoroki; Koshiro Sonomoto; Atsushi Nagayasu; Ippei Miyagawa; Satoshi Kubo; Yusuke Miyazaki; Hiroko Miyata; Ryuichiro Kanda; Takafumi Aritomi; Shingo Nakayamada; Yoshiya Tanaka
RMD open, Dec. 2024

Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review.
Ken-Ei Sada; Takako Miyamae; Kayoko Kaneko; Sakiko Isojima; Kunihiro Ichinose; Masakazu Matsushita; Kenji Oku; Yasunori Iwata; Keishi Fujio; Atsuko Murashima; Yoshiya Tanaka; Ayako Nakajima
Modern rheumatology, Dec. 2024

Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials.
Yoshiya Tanaka; Hisashi Yamanaka; Shigeyuki Toyoizumi; Tomohiro Hirose; Tsutomu Takeuchi
Modern rheumatology, Dec. 2024

Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Sae Ochi; Koshiro Sonomoto; Shingo Nakayamada; Yoshiya Tanaka
Arthritis Research and Therapy, Dec. 2024

Residual symptoms: Unmet needs for rheumatoid arthritis patients who achieved low clinical disease activity
Sae Ochi; Koshiro Sonomoto; Yoshiya Tanaka
Current Rheumatology Research, Nov. 2024

Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.
Naoaki Ohkubo; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Yoshino Inoue; Yurie Satoh-Kanda; Hiroaki Tanaka; Yasuyuki Todoroki; Hiroko Miyata; Atsushi Nagayasu; Masashi Funada; Hiroki Kobayashi; Hidenori Sakai; Shumpei Kosaka; Satsuki Matsunaga; Yukiko Tomoyose; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Oct. 2024

Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study.
Yoshiya Tanaka; Mitsumasa Kishimoto; Koshiro Sonomoto; Koichi Amano; Masayoshi Harigai; Alina Onofrei; Jacqueline O'Brien; Zachary Margolin; Christine Barr; Yasushi Mizuno; Ekta Agarwal; Naonobu Sugiyama; Hisashi Yamanaka
Rheumatology and therapy, Oct. 2024

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.
Yoshiya Tanaka; Atsushi Kumanogoh; Tatsuya Atsumi; Tomonori Ishii; Fumitoshi Tago; Mari Aoki; Shintaro Yamamuro; Shizuo Akira
RMD open, Sep. 2024, Reviewed

全身性エリテマトーデス(SLE)におけるT-bet陽性CD11c+B細胞の臨床的特徴に関する検討
轟 泰幸; 久保 智史; 永安 敦; 上野 匡庸; 神田 龍一郎; 有冨 貴史; 酒井 秀典; 田中 宏明; 園本 格士朗; 井上 嘉乃; 宮崎 佑介; 宮川 一平; 中山田 真吾; 田中 良哉
九州リウマチ, Sep. 2024

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Yusuke Miyazaki; Masashi Funada; Shingo Nakayamada; Koshiro Sonomoto; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yasuyuki Todoroki; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Sep. 2024

Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study.
Nami Okamoto; Tatsuya Atsumi; Michiaki Takagi; Nobunori Takahashi; Tsutomu Takeuchi; Naoto Tamura; Atsuo Nakajima; Ayako Nakajima; Takao Fujii; Hiroaki Matsuno; Taeko Ishii; Naoto Tsujimoto; Atsushi Nishikawa; Machiko Minatoya; Yoshiya Tanaka; Masataka Kuwana
Modern rheumatology, Aug. 2024

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study
Koshiro Sonomoto; Shingo Nakayamada; Yoshihisa Fujino; Hiroko Miyata; Satoshi Kubo; Yuya Fujita; Yoshino Inoue; Satsuki Matsunaga; Shigeru Iwata; Kentaro Hanami; Yasuyuki Todoroki; Hiroko Yoshinari-Korekoda; Akio Kawabe; Ayako Yamaguchi; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Masashi Funada; Naoaki Ohkubo; Katsuhide Kusaka; Shumpei Kosaka; Atsushi Nagayasu; Shunsuke Fukuyo; Masao Nawata; Yusuke Miyazaki; Mikiko Tokunaga; Kenichi Tanaka; Yosuke Okada; Yoshiya Tanaka
Rheumatology, Aug. 2024

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease.
Yasuhiko Nishioka; Jun Araya; Yoshiya Tanaka; Atsushi Kumanogoh
Inflammation and regeneration, Jul. 2024

The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.
Yoshiya Tanaka; Tatsuya Atsumi; Masato Okada; Tomoya Miyamura; Tomonori Ishii; Susumu Nishiyama; Ryutaro Matsumura; Atsushi Kawakami; Nobuya Hayashi; Gabriel Abreu; Sule Yavuz; Catharina Lindholm; Hussein Al-Mossawi; Tsutomu Takeuchi
Modern rheumatology, Jul. 2024

Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes.
Kenichi Tanaka; Yosuke Okada; Fumi Uemura; Yoshiya Tanaka
Scientific reports, Jun. 2024

A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry
Koshiro Sonomoto; Yoshihisa Fujino; Hiroaki Tanaka; Atsushi Nagayasu; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and Therapy, Jun. 2024

Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis.
Yoshiya Tanaka; Kei Ikeda; Yuko Kaneko; Naoki Ishiguro; Tsutomu Takeuchi
Expert review of clinical immunology, May 2024

Inflammatory Cytokines and Chemokines Are Synergistically Induced in a ROS-Dependent Manner by a Co-Culture of Corneal Epithelial Cells and Neutrophil-like Cells in the Presence of Particulate Matter
Zirui Zeng; Yasuhiro Yoshida; Duo Wang; Yuri Fujii; Mengyue Shen; Tatsuya Mimura; Yoshiya Tanaka
Antioxidants, Apr. 2024, Reviewed

Development of quality indicators for pregnancy and childbirth in patients with systemic lupus erythematosus.
Mika Hatano; Nobuyuki Yajima; Ryo Yanai; Sho Ishii; Yasushi Tsujimoto; Teruhisa Azuma; Tatsuya Atsumi; Yuko Kaneko; Hideto Kameda; Masataka Kuwana; Yoshiya Tanaka; Shiori Nakagawa; Ayako Nakajima; Yuri Hiramatsu; Daisuke Fujita; Takako Miyamae; Atsuko Murashima
Modern rheumatology, Apr. 2024

Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial.
Tetsuya Kawahara; Gen Suzuki; Shoichi Mizuno; Naoki Tominaga; Mikio Toda; Nagahiro Toyama; Tetsuya Inazu; Chie Kawahara; Yosuke Okada; Yoshiya Tanaka
The lancet. Healthy longevity, Apr. 2024

Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial.
Kenichi Tanaka; Yosuke Okada; Saeko Umezu; Ryoma Hashimoto; Yukiko Tomoyose; Rina Tateyama; Yuri Hori; Momo Saito; Akemi Tokutsu; Satomi Sonoda; Fumi Uemura; Akira Kurozumi; Yoshiya Tanaka
Journal of diabetes investigation, Apr. 2024

Two Cases of Painful Thyroiditis With Subsequent Hypothyroidism Following Cord Blood Transplant.
Rika Soga; Yosuke Okada; Kenichi Tanaka; Kenji Koikawa; Yoshiya Tanaka
Cureus, Apr. 2024

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
Yoshiya Tanaka; Satoshi Soen; Shintaro Hirata; Yosuke Okada; Saeko Fujiwara; Ikuko Tanaka; Yuriko Kitajima; Takuo Kubota; Kosuke Ebina; Yuichi Takashi; Reiko Inoue; Mika Yamauchi; Naoaki Okubo; Masanobu Ueno; Yasuhisa Ohata; Nobuaki Ito; Keiichi Ozono; Hisanori Nakayama; Masakazu Terauchi; Sakae Tanaka; Seiji Fukumoto
Journal of bone and mineral metabolism, Mar. 2024

Physician approval for pregnancy in patients with systemic lupus erythematosus showing only serological activity: A vignette survey study
Sakiko Isojima; Nobuyuki Yajima; Ryo Yanai; Yoko Miura; Shingo Fukuma; Kayoko Kaneko; Keishi Fujio; Kenji Oku; Masakazu Matsushita; Takako Miyamae; Takashi Wada; Yoshiya Tanaka; Yuko Kaneko; Ayako Nakajima; Atsuko Murashima
MODERN RHEUMATOLOGY, Mar. 2024

骨粗鬆症と骨代謝 関節リウマチ患者の骨密度は初回の生物学的/分子標的合成抗リウマチ薬(b/tsDMARDs)治療中に低下する FIRSTレジストリより
有冨 貴史; 園本 格士朗; 上野 匡庸; 大久保 直紀; 井上 嘉乃; 神田 友梨恵; 轟 泰幸; 久保 智史; 宮川 一平; 花見 健太郎; 中山田 真吾; 田中 良哉
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2024

就労全身性エリテマトーデス(SLE)患者の治療と仕事の両立を目指した効果的かつ安全な治療法の構築 B細胞「細胞内代謝」を標的とした治療法の可能性
轟 泰幸; 久保 智史; 園本 格士朗; 上野 匡庸; 大久保 直紀; 永安 敦; 神田 龍一郎; 有冨 貴史; 山形 薫; 中山田 真吾; 田中 良哉
産業医科大学雑誌, Mar. 2024

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.
Satoshi Kubo; Yusuke Miyazaki; Yasuyuki Todoroki; Atsushi Nagayasu; Ryuichiro Kanda; Takafumi Aritomi; Satsuki Matsunaga; Masanobu Ueno; Ippei Miyagawa; Koshiro Sonomoto; Kentaro Hanami; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Dec. 2023

A delayed diagnosis of fascioliasis: The importance of appropriate fecal diagnostic method.
Shumpei Kosaka; Shoichi Shimizu; Shingo Nakayamada; Aya Nawata; Nobuyuki Shimono; Mio Tanaka; Haruhiko Maruyama; Yoshio Osada; Yoshiya Tanaka
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Nov. 2023

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
Hiroaki Tanaka; Yukinori Okada; Shingo Nakayamada; Yusuke Miyazaki; Kyuto Sonehara; Shinichi Namba; Suguru Honda; Yuya Shirai; Kenichi Yamamoto; Satoshi Kubo; Katsunori Ikari; Masayoshi Harigai; Koshiro Sonomoto; Yoshiya Tanaka
Annals of the rheumatic diseases, Oct. 2023, Reviewed

Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug.
Hiroko Miyata; Koshiro Sonomoto; Shunsuke Fukuyo; Shingo Nakayamada; Kazuhisa Nakano; Shigeru Iwata; Yusuke Miyazaki; Akio Kawabe; Takatoshi Aoki; Yoshiya Tanaka
Rheumatology (Oxford, England), Oct. 2023

Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus.
Yuya Fujita; Shigeru Iwata; Shinsuke Hidese; Sayuri Ishiwata; Satoru Ide; Hiroaki Tanaka; Koshiro Sonomoto; Yusuke Miyazaki; Shingo Nakayamada; Atsuko Ikenouchi; Kotaro Hattori; Hiroshi Kunugi; Reiji Yoshimura; Yoshiya Tanaka
Rheumatology (Oxford, England), Oct. 2023

Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database.
Yuko Kaneko; Hideto Kameda; Kei Ikeda; Katsuhisa Yamashita; Ryoto Ozaki; Yoshiya Tanaka
International journal of rheumatic diseases, Oct. 2023

Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritis.
Katsuhide Kusaka; Shingo Nakayamada; Shigeru Iwata; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2023

Synovial Tissue Heterogeneity in Japanese Patients with Rheumatoid Arthritis Elucidated Using a Cell‐Type Deconvolution Approach
Sotaro Nakajima; Haruka Tsuchiya; Mineto Ota; Megumi Ogawa; Saeko Yamada; Ryochi Yoshida; Junko Maeda; Harumi Shirai; Taro Kasai; Jun Hirose; Keita Ninagawa; Yuichiro Fujieda; Takeshi Iwasaki; Yoshimi Aizaki; Hiroshi Kajiyama; Masakazu Matsushita; Eiryo Kawakami; Naoto Tamura; Toshihide Mimura; Koichiro Ohmura; Akio Morinobu; Tatsuya Atsumi; Yoshiya Tanaka; Tsutomu Takeuchi; Sakae Tanaka; Tomohisa Okamura; Keishi Fujio
Arthritis & Rheumatology, Jun. 2023

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study.
Satoshi Kubo; Yusuke Miyazaki; Koichi Amano; Kiyoshi Matsui; Hideto Kameda; Yoshino Inoue; Shingo Nakayamada; Takehisa Ogura; Yuko Kaneko; Kunihiro Yamaoka; Yoshiya Tanaka
RMD open, Apr. 2023

Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset.
Masao Nawata; Kazuki Someya; Shunpei Kosaka; Takafumi Aritomi; Masashi Funada; Yuya Fujita; Atsushi Nagayasu; Yoshihisa Fujino; Kazuyoshi Saito; Yoshiya Tanaka
Modern rheumatology, Mar. 2023

ループス腎炎・妊娠 妊娠出産に関する全身性エリテマトーデス患者の診療の質指標の開発
羽多野 美香; 矢嶋 宣幸; 柳井 亮; 石井 翔; 東 光久; 渥美 達也; 金子 祐子; 亀田 秀人; 桑名 正隆; 田中 良哉; 中川 詩織; 中島 亜矢子; 平松 ゆり; 宮前 多佳子; 村島 温子
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2023

ループス腎炎・妊娠 妊娠出産に関する全身性エリテマトーデス患者の診療の質指標の開発
羽多野 美香; 矢嶋 宣幸; 柳井 亮; 石井 翔; 東 光久; 渥美 達也; 金子 祐子; 亀田 秀人; 桑名 正隆; 田中 良哉; 中川 詩織; 中島 亜矢子; 平松 ゆり; 宮前 多佳子; 村島 温子
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2023

Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis.
Akemi Tokutsu; Yosuke Okada; Akira Kurozumi; Kenichi Tanaka; Satoshi Kubo; Yoshiya Tanaka
Journal of bone and mineral metabolism, Mar. 2023

The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
Yoshiya Tanaka; Tatsuya Atsumi; Masato Okada; Tomoya Miyamura; Tomonori Ishii; Susumu Nishiyama; Ryutaro Matsumura; Nobuya Hayashi; Gabriel Abreu; Raj Tummala; Eric F Morand; Tsutomu Takeuchi
Modern rheumatology, Jan. 2023

Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
Hiroto Tsuboi; Hirofumi Toko; Fumika Honda; Saori Abe; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Ayako Ohyama; Yuya Kondo; Kazuhisa Nakano; Yoshiya Tanaka; Toshimasa Shimizu; Hideki Nakamura; Atsushi Kawakami; Yuichiro Fujieda; Tatsuya Atsumi; Yasunori Suzuki; Mitsuhiro Kawano; Naoshi Nishina; Yuko Kaneko; Tsutomu Takeuchi; Hitomi Kobayashi; Masami Takei; Michihiro Ogasawara; Naoto Tamura; Yoshinari Takasaki; Kazuhiro Yokota; Yuji Akiyama; Toshihide Mimura; Kosaku Murakami; Tsuneyo Mimori; Shiro Ohshima; Naoto Azuma; Hajime Sano; Susumu Nishiyama; Isao Matsumoto; Takayuki Sumida
Modern Rheumatology, Jan. 2023, Reviewed

B cell activation via immunometabolism in systemic lupus erythematosus.
Shigeru Iwata; Maiko Hajime Sumikawa; Yoshiya Tanaka
Frontiers in immunology, 2023

Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.
Yasuyuki Todoroki; Satoshi Kubo; Kazuhisa Nakano; Yusuke Miyazaki; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Ippei Miyagawa; Kentaro Hanami; Keisuke Nakatsuka; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology (Oxford, England), Nov. 2022

IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4+ T cells in rheumatoid arthritis.
Kaoru Yamagata; Shingo Nakayamada; Tong Zhang; Anh Phuong Nguyen; Naoaki Ohkubo; Shigeru Iwata; Shigeaki Kato; Yoshiya Tanaka
Inflammation and regeneration, Nov. 2022

Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial.
Naoki Kimura; Takuya Kawahara; Yukari Uemura; Tatsuya Atsumi; Takayuki Sumida; Toshihde Mimura; Yasushi Kawaguchi; Hirofumi Amano; Yukiko Iwasaki; Yuko Kaneko; Toshihiro Matsui; Yoshinao Muro; Yoshitaka Imura; Takashi Kanda; Yoshiya Tanaka; Atsushi Kawakami; Masatoshi Jinnin; Tomonori Ishii; Keiju Hiromura; Yusuke Miwa; Hiroshi Nakajima; Masataka Kuwana; Yasuhiko Nishioka; Akio Morinobu; Hideto Kameda; Hitoshi Kohsaka
Rheumatology (Oxford, England), Nov. 2022

Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contribution Rate
Fumi Uemura; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Diabetes Technology and Therapeutics, Nov. 2022

Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis.
Naoaki Ohkubo; Shigeru Iwata; Kazuhisa Nakano; Ippei Miyagawa; Kentaro Hanami; Shunsuke Fukuyo; Yusuke Miyazaki; Akio Kawabe; Shingo Nakayamada; Yoshiya Tanaka
Modern rheumatology, Oct. 2022

Association between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis.
Takahiko Sugihara; Haruhito A Uchida; Hajime Yoshifuji; Yasuhiro Maejima; Taio Naniwa; Yasuhiro Katsumata; Takahiro Okazaki; Jun Ishizaki; Yohko Murakawa; Noriyoshi Ogawa; Hiroaki Dobashi; Tetsuya Horita; Yoshiya Tanaka; Shunsuke Furuta; Tsutomu Takeuchi; Yoshinori Komagata; Yoshikazu Nakaoka; Masayoshi Harigai
Modern rheumatology, Oct. 2022

SLE患者B細胞における初期解糖系亢進とIL-21シグナルを介した疾患増悪への関与
上野 匡庸; 岩田 慈; 山形 薫; 園本 格子朗; 轟 泰幸; 阿南 純平; 花見 健太郎; 宮崎 佑介; 宮田 寛子; 永安 敦; 神田 龍一郎; 有冨 貴史; 中山田 真吾; 田中 良哉
日本臨床免疫学会総会プログラム・抄録集, Oct. 2022

好酸球性多発血管炎性肉芽腫症に対する高用量コルチコステロイド併用メポリズマブ療法による寛解導入療法の安全性と有効性
上野 匡庸; 宮川 一平; 中山田 真吾; 岩田 慈; 花見 健太郎; 園本 格士朗; 宮崎 佑介; 河邊 明男; 大久保 直紀; 有冨 貴史; 木村 光一; 田中 良哉
九州リウマチ, Sep. 2022

血糖持続モニタリングを用いて月経前に増悪する反応性低血糖が改善した1例
齋藤 桃; 岡田 洋右; 鳥本 桂一; 田中 良哉
産業医科大学雑誌, Sep. 2022

T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease.
Yoshino Inoue; Shingo Nakayamada; Satoshi Kubo; Kaoru Yamagata; Koshiro Sonomoto; Shigeru Iwata; Yusuke Miyazaki; Yoshiya Tanaka
Rheumatology (Oxford, England), Aug. 2022

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus.
Yusuke Miyazaki; Shingo Nakayamada; Koshiro Sonomoto; Akio Kawabe; Yoshino Inoue; Naoaki Okubo; Shigeru Iwata; Kentaro Hanami; Yoshiya Tanaka
Rheumatology (Oxford, England), Aug. 2022

An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus.
Maiko Hajime Sumikawa; Shigeru Iwata; Mingzeng Zhang; Hiroko Miyata; Masanobu Ueno; Yasuyuki Todoroki; Atsushi Nagayasu; Ryuichiro Kanda; Koshiro Sonomoto; Keiichi Torimoto; Seunghyun Lee; Shingo Nakayamada; Kazuo Yamamoto; Yosuke Okada; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2022, Reviewed

mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors.
Mingzeng Zhang; Shigeru Iwata; Koshiro Sonomoto; Masanobu Ueno; Yuya Fujita; Junpei Anan; Yusuke Miyazaki; Naoaki Ohkubo; Maiko Hajime Sumikawa; Yasuyuki Todoroki; Hiroko Miyata; Atsushi Nagayasu; Ryuichiro Kanda; He Hao; Gulzhan Trimova; Seunghyun Lee; Shingo Nakayamada; Kei Sakata; Yoshiya Tanaka
Rheumatology (Oxford, England), Jul. 2022

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Masanobu Ueno; Ippei Miyagawa; Takafumi Aritomi; Koichi Kimura; Shigeru Iwata; Kentaro Hanami; Syunsuke Fukuyo; Satoshi Kubo; Yusuke Miyazaki; Shingo Nakayamada; Yoshiya Tanaka
Arthritis research & therapy, Jun. 2022

Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component
Yuya Shirai; Yoshimitsu Nakanishi; Akari Suzuki; Hachirou Konaka; Rika Nishikawa; Kyuto Sonehara; Shinichi Namba; Hiroaki Tanaka; Tatsuo Masuda; Moto Yaga; Shingo Satoh; Mayuko Izumi; Yumiko Mizuno; Tatsunori Jo; Yuichi Maeda; Takuro Nii; Eri Oguro-Igashira; Takayuki Morisaki; Yoichiro Kamatani; Shingo Nakayamada; Chikako Nishigori; Yoshiya Tanaka; Yoshito Takeda; Kazuhiko Yamamoto; Atsushi Kumanogoh; Yukinori Okada
Annals of the Rheumatic Diseases, Jun. 2022, Reviewed

Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia MT-4 cells to promote surrounding cell growth.
Mengyue Shen; Duo Wang; Yusuke Sennari; Zirui Zeng; Ryoko Baba; Hiroyuki Morimoto; Noriaki Kitamura; Tsukasa Nakanishi; Junichi Tsukada; Masanobu Ueno; Yasuyuki Todoroki; Shigeru Iwata; Tomo Yonezawa; Yoshiya Tanaka; Yoshio Osada; Yasuhiro Yoshida
Medical oncology (Northwood, London, England), Jun. 2022

Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy
Kimimasa Saito; Yosuke Okada; Keiichi Torimoto; Yoko Takamatsu; Yoshiya Tanaka
Sleep and Breathing, Jun. 2022

Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population.
Tetsuya Kawahara; Gen Suzuki; Shoichi Mizuno; Tetsuya Inazu; Fumiyoshi Kasagi; Chie Kawahara; Yosuke Okada; Yoshiya Tanaka
BMJ (Clinical research ed.), May 2022

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.
Ippei Miyagawa; Shingo Nakayamada; Masanobu Ueno; Yusuke Miyazaki; Shigeru Iwata; Satoshi Kubo; Koshiro Sonomoto; Junpei Anan; Naoaki Ohkubo; Yoshino Inoue; Yoshiya Tanaka
Arthritis research & therapy, Apr. 2022

Ambulatory Glucose Profileにおける血糖変動幅とCGM指標との関係 前向きコホート研究の探索的サブ解析
得津 明美; 岡田 洋右; 三田 智也; 鳥本 桂一; 若杉 理美; 片上 直人; 吉井 秀徳; 瓜生 康平; 西田 啓子; 新生 忠司; 田中 良哉; 五所 正彦; 下村 伊一郎; 綿田 裕孝
糖尿病, Apr. 2022

精神疾患マネジメントをめぐる身体科医や多職種との連携・協働 産業医科大学病院精神科リエゾンの現状 NPSLE、ステロイド精神病、せん妄を中心に
吉村 玲児; 池ノ内 篤子; 藤田 悠哉; 岩田 慈; 田中 良哉
精神神経学雑誌, Apr. 2022

Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.
Akira Kurozumi; Yosuke Okada; Tomoya Mita; Satomi Wakasugi; Naoto Katakami; Hidenori Yoshii; Kazuko Kanda; Keiko Nishida; Shinichiro Mine; Yoshiya Tanaka; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada
Diabetes research and clinical practice, Mar. 2022, Reviewed

関節リウマチ分子標的治療薬による骨代謝マーカー変化 FIRST registry 骨代謝の面からRAのQOL改善を考える
園本 格士朗; 中山田 真吾; 宮田 寛子; 船田 将史; 岩田 慈; 花見 健太郎; 藤田 悠哉; 日下 勝秀; 轟 泰幸; 有冨 貴史; 山口 絢子; 河邊 明男; 福與 俊介; 宮崎 佑介; 井上 嘉乃; 大久保 直紀; 田中 良哉
九州リウマチ, Mar. 2022

シェーグレン症候群 関節リウマチ合併二次性シェーグレン症候群に対するアバタセプトの有用性 オープンラベル多施設共同前向き観察研究(Rheumatoid Arthritis with Orencia trial toward Sjoegren's syndrome Endocrinopathy(ROSE)、ROSEII試験
本田 文香; 坪井 洋人; 東光 裕史; 安部 沙織; 高橋 広行; 田中 良哉; 中村 英樹; 川上 純; 渥美 達也; 川野 充弘; 金子 祐子; 竹内 勤; 武井 正美; 田村 直人; 高崎 芳成; 三村 俊英; 三森 経世; 大島 至郎; 佐野 統; 西山 進; 松本 功; 住田 孝之
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2022

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Sae Ochi; Koshiro Sonomoto; Shingo Nakayamada; Yoshiya Tanaka
Arthritis research & therapy, Mar. 2022

Risk Factor Analysis for Type 2 Diabetic Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study.
Fumi Uemura; Yosuke Okada; Tomoya Mita; Keiichi Torimoto; Satomi Wakasugi; Naoto Katakami; Hidenori Yoshii; Koji Matsushita; Keiko Nishida; Nobuo Inokuchi; Yoshiya Tanaka; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada
Diabetes technology & therapeutics, Feb. 2022, Reviewed

Rituximab in the Real-World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan.
Yoshiya Tanaka; Shingo Nakayamada; Kunihiro Yamaoka; Koichiro Ohmura; Shinsuke Yasuda
Modern rheumatology, Feb. 2022

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Yoshiya Tanaka; Ayako Yamaguchi; Toshiaki Miyamoto; Kazuhide Tanimura; Hideyuki Iwai; Yuko Kaneko; Tsutomu Takeuchi; Koichi Amano; Naoki Iwamoto; Atsushi Kawakami; Miho Murakami; Norihiro Nishimoto; Tatsuya Atsumi; Takayuki Sumida; Koichiro Ohmura; Tsuneyo Mimori; Hisashi Yamanaka; Keishi Fujio; Yoshihisa Fujino; Kazuyoshi Saito; Kazuhisa Nakano; Shintaro Hirata; Shingo Nakayamada
Rheumatology (Oxford, England), Feb. 2022, Reviewed

Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study.
Kenichi Tanaka; Yosuke Okada; Maiko Hajime; Yoshiya Tanaka
Journal of atherosclerosis and thrombosis, Feb. 2022

インスリン非使用2型糖尿病患者のTime in rangeと食後血糖との関連 CGMを用いた検討
上村 芙美; 岡田 洋右; 鳥本 桂一; 田中 良哉
日本内科学会雑誌, Feb. 2022

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Kenichi Tanaka; Yosuke Okada; Akemi Tokutsu; Yoshiya Tanaka
Scientific reports, Jan. 2022

Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus.
Shigeru Iwata; Yoshiya Tanaka
Frontiers in medicine, 2022

A Case of Reactive Hypoglycemia Exacerbated Before Menstruation Improved by the Use of Continuous Glucose Monitoring
Momo Saito; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Journal of UOEH, 2022

Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus.
He Hao; Shingo Nakayamada; Naoaki Ohkubo; Kaoru Yamagata; Mingzeng Zhang; Yu Shan; Shigeru Iwata; Tong Zhang; Yoshiya Tanaka
Arthritis research & therapy, Dec. 2021

持続血糖モニタリング(CGM)で評価したインスリン非使用2型糖尿病患者のTime in rangeと食後高血糖の関連
上村 芙美; 鳥本 桂一; 岡田 洋右; 田中 良哉
日本内分泌学会雑誌, Dec. 2021

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Ippei Miyagawa; Ayako Yamaguchi; Akio Kawabe; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis Research and Therapy, Dec. 2021

Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study
Akemi Tokutsu; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Diabetology and Metabolic Syndrome, Dec. 2021

Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
Fumi Uemura; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Scientific Reports, Dec. 2021

Clinical Features of Behçet's Disease Patients with Joint Symptoms in Japan: A National Multicenter Study.
Toshihiro Tono; Hirotoshi Kikuchi; Tetsuji Sawada; Mitsuhiro Takeno; Hiroko Nagafuchi; Yohei Kirino; Yoshiya Tanaka; Kunihiro Yamaoka; Shunsei Hirohata
Modern rheumatology, Nov. 2021, Reviewed

Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans).
Yuya Fujita; Shigeru Iwata; Kazuhisa Nakano; Hiroaki Adachi; Yoshiya Tanaka
Rheumatology (Oxford, England), Oct. 2021

Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; sub-analysis of prospective cohort study.
Akemi Tokutsu; Yosuke Okada; Tomoya Mita; Keiichi Torimoto; Satomi Wakasugi; Naoto Katakami; Hidenori Yoshii; Kohei Uryu; Keiko Nishida; Tadashi Arao; Yoshiya Tanaka; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada
Diabetes, obesity & metabolism, Sep. 2021, Reviewed

A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension.
Keisuke Imabayashi; Kazuhisa Nakano; Shigeru Iwata; Yoshiya Tanaka
Modern rheumatology case reports, Jul. 2021

Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
Yoshiya Tanaka; David Millson; Shigeru Iwata; Shingo Nakayamada
Rheumatology (Oxford, England), Jun. 2021

Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera.
Yoshinao Muro; Yasuhiko Yamano; Ken Yoshida; Yohsuke Oto; Kimiko Nakajima; Teruyuki Mitsuma; Shiori Kikuchi; Akihiro Matsumae; Mariko Ogawa-Momohara; Takuya Takeichi; Yasuhiro Kondoh; Masao Katayama; Yasuyuki Todoroki; Yoshiya Tanaka; Minoru Satoh; Masashi Akiyama
Journal of autoimmunity, Jun. 2021

Work Environment-related Stress Factors are Correlated with Diabetes Development in Workers with Impaired Glucose Tolerance: A 5-year Follow-up Study Using the Brief Job Stress Questionnaire (BJSQ)
SUGITO Motoko; OKADA Yosuke; TORIMOTO Keiichi; ENTA Kazuhiko; TANAKA Yoshiya
Journal of UOEH, Jun. 2021, Not reviewed

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Kunihiro Yamaoka; Yoshiya Tanaka; Hideto Kameda; Nasser Khan; Nobuhito Sasaki; Masayoshi Harigai; Yanna Song; Ying Zhang; Tsutomu Takeuchi
Drug safety, Jun. 2021

持続血糖モニタリング(CGM)で評価したインスリン非使用2型糖尿病患者のTime in rangeと食後高血糖の関連
上村 芙美; 鳥本 桂一; 岡田 洋右; 田中 良哉
糖尿病, May 2021

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Yoshino Inoue; Yoshihisa Fujino; Yoshiya Tanaka
Annals of the rheumatic diseases, Apr. 2021

Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
Kenichi Tanaka; Yosuke Okada; Hajime Maiko; Hiroko Mori; Yoshiya Tanaka
Journal of Diabetes Investigation, Apr. 2021

オキシトシン-hM3Dq-mCherryトランスジェニックラットにおける行動解析
園田 里美; 吉村 充弘; 丸山 崇; 岡田 洋右; 上田 陽一; 田中 良哉
日本内分泌学会雑誌, Apr. 2021

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
Masanobu Ueno; Ippei Miyagawa; Kazuhisa Nakano; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Yusuke Miyazaki; Akio Kawabe; Hiroko Yoshinari; Shingo Nakayamada; Yoshiya Tanaka
Arthritis research & therapy, Mar. 2021

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Yeong-Wook Song; Yi-Hsing Chen; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko
Rheumatology and therapy, Mar. 2021, Reviewed

トシリズマブに対するInfusion Reaction後に再投与により寛解導入・維持が可能であった成人スチル病の1症例
有冨 貴史; 名和田 雅夫; 船田 将史; 齋藤 和義; 田中 良哉
九州リウマチ, Mar. 2021

臨床的寛解到達後のRA患者の関節エコー及びMRIで検出されるSub clinical synovitisが患者の主観的症状に与える影響の検討
名和田 雅夫; 染谷 一貴; 有冨 貴史; 船田 将史; 中村 克己; 齋藤 和義; 田中 良哉
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2021

Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases
Yuichi Ishikawa; Kazuhisa Nakano; Kei Tokutsu; Hiroko Miyata; Yoshihisa Fujino; Shinya Matsuda; Yoshiya Tanaka
RMD Open, Mar. 2021

Similarity of response to biologics between elderly-onset rheumatoid arthritis (EORA) and non-EORA elderly patients: from the FIRST registry.
Sae Ochi; Fumitaka Mizoguchi; Kazuhisa Nakano; Yoshiya Tanaka
The Journal of rheumatology, Feb. 2021

Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry.
Sae Ochi; Fumitaka Mizoguchi; Kazuhisa Nakano; Yoshiya Tanaka
Clinical and experimental rheumatology, Feb. 2021

Time in rangeが良好なSU薬使用2型糖尿病患者の血糖変動評価 CGMを用いた検討
上村 芙美; 岡田 洋右; 鳥本 桂一; 田中 良哉
日本内科学会雑誌, Feb. 2021

Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus.
He Hao; Shingo Nakayamada; Kaoru Yamagata; Naoaki Ohkubo; Shigeru Iwata; Yoshino Inoue; Mingzeng Zhang; Tong Zhang; Yurie Kanda Satoh; Yu Shan; Takashi Otsuka; Yoshiya Tanaka
Arthritis & rheumatology (Hoboken, N.J.), Jan. 2021

血糖持続モニタリングを用いて月経前に増悪する反応性低血糖症が改善した1例
齋藤 桃; 岡田 洋右; 鳥本 桂一; 田中 良哉
日本内分泌学会雑誌, Jan. 2021

Clinical relevance of T follicular helper cells in systemic lupus erythematosus
Shingo Nakayamada; Yoshiya Tanaka
Expert Review of Clinical Immunology, 2021

Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus
Shigeru Iwata; Yoshiya Tanaka
Expert Review of Clinical Immunology, 2021

Glucose-lowering effects of 7-day treatment with sglt2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study
Akira Kurozumi; Yosuke Okada; Yoshiya Tanaka
Endocrine Journal, 2021

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability
Manabu Narisawa; Satoshi Kubo; Yosuke Okada; Kaoru Yamagata; Shingo Nakayamada; Kei Sakata; Kunihiro Yamaoka; Yoshiya Tanaka
Bone, Jan. 2021

Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Kazuhisa Nakano; Kazuyoshi Saito; Aya Nawata; Kentaro Hanami; Satoshi Kubo; Ippei Miyagawa; Yoshihisa Fujino; Shingo Nakayamada; Yoshiya Tanaka
Modern rheumatology, Jan. 2021

Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study
Kazuhisa Nakano; Yoshiya Tanaka; Kazuyoshi Saito; Yuko Kaneko; Shuntaro Saito; Masao Tanaka; Rintaro Saito; Takao Fujii; Nobuo Kuramoto; Naoki Sugimoto; Hideto Takada; Masayoshi Harigai; Sho Sasaki; Yasuo Suzuki
Modern Rheumatology, Dec. 2020

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Sae Ochi; Kazuyoshi Saito; Fumitaka Mizoguchi; Shigeaki Kato; Yoshiya Tanaka
Arthritis Research & Therapy, Dec. 2020

Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus.
Yukiko Goshima; Yosuke Okada; Keiichi Torimoto; Yoshihisa Fujino; Yoshiya Tanaka
Scientific reports, Sep. 2020

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study
Ayako Yamaguchi; Shintaro Hirata; Satoshi Kubo; Shunsuke Fukuyo; Kentaro Hanami; Kazuhisa Nakano; Shingo Nakayamada; Kazuyoshi Saito; Yoshiya Tanaka
Modern Rheumatology, Sep. 2020

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Yoshikazu Nakaoka; Mitsuaki Isobe; Yoshiya Tanaka; Tomonori Ishii; Seido Ooka; Hiroaki Niiro; Naoto Tamura; Shogo Banno; Hajime Yoshifuji; Yasushi Sakata; Atsushi Kawakami; Tatsuya Atsumi; Shunsuke Furuta; Hitoshi Kohsaka; Katsuya Suzuki; Ryoki Hara; Yasuhiro Maejima; Hiroshi Tsukamoto; Yoshinari Takasaki; Katsuhisa Yamashita; Norihiro Okada; Shinji Yamakido; Syuji Takei; Shumpei Yokota; Norihiro Nishimoto
Rheumatology (Oxford, England), Sep. 2020

Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; A pilot study
Akemi Tokutsu; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Diabetology and Metabolic Syndrome, Aug. 2020

2型糖尿病におけるHbA1c変動性と持続血糖モニタリングで評価した血糖日内変動との関係
得津 明美; 岡田 洋右; 鳥本 桂一; 田中 良哉
日本内分泌学会雑誌, Aug. 2020

2型糖尿病患者におけるメラトニン値と動脈硬化、糖尿病血管合併症との関連についての検討
田中 健一; 岡田 洋右; 元 舞子; 黒住 旭; 成澤 学; 鳥本 桂一; 田中 良哉
糖尿病, Aug. 2020

Ambulatory Glucose Profileにおける血糖変動幅とCGM指標との関係
得津 明美; 岡田 洋右; 鳥本 桂一; 黒住 旭; 成澤 学; 田中 良哉
糖尿病, Aug. 2020

内因性AVPニューロン活性化後のラットの活動・飲水・摂食行動および血糖値の評価
園田 里美; 吉村 充弘; 丸山 崇; 岡田 洋右; 田中 良哉; 上田 陽一
日本内分泌学会雑誌, Aug. 2020

A Case of Hyperparathyroidism Which Developed After Resection of a Fibroblast Growth Factor 23-producing Tumor.
Kenji Koikawa; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Internal medicine (Tokyo, Japan), Jul. 2020, Reviewed, No invitation

Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2.
Mingzeng Zhang; Shigeru Iwata; Maiko Hajime; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroko Miyata; Masanobu Ueno; He Hao; Tong Zhang; Jie Fan; Shingo Nakayamada; Kaoru Yamagata; Yoshiya Tanaka
Arthritis & rheumatology (Hoboken, N.J.), Jul. 2020

A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab.
Ryuichiro Kanda; Kazuhisa Nakano; Ippei Miyagawa; Shigeru Iwata; Shingo Nakayamada; Yoshiya Tanaka
Modern rheumatology case reports, Jul. 2020

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators.
Katsuhide Kusaka; Kazuhisa Nakano; Shigeru Iwata; Satoshi Kubo; Tomoya Nishida; Yoshiya Tanaka
Modern rheumatology case reports, Jul. 2020

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
Yoshiya Tanaka; Satoshi Soen; Naoki Ishiguro; Hisashi Yamanaka; Toshiyuki Yoneda; Sakae Tanaka; Takeshi Ohira; Takaya Nitta; Naoki Okubo; Harry Genant; Desirée van der Heijde; Tsutomu Takeuchi
RMD open, Jul. 2020

A case of autoimmune polyendocrine syndrome type 3 (APS-3) complicated with anti-N-methyl-D-aspartic acid-receptor (NMDA-R) encephalitis.
Akira Kurozumi; Yosuke Okada; Kosuke Nishio; Yoshiya Tanaka
Journal of diabetes investigation, Jun. 2020, Reviewed, No invitation

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Yeong-Wook Song; Yi-Hsing Chen; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Yoshihiro Nakashima; Teruaki Shiomi; Emi Yamada
Arthritis research & therapy, Jun. 2020, Reviewed

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Yuichi Ishikawa; Maiko Yoshikawa; Kei Sakata; Kei Sakata; Shigeru Iwata; Ippei Miyagawa; Kazuhisa Nakano; Yoshiya Tanaka
Arthritis Research and Therapy, Jun. 2020

Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD.
Takuji Nakamura; Tomomi Satoh-Nakamura; Akio Nakajima; Takafumi Kawanami; Tomoyuki Sakai; Yoshimasa Fujita; Haruka Iwao; Miyuki Miki; Yasufumi Masaki; Toshiro Okazaki; Yasuhito Ishigaki; Mitsuhiro Kawano; Kazunori Yamada; Shoko Matsui; Takako Saeki; Terumi Kamisawa; Motohisa Yamamoto; Hideaki Hamano; Tomoki Origuchi; Shintaro Hirata; Yoshiya Tanaka; Hiroto Tsuboi; Takayuki Sumida; Kazuichi Okazaki; Masao Tanaka; Tsutomu Chiba; Tsuneyo Mimori; Hisanori Umehara
Modern rheumatology, May 2020, Reviewed, No invitation

Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.
Masaru Kato; Yuko Kaneko; Yoshiya Tanaka; Masayuki Inoo; Hitomi Kobayashi-Haraoka; Koichi Amano; Masayuki Miyata; Yohko Murakawa; Hidekata Yasuoka; Shintaro Hirata; Hayato Nagasawa; Eiichi Tanaka; Nobuyuki Miyasaka; Hisashi Yamanaka; Kazuhiko Yamamoto; Isao Yokota; Tatsuya Atsumi; Tsutomu Takeuchi
Modern rheumatology, May 2020

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
Yoshiya Tanaka; Tsuneyo Mimori; Hisashi Yamanaka; Naomi Sunaga; Kazuo Morita; Junko Kimura; Tsutomu Takeuchi
Modern rheumatology, May 2020

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Hideto Kameda; Tsutomu Takeuchi; Kunihiro Yamaoka; Motohiro Oribe; Mitsuhiro Kawano; Yijie Zhou; Ahmed A Othman; Aileen L Pangan; Susumu Kitamura; Sebastian Meerwein; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2020

Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.
Takahiko Sugihara; Hitoshi Hasegawa; Haruhito A Uchida; Hajime Yoshifuji; Yoshiko Watanabe; Eisuke Amiya; Yasuhiro Maejima; Masanori Konishi; Yohko Murakawa; Noriyoshi Ogawa; Shunsuke Furuta; Yasuhiro Katsumata; Yoshinori Komagata; Taio Naniwa; Takahiro Okazaki; Yoshiya Tanaka; Tsutomu Takeuchi; Yoshikazu Nakaoka; Yoshihiro Arimura; Masayoshi Harigai; Mitsuaki Isobe
Arthritis Research & Therapy, Apr. 2020, Reviewed

The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Ippei Miyagawa; Kazuhisa Nakano; Shingo Nakayamada; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Akio Kawabe; Yusuke Miyazaki; Yoshino Inoue; Masanobu Ueno; Naoaki Ohkubo; Yuya Fujita; Yoshiya Tanaka
International journal of rheumatic diseases, Apr. 2020

FGMでSGLT-2阻害薬の短期的改善効果が確認出来た急性発症1型糖尿病の2症例
羽生 桃子; 岡田 洋右; 黒住 旭; 鳥本 桂一; 田中 良哉
糖尿病, Apr. 2020

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Yeong-Wook Song; Yi-Hsing Chen; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Yoshihiro Nakashima; Teruaki Shiomi; Emi Yamada
Arthritis research & therapy, Mar. 2020, Reviewed, No invitation

強直性脊椎炎に対してTNF-α阻害薬で加療中に発症した掌蹠膿疱症の2症例
有冨 貴史; 中野 和久; 吉成 紘子; 中山田 真吾; 岩田 慈; 福與 俊介; 宮川 一平; 河邊 明男; 宮崎 佑介; 上野 匡庸; 田中 良哉
九州リウマチ, Mar. 2020

First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.
Masatoshi Jinnin; Akiko Ohta; Shoichiro Ishihara; Hirofumi Amano; Tatsuya Atsumi; Manabu Fujimoto; Takashi Kanda; Yasushi Kawaguchi; Atsushi Kawakami; Akio Mimori; Tsuneyo Mimori; Toshihide Mimura; Yoshinao Muro; Hajime Sano; Jun Shimizu; Tsutomu Takeuchi; Yoshiya Tanaka; Kazuhiko Yamamoto; Takayuki Sumida; Hitoshi Kohsaka
Annals of the rheumatic diseases, Mar. 2020, Reviewed, No invitation

Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice.
Kuniaki Moridera; Soshi Uchida; Shinya Tanaka; Kunitaka Menuki; Hajime Utsunomiya; Kunihiro Yamaoka; Koshiro Sonomoto; Yoshiya Tanaka; Akinori Sakai
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, Mar. 2020

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
Yoshiya Tanaka; Tatsuya Atsumi; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Nobuyuki Miyasaka; Takao Koike
International journal of rheumatic diseases, Mar. 2020

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
Hideto Kameda; Kazuteru Wada; Yoshinori Takahashi; Owen Hagino; Hubert van Hoogstraten; Neil Graham; Yoshiya Tanaka
Modern rheumatology, Mar. 2020

Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages.
Gulzhan Trimova; Kaoru Yamagata; Shigeru Iwata; Shintaro Hirata; Tong Zhang; Fumi Uemura; Minoru Satoh; Norma Biln; Shingo Nakayamada; Walter P Maksymowych; Yoshiya Tanaka
Arthritis research & therapy, Feb. 2020

Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening.
Keiichi Torimoto; Yosuke Okada; Yoshiya Tanaka; Atsuko Matsuoka; Yushi Hirota; Wataru Ogawa; Yoshifumi Saisho; Isao Kurihara; Hiroshi Itoh; Shinya Inada; Masafumi Koga
Endocrine journal, Feb. 2020, Reviewed, No invitation

抗PD-1抗体投与により末梢血中濾胞性ヘルパーT細胞増加を伴う甲状腺機能低下に至った橋本病の1例
鳥本 桂一; 岡田 洋右; 久保 智史; 中山田 真吾; 田中 良哉
日本内分泌学会雑誌, Feb. 2020

バセドウ病の末梢血リンパ球フェノタイプ解析による薬剤抵抗性患者の選別に関する検討
黒住 旭; 岡田 洋右; 成澤 学; 鳥本 桂一; 宮崎 佑介; 久保 智史; 中山田 真吾; 田中 良哉
日本内科学会雑誌, Feb. 2020

Response to: 'Some concerns from Turkey' by Bilgin et al.
Yuko Kaneko; Hideto Kameda; Kei Ikeda; Tomonori Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi
Annals of the rheumatic diseases, Feb. 2020

Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
Tsutomu Takeuchi; Satoshi Soen; Naoki Ishiguro; Hisashi Yamanaka; Sakae Tanaka; Makiko Kobayashi; Naoki Okubo; Takaya Nitta; Yoshiya Tanaka
Modern rheumatology, Jan. 2020

Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
Yoshiya Tanaka; Tsutomu Takeuchi; Masato Okada; Tomonori Ishii; Hiroshi Nakajima; Shinichi Kawai; Takao Nagashima; Nobuya Hayashi; Liangwei Wang; Raj Tummala
Modern Rheumatology, Jan. 2020

Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-γ Overproduction in T Helper 1 Cells.
Shigeru Iwata; Mingzeng Zhang; He Hao; Gulzhan Trimova; Maiko Hajime; Yusuke Miyazaki; Naoaki Ohkubo; Yurie Satoh Kanda; Yasuyuki Todoroki; Hiroko Miyata; Masanobu Ueno; Atsushi Nagayasu; Shingo Nakayamada; Kei Sakata; Yoshiya Tanaka
Frontiers in immunology, 2020

Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes
Momoko Habu; Yosuke Okada; Akira Kurozumi; Yoshiya Tanaka
Journal of UOEH, 2020

Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus
Satomi Sonoda; Yosuke Okada; Keiichi Torimoto; Kei Sugai; Fumi Uemura; Kenichi Tanaka; Maiko Hajime; Hiroko Mori; Yoshiya Tanaka
Journal of UOEH, 2020

Five cases of IgG4-related disease with nasal mucosa and sinus Involvement
Masanobu Ueno; Kazuhisa Nakano; Ippei Miyagawa; Yoshiya Tanaka
Internal Medicine, 2020

A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations
Hashimoto Reia; Katsuki Asuka; Fujita Yuya; Ikenouchi Atsuko; Tanaka Yoshiya; Yoshimura Reiji
Clinical Neuropsychopharmacology and Therapeutics, 2020

Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report.
Akira Kurozumi; Yosuke Okada; Yusuke Miyazaki; Shingo Nakayamada; Yoshiya Tanaka
Journal of UOEH, 2020, Reviewed, No invitation

Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study
Yoshiya Tanaka; Hideto Kameda; Kazuyoshi Saito; Yuko Kaneko; Eiichi Tanaka; Shinsuke Yasuda; Naoto Tamura; Keishi Fujio; Takao Fujii; Toshihisa Kojima; Tatsuhiko Anzai; Chikuma Hamada; Yoshihisa Fujino; Shinya Matsuda; Hitoshi Kohsaka
MODERN RHEUMATOLOGY, Jan. 2020, Reviewed, No invitation

2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases
Yoshiya Tanaka; Masataka Kuwana; Takao Fujii; Hideto Kameda; Yoshinao Muro; Keishi Fujio; Yasuhiko Itoh; Hidekata Yasuoka; Shusaku Fukaya; Konomi Ashihara; Daisuke Hirano; Koichiro Ohmura; Yuya Tabuchi; Hisanori Hasegawa; Ryo Matsumiya; Yuichiro Shirai; Takehisa Ogura; Yumi Tsuchida; Mariko Ogawa-Momohara; Hidehiko Narazaki; Yoshino Inoue; Ippei Miyagawa; Kazuhisa Nakano; Shintaro Hirata; Masaaki Mori
Modern Rheumatology, 2020, Reviewed, No invitation

Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
Yoshiya Tanaka; Koji Oba; Tsutomu Takeuchi
Annals of the rheumatic diseases, Dec. 2019, Reviewed, No invitation

Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee.
Yuko Kaneko; Hideto Kameda; Kei Ikeda; Tomonori Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi
Annals of the rheumatic diseases, Dec. 2019

A Case of Type 2 Diabetes Developing Bilateral Iliopsoas Muscle Abscesses Caused by Streptococcus agalactiae
Otuka Takashi; Okada Yosuke; Torimoto Keiichi; Inada Yoshifumi; Suzuka Kanako; Uryu Kohei; Tanaka Yoshiya
Journal of the Japan Diabetes Society, Oct. 2019

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Manabu Iwasaki; Kou Katayama; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Teruaki Shiomi; Emi Yamada; Désirée van der Heijde
Annals of the rheumatic diseases, Oct. 2019, Reviewed, No invitation

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Yoshiya Tanaka; Tsutomu Takeuchi; Sakae Tanaka; Atsushi Kawakami; Manabu Iwasaki; Yeong Wook Song; Yi-Hsing Chen; James Cheng-Chung Wei; Sang-Heon Lee; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Rio Akazawa; Teruaki Shiomi; Emi Yamada
Annals of the rheumatic diseases, Oct. 2019, Reviewed, No invitation

Streptococcus agalactiaeによる両側腸腰筋膿瘍を呈した糖尿病の1例
大塚 隆史; 岡田 洋右; 鳥本 桂一; 稲田 良郁; 鈴鹿 佳南子; 瓜生 康平; 田中 良哉
糖尿病, Oct. 2019

Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Tsutomu Takeuchi; Hisashi Yamanaka; Kunihiro Yamaoka; Shoko Arai; Shigeyuki Toyoizumi; Ryan DeMasi; Yuri Fukuma; Tomohiro Hirose; Naonobu Sugiyama; Samuel H Zwillich; Yoshiya Tanaka
Modern rheumatology, Sep. 2019, Reviewed, No invitation

動脈硬化の予防戦略 血管内皮機能の観点から
鳥本 桂一; 岡田 洋右; 田中 良哉
糖尿病, Sep. 2019

Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study.
Ishimaru T; Fujino Y; Anzai T; Matsuda S; Tanaka Y
Modern rheumatology, Sep. 2019, Reviewed, No invitation

Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.
Mari Miyata; Shingo Kakeda; Kohsuke Kudo; Shigeru Iwata; Yoshiya Tanaka; Yi Wang; Yukunori Korogi
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Aug. 2019, Reviewed, No invitation

Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.
Tanaka K; Yamagata K; Kubo S; Nakayamada S; Sakata K; Matsui T; Yamagishi SI; Okada Y; Tanaka Y
Bone, Aug. 2019, Reviewed, No invitation

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Expert Review of Clinical Immunology, Jul. 2019

Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Akira Kurozumi; Yosuke Okada; Mototsugu Shimokawa; Yukiko Goshima; Takashi Otsuka; Manabu Narisawa; Keiichi Torimoto; Yoshiya Tanaka
Diabetes technology & therapeutics, Jul. 2019

IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.
Akira Kurozumi; Kazuhisa Nakano; Kaoru Yamagata; Yosuke Okada; Shingo Nakayamada; Yoshiya Tanaka
Bone, Jul. 2019, Reviewed, No invitation

The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method.
Nobuyuki Yajima; Yasushi Tsujimoto; Shingo Fukuma; Ken-Ei Sada; Sayaka Shimizu; Kakuya Niihata; Ryo Takahashi; Yoshihide Asano; Teruhisa Azuma; Hideto Kameda; Masataka Kuwana; Hitoshi Kohsaka; Mayumi Sugiura-Ogasawara; Katsuya Suzuki; Tsutomu Takeuchi; Yoshiya Tanaka; Naoto Tamura; Toshihiro Matsui; Tsuneyo Mimori; Shunichi Fukuhara; Tatsuya Atsumi
Modern rheumatology, Jun. 2019, Reviewed, No invitation

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease
Ippei Miyagawa; Kazuhisa Nakano; Shigeru Iwata; Shingo Nakayamada; Kazuyoshi Saito; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Akio Kawabe; Yusuke Miyazaki; Yoshiya Tanaka
Arthritis research & therapy, Jun. 2019

Addition of Canagliflozin to Insulin Improves Glycemic Control and Reduces Insulin Dose in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring
Keiichi Torimoto; Yosuke Okada; Yasunori Sato; Yoshiya Tanaka
DIABETES, Jun. 2019

Scleroderma in an ice-cream shop worker
Satoshi Kubo; Yoshiya Tanaka
Rheumatology (Oxford, England), Jun. 2019

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰
Yoshiya Tanaka; Satoshi Kubo; Ippei Miyagawa; Shigeru Iwata; Shingo Nakayamada
Seminars in Arthritis and Rheumatism, Jun. 2019

AB0412 FACTORS THAT AFFECT THE RESPONSE TO TOCILIZUMAB WITH REGARD TO WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 2-YEAR FOLLOW-UP OF THE FIRST ACT-SC STUDY
Yoshiya Tanaka; Hideto Kameda; Saito Kazuyoshi; Yuko Kaneko; Eiichi Tanaka; Shinsuke Yasuda; Naoto Tamura; Keishi Fujio; Takao Fujii; Toshihisa Kojima; Tatsuhiko Anzai; Yoshihisa Fujino; Shinya Matsuda; Hitoshi Kohsaka
Abstracts Accepted for Publication, Jun. 2019

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus.
Keiichi Torimoto; Yosuke Okada; Yoshiya Tanaka
Diabetes therapy : research, treatment and education of diabetes and related disorders, Jun. 2019, Reviewed, No invitation

Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia
Satomi Sonoda; Mitsuhiro Yoshimura; Hiromichi Ueno; Haruki Nishimura; Kazuaki Nishimura; Kentaro Tanaka; Yasuhito Motojima; Reiko Saito; Takashi Maruyama; Hirofumi Hashimoto; Yosuke Okada; Yoshiya Tanaka; Yoichi Ueta
Neuropeptides, Jun. 2019, Reviewed, No invitation

Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance.
Yuko Okabe; Takatoshi Aoki; Takashi Terasawa; Shunsuke Kinoshita; Shingo Nakayamada; Yoshiya Tanaka; Yukunori Korogi
Clinical Imaging, May 2019, Reviewed, No invitation

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
Annals of the rheumatic diseases, Apr. 2019, Reviewed, No invitation

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Yoshiya Tanaka; Kazuteru Wada; Yoshinori Takahashi; Owen Hagino; Hubert van Hoogstraten; Neil M H Graham; Hideto Kameda
Arthritis research & therapy, Apr. 2019

低血糖による血管内皮機能への直接的影響の検討
西尾 公佑; 岡田 洋右; 成澤 学; 得津 明美; 肥川 健司; 黒住 旭; 鳥本 桂一; 田中 良哉
糖尿病, Apr. 2019

ケモジェネティクスを用いたラットAVPニューロン活性後の活動・飲水・摂食行動の評価
園田 里美; 吉村 充弘; 丸山 崇; 岡田 洋右; 田中 良哉; 上田 陽一
日本内分泌学会雑誌, Apr. 2019

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Yoshiya Tanaka; Kazuteru Wada; Yoshinori Takahashi; Owen Hagino; Hubert van Hoogstraten; Neil M H Graham; Hideto Kameda
Arthritis research & therapy, Mar. 2019

Immunophenotype involved in IgG4-related disease
Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Modern Rheumatology, Mar. 2019

Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study
Tetsuya Hanaka; Takashi Kido; Hiroshi Ishimoto; Keishi Oda; Shingo Noguchi; Aya Nawata; Shingo Nakayamada; Noriho Sakamoto; Yoshiya Tanaka; Kazuhiro Yatera; Hiroshi Mukae
Respiratory Investigation, Mar. 2019, Reviewed, No invitation

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus
Ippei Miyagawa; Kazuhisa Nakano; Shingo Nakayamada; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
International Journal of Rheumatic Diseases, Mar. 2019

関節リウマチの治療(前向き臨床研究) インフリキシマブによるプログラムドコントロール治療で導入された関節リウマチの寛解維持に関するランダム化比較試験(RRRR Study)における結果報告
田中 良哉; 小池 隆夫; 宮坂 信之; 三森 経世; 竹内 勤; 平田 信太郎; 田中 榮一; 安岡 秀剛; 金子 祐子; 村上 孝作; 古賀 智裕; 中野 和久; 天野 宏一; 牛尾 一康; 渥美 達也; 猪尾 昌之; 八田 和大; 水木 伸一; 長岡 章平; 角田 慎一郎; 土橋 浩章
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
Hidemi Nakagawa; Yoshiya Tanaka; Shigetoshi Sano; Hideto Kameda; Atsuo Taniguchi; Tomoko Kashiwagi; Takeshi Kawaberi; Junko Kimura; Akimichi Morita
Advances in therapy, Mar. 2019

多彩な膠原病-4 トシリズマブの成人発症スティル病患者に対する無作為化プラセボ対照二重盲検試験
金子 祐子; 亀田 秀人; 池田 啓; 石井 智徳; 村上 孝作; 高松 漂太; 田中 良哉; 竹内 勤
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Reviewed, No invitation

シェーグレン症候群 関節リウマチ(RA)合併二次性シェーグレン症候群(SS)に対するアバタセプトの有用性
本田 文香; 坪井 洋人; 中野 和久; 田中 良哉; 中村 英樹; 川上 純; 藤枝 雄一郎; 渥美 達也; 鈴木 康倫; 川野 充弘; 金子 祐子; 竹内 勤; 原岡 ひとみ; 武井 正美; 田村 直人; 高崎 芳成; 横田 和浩; 三村 俊英; 村上 孝作; 三森 経世; 大島 至郎; 東 直人; 佐野 統; 西山 進; 松本 功; 住田 孝之
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2019, Reviewed, No invitation

Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Takeuchi T; Tanaka Y; Matsumura R; Saito K; Yoshimura M; Amano K; Atsumi T; Suematsu E; Hayashi N; Wang L; Tummala R
Modern rheumatology, Feb. 2019, Reviewed, No invitation

Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring
Maiko Hajime; Yosuke Okada; Hiroko Mori; Fumi Uemura; Satomi Sonoda; Kenichi Tanaka; Akira Kurozumi; Manabu Narisawa; Keiichi Torimoto; Yoshiya Tanaka
Diabetology and Metabolic Syndrome, Feb. 2019

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Modern rheumatology, Feb. 2019, Reviewed, No invitation

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.
Takafumi Aritomi; Takashi Kido; Kazuhisa Nakano; Yurie Satoh; Shingo Noguchi; Takanobu Jotatsu; Tetsuya Hanaka; Minoru Satoh; Yoshiya Tanaka; Kazuhiro Yatera
Internal medicine (Tokyo, Japan), Feb. 2019

Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.
Ippei Miyagawa; Shingo Nakayamada; Kazuhisa Nakano; Satoshi Kubo; Shigeru Iwata; Yusuke Miyazaki; Maiko Yoshikawa; Hiroko Yoshinari; Yoshiya Tanaka
Rheumatology (Oxford, England), Feb. 2019

ストレプトゾトシン投与ラットにおける高血糖の重症度やインスリン量と視床下部摂食促進・制御ペプチド遺伝子発現の関係
園田 里美; 眞田 賢哉; 別府 拓紀; 西村 和朗; 西村 春来; 田中 健太郎; 上野 啓通; 吉村 充弘; 丸山 崇; 岡田 洋右; 田中 良哉; 上田 陽一
日本生理学雑誌, Feb. 2019

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford, England), Jan. 2019, Reviewed, No invitation

Treatment with methotrexate and intravenous cyclophosphamide pulse therapy regulates the P-gp+CD4+ cell-related pathogenesis in a representative patient with refractory proliferative lupus nephritis
Shizuyo Tsujimura; Yoshiya Tanaka
Internal Medicine, 2019

An autopsy case with cerebral hemorrhaging due to disseminated aspergillosis during glucocorticoid therapy for overlap syndrome of systemic lupus erythematosus and systemic sclerosis
Masanobu Ueno; Kazuhisa Nakano; Hiroko Yoshinari; Shingo Nakayamada; Shigeru Iwata; Satoshi Kubo; Ippei Miyagawa; Yoshiya Tanaka
Internal Medicine, 2019

A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis.
Hiroko Mori; Yosuke Okada; Mayuko Kawaguchi; Shigeru Iwata; Maiko Yoshikawa; Satomi Sonoda; Kei Sugai; Kenichi Tanaka; Maiko Hajime; Manabu Narisawa; Yoshiya Tanaka
Internal medicine (Tokyo, Japan), 2019, Reviewed, No invitation

A Case of Marine-Lenhart Syndrome with Predominance of Plummer Disease.
Megumi Miyazaki; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Journal of UOEH, 2019, Reviewed, No invitation

AVP-hM3Dq-mCherryトランスジェニックラットにおけるAVPニューロン活性後の摂食・飲水・尿量と活動・深部体温サーカディアンリズムおよび耐糖能評価
園田 里美; 吉村 充弘; 丸山 崇; 岡田 洋右; 田中 良哉; 上田 陽一
日本内分泌学会雑誌, Dec. 2018

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Yuko Kaneko; Hideto Kameda; Kei Ikeda; Tomonoti Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi
Annals of the rheumatic diseases, Dec. 2018

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
Tomonori Ishii; Yoshiya Tanaka; Atsushi Kawakami; Kazuyoshi Saito; Kunihiro Ichinose; Hiroshi Fujii; Yuko Shirota; Tsuyoshi Shirai; Yoko Fujita; Ryu Watanabe; Shih-Wei Chiu; Takuhiro Yamaguchi; Hideo Harigae
Modern rheumatology, Nov. 2018, Reviewed, No invitation

Intracranial vessel wall lesions in patients with systematic lupus erythematosus.
Satoru Ide; Shingo Kakeda; Mari Miyata; Shigeru Iwata; Naoaki Ohkubo; Shingo Nakayamada; Koichiro Futatsuya; Keita Watanabe; Junji Moriya; Yoshihisa Fujino; Yoshiya Tanaka; Yukunori Korogi
Journal of magnetic resonance imaging : JMRI, Nov. 2018, Reviewed, No invitation

Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
Yuichi Ishikawa; Shigeru Iwata; Kentaro Hanami; Aya Nawata; Mingzeng Zhang; Kaoru Yamagata; Shintaro Hirata; Kei Sakata; Yasuyuki Todoroki; Kazuhisa Nakano; Shingo Nakayamada; Minoru Satoh; Yoshiya Tanaka
Arthritis research & therapy, Oct. 2018

Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance.
Takashi Otsuka; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Internal medicine (Tokyo, Japan), Oct. 2018, Reviewed, No invitation

Long-Term Safety and Efficacy of Weekly Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to Subcutaneous Tocilizumab Every Other Week: Results From the Open-Label Extension of the SHINOBI Study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R; SHINOBI Study Group
Modern rheumatology, Oct. 2018, Reviewed, No invitation

Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.
Masataka Torigoe; Kei Sakata; Akina Ishii; Shigeru Iwata; Shingo Nakayamada; Yoshiya Tanaka
Clinical immunology (Orlando, Fla.), Oct. 2018

Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.
Tanaka Y; Mimori T; Yamanaka H; Nakajima R; Morita K; Kimura J; Takeuchi T
Modern rheumatology, Sep. 2018, Reviewed, No invitation

消化管潰瘍を反復した骨髄異形成症候群関連結節性多発動脈炎の1例
有冨 貴史; 中野 和久; 宮川 一平; 玉城 泰太郎; 宮田 寛子; 岩田 慈; 福與 俊介; 中山田 真吾; 田中 良哉
九州リウマチ, Sep. 2018

Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka; Koji Oba; Takao Koike; Nobuyuki Miyasaka; Tsuneyo Mimori; Tsutomu Takeuchi; Shintaro Hirata; Eiichi Tanaka; Hidekata Yasuoka; Yuko Kaneko; Kosaku Murakami; Tomohiro Koga; Kazuhisa Nakano; Koichi Amano; Kazuyasu Ushio; Tatsuya Atsumi; Masayuki Inoo; Kazuhiro Hatta; Shinichi Mizuki; Shohei Nagaoka; Shinichiro Tsunoda; Hiroaki Dobashi; Nao Horie; Norihiro Sato
ARTHRITIS & RHEUMATOLOGY, Sep. 2018, Reviewed, No invitation

Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring
Keiichi Torimoto; Yosuke Okada; Maiko Hajime; Kenichi Tanaka; Yoshiya Tanaka
Diabetes Technology and Therapeutics, Sep. 2018

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: Results from a prospective randomised controlled study (the second year of the SURPRIS
Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
Annals of the Rheumatic Diseases, Sep. 2018, Reviewed, No invitation

Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Ukyo Y; Ishii Y; Yoshinari T; Baker D; GO-MONO study group
Modern rheumatology, Sep. 2018, Reviewed, No invitation

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.
Harigai M; Ishiguro N; Inokuma S; Mimori T; Ryu J; Takei S; Takeuchi T; Tanaka Y; Takasaki Y; Yamanaka H; Yoshizawa Y; Chinen I; Nakao T; Koike T
Modern rheumatology, Sep. 2018, Reviewed, No invitation

Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs
Satomi Sonoda; Mitsuhiro Yoshimura; Chikara Abe; Hironobu Morita; Hiromichi Ueno; Yasuhito Motojima; Reiko Saito; Takashi Maruyama; Hirofumi Hashimoto; Yoshiya Tanaka; Yoichi Ueta
Peptides, Jul. 2018, Reviewed, No invitation

Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
Arthritis research & therapy, Jul. 2018, Reviewed, No invitation

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
Modern rheumatology, Jul. 2018, Reviewed, No invitation

Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Shirakashi M; Yoshifuji H; Kodama Y; Chiba T; Yamamoto M; Takahashi H; Uchida K; Okazaki K; Ito T; Kawa S; Yamada K; Kawano M; Hirata S; Tanaka Y; Moriyama M; Nakamura S; Kamisawa T; Matsui S; Tsuboi H; Sumida T; Shibata M; Goto H
Scientific reports, Jul. 2018, Not reviewed, No invitation

TOCILIZUMAB DISCONTINUATION AFTER ATTAINING REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO WERE TREATED WITH TOCILIZUMAB ALONE OR IN COMBINATION WITH METHOTREXATE: RESULTS FROM A PROSPECTIVE, RANDOMISED, CONTROLLED STUDY (THE SECOND YEAR OF THE SURPR
Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
ANNALS OF THE RHEUMATIC DISEASES, Jun. 2018, Reviewed, No invitation

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab
Y. Satoh; K. Nakano; H. Yoshinari; S. Nakayamada; S. Iwata; S. Kubo; I. Miyagawa; M. Yoshikawa; Y. Miyazaki; K. Saito; Y. Tanaka
Lupus, Jun. 2018, Reviewed, No invitation

Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis
Aya Nawata; Satoshi Hisano; Shohei Shimajiri; Ke-Yong Wang; Yoshiya Tanaka; Toshiyuki Nakayama
Histopathology, Jun. 2018, Reviewed, No invitation

EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULT FROM THE LONG-TERM TREATMENT OF PHASE 3, DESIRABLE STUDY
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant H; van der Heijde D
ANNALS OF THE RHEUMATIC DISEASES, Jun. 2018, Reviewed, No invitation

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors
Xiaoxue Ma; Shingo Nakayamada; Satoshi Kubo; Kei Sakata; Kaoru Yamagata; Yusuke Miyazaki; Maiko Yoshikawa; Yukihiro Kitanaga; Mingzeng Zhang; Yoshiya Tanaka
Annals of the Rheumatic Diseases, May 2018, Reviewed, No invitation

Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: Serological evaluation of a one-year prospective study of 149 Japanese patients
Natasja S. Gudmann; Shintaro Hirata; Morten A. Karsdal; Satoshi Kubo; Anne-Christine Bay-Jensen; Yoshiya Tanaka
Clinical and Experimental Rheumatology, May 2018

インスリノーマの新しい診断指標 空腹時血糖とHbA1cの積の有用性
鳥本 桂一; 岡田 洋右; 田中 良哉; 松岡 敦子; 廣田 勇士; 小川 渉; 税所 芳史; 栗原 勲; 伊藤 裕; 稲田 慎也; 古賀 正史
糖尿病, Apr. 2018

Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome.
Tomoyuki Kakugawa; Noriho Sakamoto; Hiroshi Ishimoto; Toshimasa Shimizu; Hideki Nakamura; Aya Nawata; Chiyo Ito; Shuntaro Sato; Tetsuya Hanaka; Keishi Oda; Takashi Kido; Takuto Miyamura; Shota Nakashima; Takatoshi Aoki; Seiko Nakamichi; Yasushi Obase; Kazuyoshi Saito; Kazuhiro Yatera; Yuji Ishimatsu; Toshiyuki Nakayama; Yukunori Korogi; Atsushi Kawakami; Yoshiya Tanaka; Hiroshi Mukae
Respiratory medicine, Apr. 2018, Reviewed, No invitation

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.
Yuta Kochi; Yoichiro Kamatani; Yuya Kondo; Akari Suzuki; Eiryo Kawakami; Ryosuke Hiwa; Yukihide Momozawa; Manabu Fujimoto; Masatoshi Jinnin; Yoshiya Tanaka; Takashi Kanda; Robert G Cooper; Hector Chinoy; Simon Rothwell; Janine A Lamb; Jiří Vencovský; Heřman Mann; Koichiro Ohmura; Keiko Myouzen; Kazuyoshi Ishigaki; Ran Nakashima; Yuji Hosono; Hiroto Tsuboi; Hidenaga Kawasumi; Yukiko Iwasaki; Hiroshi Kajiyama; Tetsuya Horita; Mariko Ogawa-Momohara; Akito Takamura; Shinichiro Tsunoda; Jun Shimizu; Keishi Fujio; Hirofumi Amano; Akio Mimori; Atsushi Kawakami; Hisanori Umehara; Tsutomu Takeuchi; Hajime Sano; Yoshinao Muro; Tatsuya Atsumi; Toshihide Mimura; Yasushi Kawaguchi; Tsuneyo Mimori; Atsushi Takahashi; Michiaki Kubo; Hitoshi Kohsaka; Takayuki Sumida; Kazuhiko Yamamoto
Annals of the rheumatic diseases, Apr. 2018, Reviewed, No invitation

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Tanaka Y; Takeuchi T; Harigai M; Yamanaka H; Nakano T; Akagi K; Ukyo Y; Hsu B
Modern rheumatology, Apr. 2018, Reviewed, No invitation

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients
Tsutomu Takeuchi; Hisashi Yamanaka; Masayoshi Harigai; Ryo Tamamura; Yuichi Kato; Yoshifumi Ukyo; Toshikazu Nakano; Benjamin Hsu; Yoshiya Tanaka
Arthritis Research and Therapy, Mar. 2018, Reviewed, No invitation

Relevance of P-glycoprotein on CXCR4+ B cells to organ manifestation in highly active rheumatoid arthritis
Shizuyo Tsujimura; Tomoko Adachi; Kazuyoshi Saito; Akio Kawabe; Yoshiya Tanaka
Modern Rheumatology, Mar. 2018, Reviewed, No invitation

SLE・抗リン脂質抗体症候群1 全身性エリテマトーデス患者の診療の質指標の開発
矢嶋 宣幸; 佐田 憲映; 高橋 良; 浅野 善英; 東 光久; 亀田 秀人; 桑名 正隆; 上阪 等; 鈴木 勝也; 竹内 勤; 田中 良哉; 田村 直人; 松井 利浩; 三森 経世; 渥美 達也
日本リウマチ学会総会・学術集会プログラム・抄録集, Mar. 2018

ループス腎炎合併SLEに対するミコフェノール酸モフェチルの安全性と適正用量の検討
岩田 慈; 中野 和久; 玉城 泰太郎; 佐藤 友梨恵; 中山田 真吾; 福與 俊介; 宮川 一平; 山内 雄介; 有冨 貴史; 神田 龍一郎; 藤田 悠哉; 船田 将史; 田中 良哉
九州リウマチ, Mar. 2018

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Yoshikazu Nakaoka; Mitsuaki Isobe; Syuji Takei; Yoshiya Tanaka; Tomonori Ishii; Shumpei Yokota; Akira Nomura; Seitaro Yoshida; Norihiro Nishimoto
Annals of the rheumatic diseases, Mar. 2018, Reviewed, No invitation

Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with igG4-related disease
Satoshi Kubo; Shingo Nakayamada; Jidong Zhao; Maiko Yoshikawa; Yusuke Miyazaki; Aya Nawata; Shintaro Hirata; Kazuhisa Nakano; Kazuyoshi Saito; Yoshiya Tanaka
Rheumatology (United Kingdom), Mar. 2018, Reviewed, No invitation

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Takuya Kobayashi; Daisaku Masuda; Shizuya Yamashita; Yoshiya Tanaka
Journal of Diabetes Investigation, Mar. 2018, Reviewed, No invitation

難治性高安動脈炎患者を対象とした長期延長試験で確認されたtocilizumabによるステロイド減量効果 第III相試験の結果(TAKT試験)(Long-Term Extension Confirmed Steroid-Sparing Effect of Tocilizumab in Patient with Refractory Takayasu Arteritis: Result of Phase 3 Trial(TAKT Study))
中岡 良和; 磯部 光章; 武井 修治; 田中 良哉; 石井 智徳; 横田 俊平; 野村 旭; 吉田 征太郎; 西本 憲弘
日本循環器学会学術集会抄録集, Mar. 2018, Reviewed, No invitation

Relation between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring
Fumi Uemura; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Diabetes Technology and Therapeutics, Feb. 2018, Reviewed, No invitation

Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
Takeuchi T; Tanaka Y; Yamanaka H; Harigai M; Nakano T; Akagi K; Ukyo Y; Hsu B
Modern rheumatology, Feb. 2018, Reviewed, No invitation

Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study
Yoshiya Tanaka; Kiyotaka Yamazaki; Ryo Nakajima; Shuichi Komatsu; Ataru Igarashi; Toshiro Tango; Tsutomu Takeuchi
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis
Yoshiya Tanaka; Tsutomu Takeuchi; Hisanori Umehara; Toshihiro Nanki; Nobuyuki Yasuda; Fumitoshi Tago; Makoto Kawakubo; Yasumi Kitahara; Seiichiro Hojo; Tetsu Kawano; Toshio Imai
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

Erratum to: A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period (Modern Rheumatology, (2018), 28, 1, (76-84), 10.1080/14397595.2017.1332507)
Atsushi Ogata; Yoshiya Tanaka; Tomonori Ishii; Motohide Kaneko; Hiroko Miwa; Shino Ohsawa; SHINOBI study group
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
Yoshiya Tanaka; Taeko Ishii; Zhihong Cai; Douglas Schlichting; Terence Rooney; William Macias
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

Design characteristics of the Corrona Japan rheumatoid arthritis registry
Hisashi Yamanaka; Mitsumasa Kishimoto; Dimitrios A Pappas; Jeffrey D Greenberg; Joel M Kremer; Yoshiya Tanaka
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
Tanaka S; Tanaka Y; Ishiguro N; Yamanaka H; Takeuchi T
Modern Rheumatology, Jan. 2018, Reviewed, No invitation

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis.
Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kazuhisa Nakano; Shigeru Iwata; Ippei Miyagawa; Xiaoxue Ma; Gulzhan Trimova; Kei Sakata; Yoshiya Tanaka
Frontiers in immunology, 2018

A case of prolonged undetected hypoglycemia even after weight gain in a patient with anorexia nervosa
Tadashi Arao; Yosuke Okada; Keiichi Torimoto; Takashi Otsuka; Yoshiya Tanaka
Journal of the Japan Diabetes Society, 2018

Survey on insulin needles inappropriately discarded in shinkansen trains: Measures to prevent needlestick accidents by train cleaning staff
Motoko Sugito; Yosuke Okada; Keiichi Torimoto; Kazuhiko Enta; Yoshiya Tanaka
Journal of the Japan Diabetes Society, 2018

IgG4-related pleuritis with elevated adenosine deaminase in pleural effusion
Atsushi Nagayasu; Satoshi Kubo; Kazuhisa Nakano; Shingo Nakayamada; Shigeru Iwata; Ippei Miyagawa; Shunsuke Fukuyo; Kazuyoshi Saito; Yoshiya Tanaka
Internal Medicine, 2018

[Secondary osteoporosis. Bone metabolic disorder in Rheumatoid arthritis.]
Nakano K; Okada Y; Tanaka Y
Clinical calcium, 2018, Reviewed, No invitation

Successful management of pregnancy in a patient with systemic lupus erythematosus-associated pulmonary arterial hypertension
Akio Kawabe; Kazuhisa Nakano; Yukiyo Aiko; Satoshi Aramaki; Takeshi Onoue; Dan Okura; Yoshiya Tanaka
Internal Medicine, 2018, Reviewed, No invitation

Association between diabetic microangiopathies and glycemic variability assessed by continuous glucose monitoring
Satomi Sonoda; Yosuke Okada; Hiroko Mori; Fumi Uemura; Kei Sugai; Maiko Hajime; Kenichi Tanaka; Akira Kurozumi; Manabu Narisawa; Keiichi Torimoto; Yoshiya Tanaka
Journal of UOEH, 2018, Reviewed, No invitation

Comparison of the effects of teneligliptin and sitagliptin, two dipeptidyl peptidase 4 inhibitors with different half-lives, on glucose fluctuation and glucagon-like peptide-1 in type 2 diabetes mellitus
Akira Kurozumi; Yosuke Okada; Kei Sugai; Keiichi Torimoto; Yoshiya Tanaka
Journal of UOEH, 2018, Reviewed, No invitation

Type 2 diabetes and vascular endothelial dysfunction
Keiichi Torimoto; Yosuke Okada; Yoshiya Tanaka
Journal of UOEH, 2018, Reviewed, No invitation

Hyperparathyroidism-jaw tumor syndrome confirmed by preoperative genetic testing
Kenji Koikawa; Yosuke Okada; Hiroko Mori; Mayuko Kawaguchi; Shinya Uchino; Yoshiya Tanaka
Internal Medicine, 2018, Reviewed, No invitation

The effects of mitiglinide and repaglinide on postprandial hyperglycemia in patients undergoing methylprednisolone pulse therapy
Kenichi Tanaka; Yosuke Okada; Hiroko Mori; Keiichi Torimoto; Tadashi Arao; Yoshiya Tanaka
Internal Medicine, 2018, Reviewed, No invitation

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus
Yoshiya Tanaka; Satoshi Kubo; Shigeru Iwata; Maiko Yoshikawa; Shingo Nakayamada
Clinical Immunology, Jan. 2018, Reviewed, No invitation

Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring
Maiko Hajime; Yosuke Okada; Hiroko Mori; Takashi Otsuka; Mayuko Kawaguchi; Megumi Miyazaki; Fumi Kuno; Kei Sugai; Satomi Sonoda; Kenichi Tanaka; Akira Kurozumi; Manabu Narisawa; Keiichi Torimoto; Tadashi Arao; Yoshiya Tanaka
Journal of Diabetes Investigation, Jan. 2018, Reviewed, No invitation

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
Rheumatology (Oxford), 2018, Not reviewed, No invitation

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus, 2018, Not reviewed, No invitation

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
Kubo S; Nakayamada S; Nakano K; Sawamukai N; Hirata S; Hanami K; Saito K; Tanaka Y
Clin Immunol, 2018, Not reviewed, No invitation

Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus
Mari Miyata; Shingo Kakeda; Shigeru Iwata; Shingo Nakayamada; Satoru Ide; Keita Watanabe; Junji Moriya; Yoshiya Tanaka; Yukunori Korogi
Scientific Reports, Dec. 2017, Reviewed, No invitation

Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome with other sets of criteria in Japanese patients
Hiroto Tsuboi; Shinya Hagiwara; Hiromitsu Asashima; Hiroyuki Takahashi; Tomoya Hirota; Hisashi Noma; Hisanori Umehara; Atsushi Kawakami; Hideki Nakamura; Hajime Sano; Kazuo Tsubota; Yoko Ogawa; Etsuko Takamura; Ichiro Saito; Hiroko Inoue; Seiji Nakamura; Masafumi Moriyama; Tsutomu Takeuchi; Yoshiya Tanaka; Shintaro Hirata; Tsuneyo Mimori; Isao Matsumoto; Takayuki Sumida
ANNALS OF THE RHEUMATIC DISEASES, Dec. 2017, Reviewed, No invitation

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis.
Koji Oba; Nao Horie; Norihiro Sato; Kazuyoshi Saito; Tsutomu Takeuchi; Tsuneyo Mimori; Nobuyuki Miyasaka; Takao Koike; Yoshiya Tanaka
Contemporary clinical trials communications, Dec. 2017, Reviewed, No invitation

Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head
Yuma Sakamoto; Takuaki Yamamoto; Nobuhiko Sugano; Daisuke Takahashi; Toshiyuki Watanabe; Takashi Atsumi; Junichi Nakamura; Yukiharu Hasegawa; Koichi Akashi; Ichiei Narita; Takeshi Miyamoto; Tsutomu Takeuchi; Katsunori Ikari; Koichi Amano; Atsuhiro Fujie; Toshikazu Kubo; Yoshifumi Tada; Ayumi Kaneuji; Hiroaki Nakamura; Tomoya Miyamura; Tamon Kabata; Ken Yamaji; Takahiro Okawa; Akihiro Sudo; Kenji Ohzono; Yoshiya Tanaka; Yuji Yasunaga; Shuichi Matsuda; Yuuki Imai; Masato Akiyama; Michiaki Kubo; Yoichiro Kamatani; Yukihide Iwamoto; Shiro Ikegawa
SCIENTIFIC REPORTS, Nov. 2017, Reviewed, No invitation

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: Secondary analyses from the RA-BEAM study
Edward C Keystone; Peter C Taylor; Yoshiya Tanaka; Carol Gaich; Amy M Delozier; Anna Dudek; Jorge Velasco Zamora; Jose Arturo Covarrubias Cobos; Terence Rooney; Stephanie De Bono; Vipin Arora; Bruno Linetzky; Michael E Weinblatt
Annals of the Rheumatic Diseases, Nov. 2017, Reviewed, No invitation

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
Kevin L. Winthrop; Jeffrey R. Curtis; Stephen Lindsey; Yoshiya Tanaka; Kunihiro Yamaoka; Hernan Valdez; Tomohiro Hirose; Chudy I. Nduaka; Lisy Wang; Alan M. Mendelsohn; Haiyun Fan; Connie Chen; Eustratios Bananis
Arthritis and Rheumatology, Oct. 2017, Reviewed, No invitation

Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients
Satoshi Kubo; Shingo Nakayamada; Maiko Yoshikawa; Yusuke Miyazaki; Kei Sakata; Kazuhisa Nakano; Kentaro Hanami; Shigeru Iwata; Ippei Miyagawa; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Oct. 2017, Reviewed, No invitation

A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease
Yasufumi Masaki; Shoko Matsui; Takako Saeki; Hiroto Tsuboi; Shintaro Hirata; Yasumori Izumi; Taiichiro Miyashita; Keita Fujikawa; Hiroaki Dobashi; Kentaro Susaki; Hisanori Morimoto; Kazutaka Takagi; Mitsuhiro Kawano; Tomoki Origuchi; Yoko Wada; Naoki Takahashi; Masanobu Horikoshi; Hiroshi Ogishima; Yasunori Suzuki; Takafumi Kawanami; Haruka Kawanami Iwao; Tomoyuki Sakai; Yoshimasa Fujita; Toshihiro Fukushima; Masatoshi Saito; Ritsuro Suzuki; Yuko Morikawa; Tadashi Yoshino; Shigeo Nakamura; Masaru Kojima; Nozomu Kurose; Yasuharu Sato; Yoshiya Tanaka; Susumu Sugai; Takayuki Sumida
Modern Rheumatology, Sep. 2017, Reviewed, No invitation

Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells
Ippei Miyagawa; Shingo Nakayamada; Kazuhisa Nakano; Kaoru Yamagata; Kei Sakata; Kunihiro Yamaoka; Yoshiya Tanaka
JOURNAL OF IMMUNOLOGY, Sep. 2017, Reviewed, No invitation

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
Keiichi Torimoto; Yosuke Okada; Kenji Koikawa; Yoshiya Tanaka
DIABETOLOGY & METABOLIC SYNDROME, Aug. 2017, Reviewed, No invitation

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study
Satoshi Kubo; Kunihiro Yamaoka; Koichi Amano; Shuji Nagano; Shigeto Tohma; Eiichi Suematsu; Hayato Nagasawa; Kanako Iwata; Yoshiya Tanaka
RHEUMATOLOGY, Aug. 2017, Reviewed, No invitation

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Tatsuya Atsumi; Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Shinsuke Yasuda; Yuji Yamanishi; Yasuhiko Kita; Tsukasa Matsubara; Masahiro Iwamoto; Toshiharu Shoji; Osamu Togo; Toshiyuki Okada; Desiree van der Heijde; Nobuyuki Miyasaka; Takao Koike
ANNALS OF THE RHEUMATIC DISEASES, Aug. 2017, Reviewed, No invitation

Role of P-glycoprotein on CD69+ CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy
Shizuyo Tsujimura; Tomoko Adachi; Kazuyoshi Saito; Yoshiya Tanaka
RMD Open, Jul. 2017, Reviewed, No invitation

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials
Stanley B. Cohen; Yoshiya Tanaka; Xavier Mariette; Jeffrey R. Curtis; Eun Bong Lee; Peter Nash; Kevin L. Winthrop; Christina Charles-Schoeman; Krishan Thirunavukkarasu; Ryan DeMasi; Jamie Geier; Kenneth Kwok; Lisy Wang; Richard Riese; Jürgen Wollenhaupt
Annals of the Rheumatic Diseases, Jul. 2017, Reviewed, No invitation

Metabolic Reprogramming Commits Differentiation of Human CD27(+)IgD(+) B Cells to Plasmablasts or CD27(-)IgD(-) Cells
Masataka Torigoe; Shigeru Iwata; Shingo Nakayamada; Kei Sakata; Mingzeng Zhang; Maiko Hajime; Yusuke Miyazaki; Manabu Narisawa; Koji Ishii; Hirotaka Shibata; Yoshiya Tanaka
JOURNAL OF IMMUNOLOGY, Jul. 2017, Reviewed, No invitation

Abatacept therapy reduces CD28(+)CXCR5(+) follicular helper-like T cells in patients with rheumatoid arthritis
S. Fukuyo; S. Nakayamada; S. Iwata; S. Kubo; K. Saito; Y. Tanaka
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Jul. 2017, Reviewed, No invitation

Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring
Keiichi Torimoto; Yosuke Okada; Sachiko Sugino; Yoshiya Tanaka
JOURNAL OF DIABETES INVESTIGATION, May 2017, Reviewed, No invitation

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Daniel Aletaha; Clifton O Bingham; Yoshiya Tanaka; Prasheen Agarwal; Regina Kurrasch; Paul P Tak; Sharon Popik
The Lancet, Mar. 2017, Reviewed, No invitation

Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study
Tsutomu Takeuchi; Ryo Nakajima; Shuichi Komatsu; Kiyotaka Yamazaki; Tomohiro Nakamura; Naoki Agata; Ataru Igarashi; Toshiro Tango; Yoshiya Tanaka
Advances in Therapy, Mar. 2017, Reviewed, No invitation

Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study
Yoshiya Tanaka; Tsutomu Takeuchi; Naotsugu Akashi; Yasushi Takita; Birgit Kovacs; Sawako Kariyasu
MODERN RHEUMATOLOGY, Mar. 2017, Reviewed, No invitation

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study
Yoshiya Tanaka; Hisashi Yamanaka; Naoki Ishiguro; Nobuyuki Miyasaka; Katsuyoshi Kawana; Junko Kimura; Naoki Agata; Tsutomu Takeuchi
ARTHRITIS RESEARCH & THERAPY, Mar. 2017, Reviewed, No invitation

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
Yoshiya Tanaka; Hisashi Yamanaka; Tsutomu Takeuchi; Makoto Inoue; Kazuyoshi Saito; Yukihiko Saeki; Sang Joon Lee; Yoshihiro Nambu
MODERN RHEUMATOLOGY, Mar. 2017, Reviewed, No invitation

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study
Naoki Ishiguro; Tatsuya Atsumi; Masayoshi Harigai; Tsuneyo Mimori; Norihiro Nishimoto; Takayuki Sumida; Tsutomu Takeuchi; Yoshiya Tanaka; Ayako Nakasone; Nobuhiro Takagi; Hisashi Yamanaka
MODERN RHEUMATOLOGY, Mar. 2017, Reviewed, No invitation

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor; Edward C. Keystone; Desiree Van Der Heijde; Michael E. Weinblatt; Liliana Del Carmen Morales; Jaime Reyes Gonzaga; Sergey Yakushin; Taeko Ishii; Kahaku Emoto; Scott Beattie; Vipin Arora; Carol Gaich; Terence Rooney; Douglas Schlichting; William L. Macias; Stephanie De Bono; Yoshiya Tanaka
New England Journal of Medicine, Feb. 2017, Reviewed, No invitation

P2-34 全身性エリテマトーデスは末梢血T細胞異常の違いにより3つのサブグループにわけられる
久保 智史; 中山田 真吾; 好川 真以子; 宮崎 祐介; 阪田 圭; 中野 和久; 岩田 慈; 宮川 一平; 田中 良哉
日本臨床免疫学会会誌, 2017

A case of acromegaly in which a pituitary gland tumor was reduced significantly by administering octreotide long acting release (lar) and could be removed surgically
Tadashi Arao; Yosuke Okada; Fumi Uemura; Shigeru Nishizawa; Yoshiya Tanaka
Journal of UOEH, 2017, Reviewed, No invitation

Comparison between effectiveness of 100 Mg/day sitagliptin and a switch to mitiglinide calcium hydrate/voglibose from 50 Mg/day sitagliptin in patients with type 2 diabetes
Tadashi Arao; Yosuke Okada; Keiichi Torimoto; Kei Sugai; Takashi Otsuka; Akira Kurozumi; Yoshiya Tanaka
Journal of UOEH, 2017, Reviewed, No invitation

The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus
Hiroko Mori; Yosuke Okada; Yoshiya Tanaka
INTERNAL MEDICINE, 2017, Reviewed, No invitation

Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus
Kenichi Tanaka; Yosuke Okada; Hiroko Mori; Megumi Miyazaki; Fumi Kuno; Satomi Sonoda; Kei Sugai; Maiko Hajime; Akira Kurozumi; Manabu Narisawa; Keiichi Torimoto; Tadashi Arao; Shinichiro Mine; Yoshiya Tanaka
ENDOCRINE JOURNAL, 2017, Reviewed, No invitation

Factors influencing inter-day glycemic variability in diabetic outpatients receiving insulin therapy
Hiroko Mori; Yosuke Okada; Akira Kurozumi; Manabu Narisawa; Yoshiya Tanaka
JOURNAL OF DIABETES INVESTIGATION, Jan. 2017, Reviewed, No invitation

Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis
Akio Kawabe; Shizuyo Tsujimura; Kazuyoshi Saito; Yoshiya Tanaka
INTERNAL MEDICINE, 2017, Reviewed, No invitation

Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels
Keiichi Torimoto; Yosuke Okada; Akira Kurozumi; Manabu Narisawa; Tadashi Arao; Yoshiya Tanaka
INTERNAL MEDICINE, 2017, Reviewed, No invitation

Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study
Kenichi Tanaka; Yosuke Okada; Hiroko Mori; Yoshifumi Inada; Kanako Suzuka; Kohei Uriu; Yoshiya Tanaka
Diabetology International, Dec. 2016, Reviewed, No invitation

Prediction of Femoral Neck Strength in Patients with Diabetes Mellitus with Trabecular Bone Analysis and Tomosynthesis Images
Masami Fujii; Takatoshi Aoki; Yosuke Okada; Hiroko Mori; Shunsuke Kinoshita; Yoshiko Hayashida; Maiko Hajime; Kenichi Tanaka; Yoshiya Tanaka; Yukunori Korogi
RADIOLOGY, Dec. 2016, Reviewed, No invitation

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Kaneko Y; Atsumi T; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
Annals of the rheumatic diseases, Nov. 2016, Reviewed, No invitation

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-
Tanaka Y; Mori H; Aoki T; Atsumi T; Kawahito Y; Nakayama H; Tohma S; Yamanishi Y; Hasegawa H; Tanimura K; Negoro N; Ueki Y; Kawakami A; Eguchi K; Saito K; Okada Y
Journal of bone and mineral metabolism, Nov. 2016, Reviewed, No invitation

Erratum to: Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis (BioDrugs, 10.1007/s40259-016-0190-5)
Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Yoshiya Tanaka
BioDrugs, Oct. 2016, Reviewed, No invitation

Neuropsychiatry systemic lupus erythematosus
Yoshiya Tanaka
Brain and Nerve, Sep. 2016, Reviewed, No invitation

Baricitinib for the treatment of rheumatoid arthritis
Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, Sep. 2016, Reviewed, No invitation

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies
Robin L. Thurmond; Andrew Greenspan; Waldemar Radziszewski; Xie L. Xu; Ye Miao; Bin Chen; TingTing Ge; Bei Zhou; Daniel G. Baker; Dace Pavlova; Christopher T. Ritchlin; Yoshiya Tanaka; Tsutomu Takeuchi; Josef S. Smolen
JOURNAL OF RHEUMATOLOGY, Sep. 2016, Reviewed, No invitation

Response to: ‘Denosumab, cortical bone and bone erosion in rheumatoid arthritis’ by Rossini et al
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant H; van der Heijde D
Annals of the Rheumatic Diseases, Aug. 2016, Not reviewed, No invitation

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: Current evidence and future directions
Georg Schett; Paul Emery; Yoshiya Tanaka; Gerd Burmester; David S Pisetsky; Esperanza Naredo; Bruno Fautrel; Ronald Van Vollenhoven
Annals of the Rheumatic Diseases, Aug. 2016, Reviewed, No invitation

B-cell subsets, signaling and their roles in secretion of autoantibodies
S. Iwata; Y. Tanaka
LUPUS, Jul. 2016, Reviewed, No invitation

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of th
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T; GO-FORTH study group
Modern rheumatology, Jul. 2016, Reviewed, No invitation

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Kevin L. Winthrop; S. H. Park; A. Gul; M. H. Cardiel; J. J. Gomez-Reino; Y. Tanaka; K. Kwok; T. Lukic; E. Mortensen; D. Ponce De Leon; R. Riese; H. Valdez
Annals of the Rheumatic Diseases, Jun. 2016, Reviewed, No invitation

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
Tsutomu Takeuchi; Yoshiya Tanaka; Naoki Ishiguro; Hisashi Yamanaka; Toshiyuki Yoneda; Takeshi Ohira; Naoki Okubo; Harry K. Genant; Desiree van der Heijde
ANNALS OF THE RHEUMATIC DISEASES, Jun. 2016, Reviewed, No invitation

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi; Yoshiya Tanaka; Manabu Iwasaki; Hiroaki Ishikura; Satoshi Saeki; Yuichiro Kaneko
ANNALS OF THE RHEUMATIC DISEASES, Jun. 2016, Reviewed, No invitation

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).
Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Takasaki Y; Mimori T; Hiramatsu K; Komatsu S; Tanaka Y
Rheumatology and therapy, Jun. 2016, Reviewed, No invitation

Thin-section chest CT findings in polymyalgia rheumatica: A comparison between with and without rheumatoid arthritis
Shunsuke Kinoshita; Takatoshi Aoki; Hiroyuki Takahashi; Hodaka Oki; Yoshiko Hayashida; Kazuyoshi Saito; Yoshiya Tanaka; Yukunori Korogi
Clinical Imaging, May 2016, Reviewed, No invitation

Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes
Akira Kurozumi; Yosuke Okada; Hiroko Mori; Takuya Kobayashi; Daisaku Masuda; Shizuya Yamashita; Yoshiya Tanaka
ENDOCRINE JOURNAL, May 2016, Reviewed, No invitation

Overexpression of peroxiredoxin 4 affects intestinal function in a dietary mouse model of nonalcoholic fatty liver disease
Aya Nawata; Hirotsugu Noguchi; Yuichi Mazaki; Toshihiro Kurahashi; Hiroto Izumi; Ke-Yong Wang; Xin Guo; Hidetaka Uramoto; Kimitoshi Kohno; Hatsumi Taniguchi; Yoshiya Tanaka; Junichi Fujii; Yasuyuki Sasaguri; Akihide Tanimoto; Toshiyuki Nakayama; Sohsuke Yamada
PLoS ONE, Apr. 2016, Reviewed, No invitation

Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia
Atsushi Ogasawara; Shingo Kakeda; Keita Watanabe; Satoru Ide; Issei Ueda; Yu Murakami; Junji Moriya; Koichiro Futatsuya; Toru Sato; Shingo Nakayamada; Kazuyoshi Saito; Yoshiya Tanaka; Tian Liu; Yi Wang; Yukunori Korogi
European Radiology, Apr. 2016, Reviewed, No invitation

Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold
Koshiro Sonomoto; Kunihiro Yamaoka; Hiroaki Kaneko; Kaoru Yamagata; Kei Sakata; Xiangmei Zhang; Masahiro Kondo; Yukichi Zenke; Ken Sabanai; Shingo Nakayamada; Akinori Sakai; Yoshiya Tanaka
PLOS ONE, Apr. 2016, Reviewed, No invitation

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, double-blind, randomized placebo-controlled study
Yoshiya Tanaka; Kahaku Emoto; Zhihong Cai; Takehiro Aoki; Douglas Schlichting; Terence Rooney; William Macias
Journal of Rheumatology, Mar. 2016, Reviewed, No invitation

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg; M. Petri; K. Kalunian; Y. Tanaka; M. B. Urowitz; R. W. Hoffman; M. Morgan-Cox; N. Iikuni; M. Silk; D. J. Wallace
Annals of the Rheumatic Diseases, Feb. 2016, Reviewed, No invitation

Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study
Tomomi Tsuru; Yoshiya Tanaka; Mitsumasa Kishimoto; Kazuyoshi Saito; Seiji Yoshizawa; Yoshinari Takasaki; Tomoya Miyamura; Hiroaki Niiro; Shinji Morimoto; Junichi Yamamoto; Rocio Lledo-Garcia; Jing Shao; Shuichiro Tatematsu; Osamu Togo; Takao Koike
Modern Rheumatology, Jan. 2016, Reviewed, No invitation

Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Satoshi Kubo; Yoshiya Tanaka
Inflammation and Regeneration, 2016

学会特別企画 分子標的薬のアニュアルレビュー2 膠原病における分子標的薬の動向
齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2016

P1-17 nailfold videocapillaroscopy（NVC）による病期評価を用いた強皮症の病態評価の検討
久保 智史; 中山田 真吾; 中野 和久; 好川 真以子; 宮崎 祐介; 佐藤 友梨恵; 轟 泰幸; 平田 信太郎; 岩田 慈; 齋藤 和義; 佐藤 実; 田中 良哉
日本臨床免疫学会会誌, 2016

P1-24 全身性エリテマトーデスにおけるCD4⁺cell上P糖蛋白質/CXCR3の組織侵襲性への関与
辻村 静代; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2016

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: A case report
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Yusuke Miyazaki; Maiko Yoshikawa; Keiichi Torimoto; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Endocrinology, Diabetes and Metabolism Case Reports, 2016, Reviewed, No invitation

A case of resistance to thyroid hormone (RTH) with a negative family history with diagnosis based on persistent palpitations
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Yoshiya Tanaka
Journal of UOEH, 2016, Reviewed, No invitation

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
Yoshiya Tanaka; Hisashi Yamanaka; Naoki Ishiguro; Nobuyuki Miyasaka; Katsuyoshi Kawana; Katsutoshi Hiramatsu; Tsutomu Takeuchi
RMD Open, 2016, Reviewed, No invitation

A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by dapagliflozin
Hiroko Mori; Yosuke Okada; Mayuko Kawaguchi; Yoshiya Tanaka
Journal of UOEH, 2016, Reviewed, No invitation

T follicular helper (Tfh) cells in autoimmune diseases
Shingo Nakayamada; Yoshiya Tanaka
Japanese Journal of Clinical Immunology, 2016, Reviewed, No invitation

Two Sisters with Graves' Disease and Similar Clinical Features who Tested Positive for Anti-insulin Antibodies after Thiamazole Treatment
Keiichi Torimoto; Yosuke Okada; Hiroko Mori; Yoshiya Tanaka
INTERNAL MEDICINE, 2016, Reviewed, No invitation

Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study
Tetsuya Kawahara; Gen Suzuki; Tetsuya Inazu; Shoichi Mizuno; Fumiyoshi Kasagi; Yosuke Okada; Yoshiya Tanaka
BMJ OPEN, 2016, Reviewed, No invitation

Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial
Hiroto Tsuboi; Isao Matsumoto; Shinya Hagiwara; Tomoya Hirota; Hiroyuki Takahashi; Hiroshi Ebe; Masahiro Yokosawa; Mizuki Yagishita; Hidenori Takahashi; Izumi Kurata; Ayako Ohyama; Fumika Honda; Hiromitsu Asashima; Haruka Miki; Naoto Umeda; Yuya Kondo; Shintaro Hirata; Kazuyoshi Saito; Yoshiya Tanaka; Yoshiro Horai; Hideki Nakamura; Atsushi Kawakami; Takayuki Sumida
MODERN RHEUMATOLOGY, 2016, Reviewed, No invitation

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
Tsutomu Takeuchi; Kazuhiko Yamamoto; Hisashi Yamanaka; Naoki Ishiguro; Yoshiya Tanaka; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Mariko Kobayashi; Toshiharu Shoji; Osamu Togo; Nobuyuki Miyasaka; Takao Koike
MODERN RHEUMATOLOGY, 2016, Reviewed, No invitation

Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
Tsutomu Takeuchi; Yoshiya Tanaka; Hisashi Yamanaka; Kanzo Amano; Ryuji Nagamine; Won Park; Kazuko Shiozawa; Michishi Tsukano; James Cheng-Chung Wei; Jing Shao; Osamu Togo; Hideki Mashimo
MODERN RHEUMATOLOGY, Jan. 2016, Reviewed, No invitation

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Hisashi Yamanaka; Yoshiya Tanaka; Tsutomu Takeuchi; Naonobu Sugiyama; Hirotoshi Yuasa; Shigeyuki Toyoizumi; Yosuke Morishima; Tomohiro Hirose; Samuel Zwillich
ARTHRITIS RESEARCH & THERAPY, Jan. 2016, Reviewed, No invitation

Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjogren's syndrome
Jidong Zhao; Satoshi Kubo; Shingo Nakayamada; Shohei Shimajiri; Xiangmei Zhang; Kunihiro Yamaoka; Yoshiya Tanaka
MODERN RHEUMATOLOGY, 2016, Reviewed, No invitation

Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Yoshiya Tanaka
INTERNAL MEDICINE, 2016, Reviewed, No invitation

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Masayoshi Harigai; Naoki Ishiguro; Shigeko Inokuma; Tsuneyo Mimori; Junnosuke Ryu; Syuji Takei; Tsutomu Takeuchi; Yoshiya Tanaka; Yoshinari Takasaki; Hisashi Yamanaka; Masahiko Watanabe; Hiroshi Tamada; Takao Koike
MODERN RHEUMATOLOGY, 2016, Reviewed, No invitation

Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study
Hisashi Yamanaka; Shouhei Nagaoka; Soo-Kon Lee; Sang-Cheol Bae; Tsuyoshi Kasama; Hitomi Kobayashi; Yuichi Nishioka; Yukitaka Ueki; Yohei Seto; Makoto Nishinarita; Naoto Tamura; Noriko Kimura; Kazuyoshi Saito; Tetsuya Tomita; Yasushi Nawata; Sadahiro Suzuki; Yoshiaki Ishigatsubo; Yasuhiko Munakata; Yuichi Makino; Eisuke Inoue; Yoshiya Tanaka; Tsutomu Takeuchi
MODERN RHEUMATOLOGY, 2016, Reviewed, No invitation

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
Yoshiya Tanaka; Tsutomu Takeuchi; Nobuyuki Miyasaka; Takayuki Sumida; Tsuneyo Mimori; Takao Koike; Kazuhiro Endo; Naomi Mashino; Kazuhiko Yamamoto
MODERN RHEUMATOLOGY, Jan. 2016, Reviewed, No invitation

Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab
Masao Nawata; Kazuyoshi Saito; Shunsuke Fukuyo; Shintaro Hirata; Yoshiya Tanaka
MODERN RHEUMATOLOGY, 2016, Not reviewed, No invitation

Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score.
Hirata S; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi, 2016, Not reviewed, No invitation

New assessment method in rheumatoid arthritis
Hirata S; Tanaka Y
Nihon Rinsho, 2016, Not reviewed, No invitation

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
Clin Exp Rheumatol, 2016, Not reviewed, No invitation

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice
Hirata, Shintaro; Li, Wanying; Kubo, Satoshi; Fukuyo, Shunsuke; Mizuno, Yasushi; Hanami, Kentaro; Sawamukai, Norifumi; Yamaoka, Kunihiro; Saito, Kazuyoshi; Defranoux; Nadine A; Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2016, Not reviewed, No invitation

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching
Kubo, Satoshi; Nakayamada, Shingo; Nakano, Kazuhisa; Hirata, Shintaro; Fukuyo, Shunsuke; Miyagawa, Ippei; Hanami, Kentaro; Saito, Kazuyoshi; Tanaka, Yoshiya
ANNALS OF THE RHEUMATIC DISEASES, 2016, Not reviewed, No invitation

Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Ishii Y; Nakajima H; Baker D; Miyasaka N; Koike T
Modern rheumatology, 2016, Reviewed, No invitation

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Annals of the rheumatic diseases, Jan. 2016, Reviewed, No invitation

Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis
Shingo Nakayamada; Yoshiya Tanaka
Clinical calcium, Dec. 2015

Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation
Sheau-Pey Wang; Shigeru Iwata; Shingo Nakayamada; Hiroaki Niiro; Siamak Jabbarzadeh-Tabrizi; Masahiro Kondo; Satoshi Kubo; Maiko Yoshikawa; Yoshiya Tanaka
RHEUMATOLOGY, Aug. 2015, Reviewed, No invitation

Histamine inhibits differentiation of skin fibroblasts into myofibroblasts
Lin Lin; Kaoru Yamagata; Shingo Nakayamada; Norifumi Sawamukai; Kunihiro Yamaoka; Kei Sakata; Kazuhisa Nakano; Yoshiya Tanaka
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Jul. 2015, Reviewed, No invitation

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
Yoshiya Tanaka; Tsutomu Takeuchi; Hisashi Yamanaka; Hiroyuki Nakamura; Shigeyuki Toyoizumi; Samuel Zwillich
MODERN RHEUMATOLOGY, Jul. 2015, Reviewed, No invitation

Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.
Yamanaka H; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Tanaka Y; Suzuki H; Shinmura Y; Koike T
Modern rheumatology, Jul. 2015, Reviewed, No invitation

Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus
S. Iwata; K. Yamaoka; H. Niiro; S. Jabbarzadeh-Tabrizi; S. P. Wang; M. Kondo; M. Yoshikawa; K. Akashi; Yoshiya Tanaka
Lupus, Jun. 2015, Reviewed, No invitation

Mesenchymal stem cells for the treatment and repair of inflammatory arthritis
Yoshiya Tanaka; Koshiro Sonomoto; Masahiro Kondo; Koichi Oshita; Zhang Xiang-Mei; Shunsuke Fukuyo; Kunihiro Yamaoka
Japanese Journal of Clinical Immunology, May 2015, Reviewed, No invitation

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study
Atsushi Ogata; Koichi Amano; Hiroaki Dobashi; Masayuki Inoo; Tomonori Ishii; Tsuyoshi Kasama; Shinichi Kawai; Atsushi Kawakami; Tatsuya Koike; Hisaaki Miyahara; Toshiaki Miyamoto; Yasuhiko Munakata; Akira Murasawa; Norihiro Nishimoto; Noriyoshi Ogawa; Tomohiro Ojima; Hajime Sano; Kenrin Shi; Eisuke Shono; Eiichi Suematsu; Hiroki Takahashi; Yoshiya Tanaka; Hiroshi Tsukamoto; Akira Nomura
JOURNAL OF RHEUMATOLOGY, May 2015, Reviewed, No invitation

A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study
Shintaro Hirata; Wanying Li; Nadine Defranoux; Guy Cavet; Rebecca Bolce; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
MODERN RHEUMATOLOGY, May 2015, Reviewed, No invitation

Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells
Masahiro Kondo; Kunihiro Yamaoka; Kei Sakata; Koshiro Sonomoto; Lin Lin; Kazuhisa Nakano; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, May 2015, Reviewed, No invitation

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
Tsutomu Takeuchi; Tsukasa Matsubara; Shuji Ohta; Masaya Mukai; Koichi Amano; Shigeto Tohma; Yoshiya Tanaka; Hisashi Yamanaka; Nobuyuki Miyasaka
RHEUMATOLOGY, Apr. 2015, Reviewed, No invitation

Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study
Hayato Yamazaki; Ryoko Sakai; Ryuji Koike; Yasunari Miyazaki; Michi Tanaka; Toshihiro Nanki; Kaori Watanabe; Shinsuke Yasuda; Takashi Kurita; Yuko Kaneko; Yoshiya Tanaka; Yasuhiko Nishioka; Yoshinari Takasaki; Kenji Nagasaka; Hayato Nagasawa; Shigeto Tohma; Makoto Dohi; Takahiko Sugihara; Haruhito Sugiyama; Yasushi Kawaguchi; Naohiko Inase; Sae Ochi; Hiroyuki Hagiyama; Hitoshi Kohsaka; Nobuyuki Miyasaka; Masayoshi Harigai
JOURNAL OF RHEUMATOLOGY, Apr. 2015, Reviewed, No invitation

Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus.
Ishizaki J; Saito K; Nawata M; Mizuno Y; Tokunaga M; Sawamukai N; Tamura M; Hirata S; Yamaoka K; Hasegawa H; Tanaka Y
Rheumatology (Oxford, England), Mar. 2015, Reviewed, No invitation

Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim an
Tsuboi, Hiroto; Matsumoto, Isao; Hagiwara, Shinya; Hirota, Tomoya; Takahashi, Hiroyuki; Ebe, Hiroshi; Yokosawa, Masahiro; Hagiya, Chihiro; Asashima, Hiromitsu; Takai, Chinatsu; Miki, Haruka; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Hirata, Shintaro; Saito, Kazuyoshi; Tanaka, Yoshiya; Horai, Yoshiro; Nakamura, Hideki; Kawakami, Atsushi; Sumida, Takayuki
MODERN RHEUMATOLOGY, Mar. 2015, Not reviewed, No invitation

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R; Cho SK; Nanki T; Watanabe K; Yamazaki H; Tanaka M; Koike R; Tanaka Y; Saito K; Hirata S; Amano K; Nagasawa H; Sumida T; Hayashi T; Sugihara T; Dobashi H; Yasuda S; Sawada T; Ezawa K; Ueda A; Fujii T; Migita K; Miyasaka N; Harigai M; REAL Study Group
Arthritis research & therapy, Mar. 2015, Reviewed, No invitation

Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus
Shingo Nakayamada; Shigeru Iwata; Yoshiya Tanaka
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, Feb. 2015, Reviewed, No invitation

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
Keiichi Torimoto; Yosuke Okada; Hiroko Mori; Takashi Otsuka; Mayuko Kawaguchi; Megumi Matsuda; Fumi Kuno; Kei Sugai; Satomi Sonoda; Maiko Hajime; Kenichi Tanaka; Tadashi Arao; Yoshiya Tanaka
CARDIOVASCULAR DIABETOLOGY, Feb. 2015, Reviewed, No invitation

A case of type 2 diabetes mellitus with large abscesses in the paravertebral, iliopsoas and gluteus muscles associated with pyogenic sacroiliitis and pubic bone destruction
Koji Matsushita; Yosuke Okada; Tadashi Arao; Hideomi Kondo; Yoshiya Tanaka
Journal of the Japan Diabetes Society, 2015

A Case of Type 2 Diabetes Mellitus with NASH Successfully Treated Using Integrated Therapy Including Ipragliflozin
Mori Hiroko; Okada Yosuke; Kawaguchi Mayuko; Hiura Masaaki; Abe Shintaro; Siba Eisuke; Shimajiri Masahira; Harada Masaru; Tanaka Yoshiya
Journal of the Japan Diabetes Society, 2015

P1-017 炎症性サイトカインはTET3依存性DNA脱メチル化を介し滑膜細胞に攻撃的表現型を付与する
河邊 明男; 中野 和久; 山形 薫; 中山田 真吾; 田中 良哉
日本臨床免疫学会会誌, 2015

ランチョンセミナー3 JAK阻害薬の可能性を考える～基礎と臨床の立場から～
田中 良哉
日本臨床免疫学会会誌, 2015

P7-001 Propensity score-matchingを用いた実臨床におけるアバタセプト（ABT）とトシリズマブ（TCZ）の効果と安全性の比較試験
久保 智史; 中山田 真吾; 中野 和久; 澤向 範文; 平田 信太郎; 宮川 一平; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2015

P7-009 IgG4関連疾患における末梢血リンパ球フェノタイプの解析
久保 智史; 中山田 真吾; 中野 和久; 平田 信太郎; 宮崎 祐介; 好川 真以子; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2015

P7-021 治療抵抗性増殖性ループス腎炎におけるP糖蛋白質発現CD69⁺CD4⁺cellの関与
辻村 静代; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2015

P7-020 メトトレキサートにて関節リウマチ治療中に悪性リンパ腫を発症した症例の検討
齋藤 和義; 中野 和久; 中山田 真吾; 久保 智史; 澤向 範文; 平田 信太郎; 宮川 一平; 岩田 慈; 花見 健太郎; 田中 良哉
日本臨床免疫学会会誌, 2015

P7-030 関節リウマチにおいてベースライン14-3-3η低値はtocilizumabによる1年後のDAS28-ESR寛解達成を予測する
平田 信太郎; 花見 健太郎; 山形 薫; 宮川 一平; 久保 智史; 岩田 慈; 澤向 範文; 中野 和久; 中山田 真吾; 齋藤 和義; Marotta Anthony; 田中 良哉
日本臨床免疫学会会誌, 2015

P1-001 関節リウマチ（RA）滑膜線維芽細胞（FLS）において軟骨破壊因子MMP-13の発現制御に関わるRor1シグナル基盤の解明
山形 薫; 中山田 真吾; 中野 和久; 田中 良哉
日本臨床免疫学会会誌, 2015

Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis
SONOMOTO Koshiro; TANAKA Yohisya
Japanese Journal of Clinical Immunology, 2015

Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis
Yoshiya Tanaka
Clinical and Experimental Rheumatology, 2015, Reviewed, No invitation

The importance of B cell-T cell interaction in autoimmune diseases
Shigeru Iwata; Yoshiya Tanaka
Japanese Journal of Clinical Immunology, 2015, Reviewed, No invitation

Prednisolone dosing regimen for treatment of subacute thyroiditis
Tadashi Arao; Yosuke Okada; Keiichi Torimoto; Akira Kurozumi; Manabu Narisawa; Sunao Yamamoto; Yoshiya Tanaka
Journal of UOEH, 2015, Reviewed, No invitation

Secondary Adrenocortical Insufficiency Complicated by Marked Hypercalcemia and Eosinophilia: A Case Report
Sunao Yamamoto; Yosuke Okada; Tadashi Arao; Yoshiya Tanaka
Journal of UOEH, 2015, Reviewed, No invitation

A case of Graves' disease with remarkable psychiatric symptoms
Fumi Kuno; Yosuke Okada; Tadashi Arao; Akira Kurozumi; Yoshiya Tanaka
Journal of UOEH, 2015, Reviewed, No invitation

Abnormal expression of chemokine receptor on b cells in patients with SLE
Maiko Yoshkawa; Shingo Nakayamada; Shigera Iwata; Satoshi Kubo; Naoki Yunoue; Sheau-Pey Wang; Yoshiya Tanaka
Japanese Journal of Clinical Immunology, 2015, Reviewed, No invitation

Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: A case report
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Mandbu Narisawa; Keiichi Torimoto; Sunao Yamamoto; Yoshiya Tanaka
ENDOCRINE JOURNAL, Jan. 2015, Reviewed, No invitation

Incidence of Vitamin D Deficiency and Its Relevance to Bone Metabolism in Japanese Postmenopausal Women with Type 2 Diabetes Mellitus
Hiroko Mori; Yosuke Okada; Yoshiya Tanaka
INTERNAL MEDICINE, 2015, Reviewed, No invitation

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study
Tsutomu Takeuchi; Yoshiya Tanaka; David Close; Alex Godwood; Chi-Yuan Wu; Didier Saurigny
MODERN RHEUMATOLOGY, Jan. 2015, Reviewed, No invitation

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
Tsutomu Takeuchi; Hisashi Yamanaka; Yoshiya Tanaka; Takeo Sakurai; Kazuyoshi Saito; Hideo Ohtsubo; Sang Joon Lee; Yoshihiro Nambu
MODERN RHEUMATOLOGY, 2015, Reviewed, No invitation

Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis A Potential Target for Abatacept Therapy
Shigeru Iwata; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Naoki Yunoue; Sheau-Pey Wang; Maiko Yoshikawa; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Jan. 2015, Reviewed, No invitation

Serum 14-3-3 eta level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab
Hirata, Shintaro; Marotta, Anthony; Gui, Yuan; Hanami, Kentaro; Tanaka, Yoshiya
ARTHRITIS RESEARCH & THERAPY, 2015, Reviewed, No invitation

JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients
Hirata, Shintaro; Gudman; Natasja Staehr; Hanami, Kentaro; Kubo, Satoshi; Bay-Jensen, Anne C; Karsdal, Morten Asser; Tanaka, Yoshiya
ARTHRITIS & RHEUMATOLOGY, 2015, Not reviewed, No invitation

Combination therapy for early rheumatoid arthritis: a treatment holiday perspective.
Hirata S; Tanaka Y
Expert Rev Clin Pharmacol, 2015, Reviewed, Invited

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
Ann Rheum Dis, 2015, Reviewed, No invitation

Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.
Kaneko Y; Koike T; Oda H; Yamamoto K; Miyasaka N; Harigai M; Yamanaka H; Ishiguro N; Tanaka Y; Takeuchi T
Modern rheumatology, Jan. 2015, Reviewed, No invitation

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
Satoshi Kubo; Kunihiro Yamaoka; Masahiro Kondo; Kaoru Yamagata; Jidong Zhao; Shigeru Iwata; Yoshiya Tanaka
ANNALS OF THE RHEUMATIC DISEASES, Dec. 2014, Reviewed, No invitation

14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata; Kentaro Hanami; Anthony Marotta; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Dec. 2014, Not reviewed, No invitation

Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats
Xiangmei Zhang; Kunihiro Yamaoka; Koshiro Sonomoto; Hiroaki Kaneko; Makoto Satake; Yuka Yamamoto; Masahiro Kondo; Jidong Zhao; Ippei Miyagawa; Kaoru Yamagata; Shunsuke Fukuyo; Yosuke Okada; Yoshiya Tanaka
PLOS ONE, Dec. 2014, Reviewed, No invitation

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R; Cho SK; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Amano K; Tanaka Y; Sumida T; Ihata A; Yasuda S; Nakajima A; Sugihara T; Tamura N; Fujii T; Dobashi H; Miura Y; Miyasaka N; Harigai M; REAL study group
Rheumatology international, Dec. 2014, Reviewed, No invitation

[Updates on Lifestyle-Related Diseases and Bone Metabolism. Bisphosphonates for lifestyle-related disease].
Okada Y; Tanaka Y
Clinical calcium, Nov. 2014, Reviewed, No invitation

Pterostilbene surpassed resveratrol for anti-inflammatory application: Potency consideration and pharmacokinetics perspective
Qiu-Yi Choo; Samuel Chao Ming Yeo; Paul C. Ho; Yoshiya Tanaka; Hai-Shu Lin
JOURNAL OF FUNCTIONAL FOODS, Nov. 2014, Reviewed, No invitation

Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjogren Syndrome and Healthy Controls.
Shintaro Hirata; Shingo Nakayamada; Satoshi Kubo; Maiko Yoshikawa; Naoki Yunoue; Kazuhisa Nakano; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS & RHEUMATOLOGY, Oct. 2014, Not reviewed, No invitation

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Nobuyuki Miyasaka; Takao Koike
MODERN RHEUMATOLOGY, Sep. 2014, Reviewed, No invitation

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial
Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Yoshiya Tanaka; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Yoshiharu Sakamaki; Desiree van der Heijde; Nobuyuki Miyasaka; Takao Koike
MODERN RHEUMATOLOGY, Sep. 2014, Reviewed, No invitation

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Nobuyuki Miyasaka; Takao Koike
MODERN RHEUMATOLOGY, Sep. 2014, Reviewed, No invitation

A case of teriparatide-induced severe hypophosphatemia and hypercalcemia
Maiko Hajime; Yosuke Okada; Hiroko Mori; Yoshiya Tanaka
JOURNAL OF BONE AND MINERAL METABOLISM, Sep. 2014, Reviewed, No invitation

Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia (R) as Biological Intensive Treatment for RA (ORBIT) study
Yoshiya Tanaka; Satoshi Kubo; Hisashi Yamanaka; Koichi Amano; Shintaro Hirata; Eiichi Tanaka; Hayato Nagasawa; Hidekata Yasuoka; Tsutomu Takeuchi
MODERN RHEUMATOLOGY, Sep. 2014, Not reviewed, No invitation

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial
Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Yoshiya Tanaka; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Koichi Iwai; Yoshiharu Sakamaki; Desiree van der Heijde; Nobuyuki Miyasaka; Takao Koike
MODERN RHEUMATOLOGY, Jul. 2014, Reviewed, No invitation

IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent
Shunsuke Fukuyo; Kunihiro Yamaoka; Koshiro Sonomoto; Koichi Oshita; Yosuke Okada; Kazuyoshi Saito; Yasuhiro Yoshida; Tamotsu Kanazawa; Yasuhiro Minami; Yoshiya Tanaka
RHEUMATOLOGY, Jul. 2014, Reviewed, No invitation

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
Cho SK; Sakai R; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Tanaka Y; Nakajima A; Yasuda S; Ihata A; Ezawa K; Won S; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Miyasaka N; Bae SC; Harigai M; RESEARCH investigators; REAL Study Group
Modern rheumatology, Jul. 2014, Reviewed, No invitation

Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes
Keiichi Torimoto; Yosuke Okada; Hiroko Mori; Yoshiya Tanaka
CARDIOVASCULAR DIABETOLOGY, Jun. 2014, Reviewed, No invitation

Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: Results from the Japanese studies
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Modern Rheumatology, May 2014, Reviewed, No invitation

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors
Yoshiya Tanaka; Tsutomu Takeuchi; Koichi Amano; Kazuyoshi Saito; Kentaro Hanami; Masao Nawata; Shunsuke Fukuyo; Hideto Kameda; Yuko Kaneko; Takahiko Kurasawa; Hayato Nagasawa; Daisuke Hoshi; Eri Sato; Hisashi Yamanaka
MODERN RHEUMATOLOGY, May 2014, Reviewed, No invitation

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial
Hisashi Yamanaka; Naoki Ishiguro; Tsutomu Takeuchi; Nobuyuki Miyasaka; Masaya Mukai; Tsukasa Matsubara; Shoji Uchida; Hideto Akama; Hartmut Kupper; Vipin Arora; Yoshiya Tanaka
RHEUMATOLOGY, May 2014, Reviewed, No invitation

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
Hiroko Mori; Yosuke Okada; Tadashi Arao; Yoshiya Tanaka
JOURNAL OF DIABETES INVESTIGATION, May 2014, Reviewed, No invitation

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis
Ippei Miyagawa; Shingo Nakayamada; Kazuyoshi Saito; Kentaro Hanami; Masao Nawata; Norifumi Sawamukai; Kazuhisa Nakano; Kunihiro Yamaoka; Yoshiya Tanaka
MODERN RHEUMATOLOGY, May 2014, Reviewed, No invitation

Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan
Hiroto Tsuboi; Hiromitsu Asashima; Chinatsu Takai; Shinya Hagiwara; Chihiro Hagiya; Masahiro Yokosawa; Tomoya Hirota; Hisanori Umehara; Atsushi Kawakami; Hideki Nakamura; Hajime Sano; Kazuo Tsubota; Yoko Ogawa; Etsuko Takamura; Ichiro Saito; Hiroko Inoue; Seiji Nakamura; Masafumi Moriyama; Tsutomu Takeuchi; Yoshiya Tanaka; Shintaro Hirata; Tsuneyo Mimori; Hajime Yoshifuji; Akiko Ohta; Isao Matsumoto; Takayuki Sumida
MODERN RHEUMATOLOGY, May 2014, Not reviewed, No invitation

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
Koshiro Sonomoto; Kunihiro Yamaoka; Satoshi Kubo; Shintaro Hirata; Shunsuke Fukuyo; Keisuke Maeshima; Katsunori Suzuki; Kazuyoshi Saito; Yoshiya Tanaka
RHEUMATOLOGY, May 2014, Not reviewed, No invitation

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients
Takao Koike; Masayoshi Harigai; Naoki Ishiguro; Shigeko Inokuma; Syuji Takei; Tsutomu Takeuchi; Hisashi Yamanaka; Shigenori Haruna; Naoko Ushida; Katsuyoshi Kawana; Yoshiya Tanaka
MODERN RHEUMATOLOGY, May 2014, Reviewed, No invitation

Glucose variability before and after treatment of a patient with Graves' disease complicated by diabetes mellitus: Assessment by continuous glucose monitoring
Keiichi Torimoto; Yosuke Okada; Tadashi Arao; Hiroko Mori; Sunao Yamamoto; Manabu Narisawa; Akira Kurozumi; Yoshiya Tanaka
ENDOCRINE JOURNAL, Apr. 2014, Reviewed, No invitation

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Nobuyuki Miyasaka; Masaya Mukai; Tsukasa Matsubara; Shoji Uchida; Hideto Akama; Hartmut Kupper; Vipin Arora; Yoshiya Tanaka
ANNALS OF THE RHEUMATIC DISEASES, Mar. 2014, Reviewed, No invitation

Efficacy and safety of reducing duration of infliximab infusion
Shunsuke Fukuyo; Kazuyoshi Saito; Kunihiro Yamaoka; Norifumi Sawamukai; Shintaro Hirata; Masao Nawata; Shigeru Iwata; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Mar. 2014, Not reviewed, No invitation

Tomosynthesis of the wrist and hand in patients with rheumatoid arthritis: Comparison with radiography and MRI
Takatoshi Aoki; Masami Fujii; Yoshiko Yamashita; Hiroyuki Takahashi; Hodaka Oki; Yoshiko Hayashida; Kazuyoshi Saito; Yoshiya Tanaka; Yukunori Korogi
American Journal of Roentgenology, Feb. 2014, Reviewed, No invitation

Apathetic Hyperthyroidism with Heart Failure in an Elderly Patient with Plummerʼs Disease
NARISAWA Manabu; OKADA Yosuke; ARAO Tadashi; KUNO Fumi; TANAKA Yoshiya
J UOEH, 2014

A Case of Parathyroid Carcinoma with a Highly Aggressive Clinical Course
MORI Hiroko; OKADA Yosuke; ARAO Tadashi; TANAKA Yoshiya
J UOEH, 2014

S4-3 サイトカイン・シグナル伝達とその阻害治療(S4 生物学的製剤がもたらした新たな治療戦略,シンポジウム4,第26回日本アレルギー学会春季臨床大会)
山岡 邦宏; 田中 良哉
アレルギー, 2014

An Approach to Bone and Cartilage Repair of Rheumatoid Arthritis by Mesenchymal Stem Cells
SONOMOTO Koshiro; YAMAOKA Kunihiro; TANAKA Yoshiya
J UOEH, 2014

HIV-associated nephropathy with amoebic enteritis: A case report and literature review
Katsunori Suzuki; Kazuyoshi Saito; Yoshiya Tanaka
Japanese Journal of Geriatrics, 2014, Reviewed, No invitation

Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis
Yoshiya Tanaka; Shintaro Hirata
Drugs, 2014, Reviewed, No invitation

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Yasuo Suzuki; Hajime Nawata; Satoshi Soen; Saeko Fujiwara; Hisanori Nakayama; Ikuko Tanaka; Keiichi Ozono; Akira Sagawa; Ryoichi Takayanagi; Hiroyuki Tanaka; Takami Miki; Naomi Masunari; Yoshiya Tanaka
Journal of Bone and Mineral Metabolism, 2014, Reviewed, No invitation

Clinical trials express: Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
Toshitaka Nakamura; Toshio Matsumoto; Toshitsugu Sugimoto; Takayuki Hosoi; Takami Miki; Itsuo Gorai; Hideki Yoshikawa; Yoshiya Tanaka; Sakae Tanaka; Teruki Sone; Tetsuo Nakano; Masako Ito; Shigeyuki Matsui; Toshiyuki Yoneda; Hideo Takami; Ko Watanabe; Taisuke Osakabe; Masataka Shiraki; Masao Fukunaga
Journal of Clinical Endocrinology and Metabolism, 2014, Reviewed, No invitation

Systemic lupus erythematosus: Prediction by MRI of the subsequent development of brain lesions
Koichiro Futatsuya; Shingo Kakeda; Yoko Kaichi; Junji Moriya; Norihiro Ohnari; Kazuyoshi Saito; Yoshiya Tanaka; Yukunori Korogi
Academic Radiology, 2014, Reviewed, No invitation

Brain MR findings in patients with systemic lupus erythematosus with and without antiphospholipid antibody syndrome
Y. Kaichi; Shingo Kakeda; J. Moriya; N. Ohnari; K. Saito; Y. Tanaka; F. Tatsugami; S. Date; K. Awai; Y. Korogi
American Journal of Neuroradiology, Jan. 2014, Reviewed, No invitation

Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Takayuki Katsuyama; Kazuyoshi Saito; Satoshi Kubo; Masao Nawata; Yoshiya Tanaka
ARTHRITIS RESEARCH & THERAPY, 2014, Reviewed, No invitation

Type 2 Diabetes Mellitus Complicated by Hypertension in Japanese Patients: Switching Treatment from High-dose Angiotensin II Receptor Blockers to Losartan Plus Hydrochlorothiazide
Sunao Yamamoto; Yosuke Okada; Hiroko Mori; Keiko Nishida; Kohei Uriu; Yoshiya Tanaka
INTERNAL MEDICINE, 2014, Reviewed, No invitation

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study
Satoshi Kubo; Kazuyoshi Saito; Shintaro Hirata; Shunsuke Fukuyo; Kunihiro Yamaoka; Norifumi Sawamukai; Masao Nawata; Shigeru Iwata; Yasushi Mizuno; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Jan. 2014, Not reviewed, No invitation

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naolci Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Syuji Takei; Yoshiya Tanaka; Yoko Sano; Hitomi Yaguramaki; Hisashi Yamanaka
JOURNAL OF RHEUMATOLOGY, Jan. 2014, Reviewed, No invitation

IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells
Masahiro Kondo; Kunihiro Yamaoka; Koshiro Sonomoto; Shunsuke Fukuyo; Koichi Oshita; Yosuke Okada; Yoshiya Tanaka
PLoS ONE, Nov. 2013, Reviewed, No invitation

Recent progress in neuropsychiatric systemic lupus erythematosus
Yoshiya Tanaka
Brain and Nerve, Nov. 2013, Reviewed, No invitation

Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis
Sonosuke Yukawa; Kunihiro Yamaoka; Norifumi Sawamukai; Shohei Shimajiri; Satoshi Kubo; Ippei Miyagawa; Koshiro Sonomoto; Kazuyoshi Saito; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Nov. 2013, Reviewed, No invitation

The Histone Deacetylase Inhibitors MS-275 and SAHA Suppress the p38 Mitogen-Activated Protein Kinase Signaling Pathway and Chemotaxis in Rheumatoid Arthritic Synovial Fibroblastic E11 Cells
Qiu-Yi Choo; Paul C. Ho; Yoshiya Tanaka; Hai-Shu Lin
MOLECULES, Nov. 2013, Reviewed, No invitation

Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study
Yoshiya Tanaka; Shinichi Kawai; Tsutomu Takeuchi; Kazuhiko Yamamoto; Nobuyuki Miyasaka
MODERN RHEUMATOLOGY, Nov. 2013, Reviewed, No invitation

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Watanabe K; Sakai R; Koike R; Sakai F; Sugiyama H; Tanaka M; Komano Y; Akiyama Y; Mimura T; Kaneko M; Tokuda H; Iso T; Motegi M; Ikeda K; Nakajima H; Taki H; Kubota T; Kodama H; Sugii S; Kuroiwa T; Nawata Y; Shiozawa K; Ogata A; Sawada S; Matsukawa Y; Okazaki T; Mukai M; Iwahashi M; Saito K; Tanaka Y; Nanki T; Miyasaka N; Harigai M
Modern rheumatology, Nov. 2013, Reviewed, No invitation

Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
The Journal of rheumatology, Oct. 2013, Reviewed, No invitation

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
Keiichi Torimoto; Yosuke Okada; Hiroko Mori; Maiko Hajime; Kenichi Tanaka; Akira Kurozumi; Manabu Narisawa; Sunao Yamamoto; Tadashi Arao; Hirofumi Matsuoka; Nobuo Inokuchi; Yoshiya Tanaka
LIPIDS IN HEALTH AND DISEASE, Sep. 2013, Reviewed, No invitation

Dopamine D2-like receptor signaling suppresses human osteoclastogenesis
Kentaro Hanami; Kazuhisa Nakano; Kazuyoshi Saito; Yosuke Okada; Kunihiro Yamaoka; Satoshi Kubo; Masahiro Kondo; Yoshiya Tanaka
BONE, Sep. 2013, Reviewed, No invitation

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 we
Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D; GO-MONO study group
Annals of the rheumatic diseases, Sep. 2013, Reviewed, No invitation

A multi-biomarker score measures rheumatoid arthritis disease activity in the best study
Shintaro Hirata; Linda Dirven; Yijing Shen; Michael Centola; Guy Cavet; Willem F. Lems; Yoshiya Tanaka; Thomas W. J. Huizinga; Cornelia F. Allaart
Rheumatology (United Kingdom), Jul. 2013, Reviewed, No invitation

D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells
Tomoko Mori; Kenji Kabashima; Shoko Fukamachi; Etsushi Kuroda; Jun-ichi Sakabe; Miwa Kobayashi; Saeko Nakajima; Kazuhisa Nakano; Yoshiya Tanaka; Sho Matsushita; Motonobu Nakamura; Yoshiki Tokura
Journal of Dermatological Science, Jul. 2013, Reviewed, No invitation

Efficacy of -glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type2 diabetes mellitus by continuous glucose monitoring
Akira Kurozumi; Yosuke Okada; Hiroko Mori; Tadashi Arao; Yoshiya Tanaka
JOURNAL OF DIABETES INVESTIGATION, Jul. 2013, Reviewed, No invitation

Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
Hiroko Mori; Yosuke Okada; Yoshiya Tanaka
Diabetology International, Jun. 2013, Reviewed, No invitation

Osteoporosis
OKADA Yosuke; MORI Hiroko; TANAKA Yoshiya
Nihon Naika Gakkai Kaishi, Apr. 2013

[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment topics: I. Pathophysiology, diagnosis and treatment; 12. Osteoporosis].
Okada Y; Mori H; Tanaka Y
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, Apr. 2013, Reviewed, No invitation

Next stage of RA treatment: Is TNF inhibitor-free remission a possible treatment goal?
Yoshiya Tanaka
Annals of the Rheumatic Diseases, Apr. 2013, Reviewed, No invitation

Janus kinase inhibitors in autoimmune diseases
John J. O'Shea; Apostolos Kontzias; Kunihiro Yamaoka; Yoshiya Tanaka; Arian Laurence
ANNALS OF THE RHEUMATIC DISEASES, Apr. 2013, Reviewed, No invitation

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham 3rd; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Annals of the rheumatic diseases, Apr. 2013, Reviewed, No invitation

関節リウマチの治療 生物学的製剤(TNF阻害薬) 中等度活動性を有する関節リウマチ患者におけるエタネルセプト療法の有効性の検討 ENCOURAGE Study(ENBREL Outcome in RA patients for Growing Evidence):第I期(1年投与)の成績
山中 寿; 瀬戸 洋平; 長岡 章平; 西岡 雄一; 原岡 ひとみ; 笠間 毅; 齋藤 和義; 池田 啓; 植木 幸孝; 宗像 靖彦; 西成田 眞; 天野 宏一; 長嶺 隆二; 縄田 泰史; 田村 直人; 金物 壽久; 難波 大夫; 冨田 哲也; 田中 良哉; 竹内 勤; ENCOURAGE Studyグループ
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013

Diagnosis of early-stage rheumatoid arthritis: Usefulness of unenhanced and gadolinium-enhanced MR images at 3 T
Takatoshi Aoki; Yoshiko Yamashita; Kazuyoshi Saito; Yoshiya Tanaka; Yukunori Korogi
Clinical Imaging, Mar. 2013, Reviewed, No invitation

Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus
Tomoko Toyota; Naoki Akamatsu; Akihiro Tanaka; Taisaku Shouzaki; Sadatoshi Tsuji; Kazuyoshi Saito; Yoshiya Tanaka
Epilepsia, Mar. 2013, Reviewed, No invitation

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
Désirée Van Der Heijde; Yoshiya Tanaka; Roy Fleischmann; Edward Keystone; Joel Kremer; Cristiano Zerbini; Mario H. Cardiel; Stanley Cohen; Peter Nash; Yeong-Wook Song; Dana Tegzová; Bradley T. Wyman; David Gruben; Birgitta Benda; Gene Wallenstein; Sriram Krishnaswami; Samuel H. Zwillich; John D. Bradley; Carol A. Connell
Arthritis and Rheumatism, Mar. 2013, Reviewed, No invitation

Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) of the wrist and finger at 3T: Comparison with chemical shift selective fat suppression images
Takatoshi Aoki; Yoshiko Yamashita; Hodaka Oki; Hiroyuki Takahashi; Yoshiko Hayashida; Kazuyoshi Saito; Yoshiya Tanaka; Yukunori Korogi
Journal of Magnetic Resonance Imaging, Mar. 2013, Reviewed, No invitation

Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjogren's syndrome
Sunao Yamamoto; Yosuke Okada; Hiroko Mori; Shintaro Hirata; Kazuyoshi Saito; Nobuo Inokuchi; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Mar. 2013, Not reviewed, No invitation

Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus.
Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Katsuki A; Saito K; Tanaka Y; Nakamura J
Human psychopharmacology, Mar. 2013, Reviewed, No invitation

Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients.
Tsuboi H; Hagiwara S; Asashima H; Umehara H; Kawakami A; Nakamura H; Sano H; Tsubota K; Ogawa Y; Takamura E; Saito I; Inoue H; Nakamura S; Moriyama M; Takeuchi T; Tanaka Y; Hirata S; Mimori T; Matsumoto I; Sumida T
Modern rheumatology, Mar. 2013, Reviewed, No invitation

A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study.
Kameda H; Kanbe K; Sato E; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Yamanaka H; Takeuchi T; Japan Biological Agent; Integrated Consortium; JBASIC
Annals of the rheumatic diseases, Feb. 2013, Reviewed, No invitation

Erratum to: DNA methylome signature in rheumatoid arthritis
Firestein Gary S
Jpn. J. Clin. Immunol., 2013

P5-08  TofacitinibのRA患者末梢血リンパ球への影響 —治療効果，感染症発症の視点から—
園本 格士朗; 山岡 邦宏; 久保 智史; 前島 圭佑; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P6-06  Mesenchymal stem cells as an ideal cell therapy tool for rheumatoid arthritis in combination with nano-fiber scaffold
張 香梅; 山岡 邦宏; 園本 格士朗; 佐竹 真; 兼子 博章; 山本 由香; 近藤 真弘; 山形 薫; 趙 継東; 福興 俊介; 岡田 洋右; 田中 良哉
Jpn. J. Clin. Immunol., 2013

P6-04  SOX9のリン酸化抑制を介したIL-17によるヒト間葉系幹細胞の軟骨細胞分化抑制作用
近藤 真弘; 山岡 邦宏; 園本 格士朗; 福與 俊介; 尾下 浩一; 岡田 洋右; 田中 良哉
日本臨床免疫学会会誌, 2013

P9-13  既存治療抵抗性の多発血管炎性肉芽腫症（ウェゲナー肉芽腫症：GPA）にリツキシマブ（RTX）が奏功した1例
石川 雄一; 齋藤 和義; 中山田 真吾; 山田 彩; 齋藤 昌大; 吉成 紘子; 宮崎 佑介; 久保 智史; 福與 俊介; 園本 格士朗; 中野 和久; 山岡 邦宏; 田中 良哉
日本臨床免疫学会会誌, 2013

P5-10  関節リウマチにおけるヘルパーT細胞の病原性とアバタセプト治療反応性への関与
福與 俊介; 中山田 真吾; 岩田 慈; 久保 智史; 山岡 邦宏; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P5-07  JAK阻害薬tofacitinibはIRF7の発現抑制を介して樹状細胞のT細胞刺激能を抑制する
久保 智史; 山岡 邦宏; 近藤 真弘; 山形 薫; 趙 繼東; 岩田 慈; 田中 良哉
日本臨床免疫学会会誌, 2013

W1-1  Tfh細胞とTh1細胞の分化における可塑性とSLEにおけるヘルパーT細胞バランス異常
湯之上 直樹; 中山田 真吾; 久保 智史; 好川 真以子; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P1-05  P糖蛋白質発現CD69⁺CD4⁺cellのSLE臨床病態への関与
辻村 静代; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P1-04  全身性エリテマトーデスにおける樹状細胞-T細胞-B細胞軸の異常による病態形成
久保 智史; 中山田 真吾; 湯之上 直樹; 好川 真以子; Wang Sheau-Pey; 田中 良哉
日本臨床免疫学会会誌, 2013

W7-4  SLEに対するB細胞制御療法とリンパ球動態からみた病態の多様性
中山田 真吾; 岩田 慈; 好川 真以子; 久保 智史; 湯之上 直樹; 山岡 邦宏; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P1-06  Tfh細胞とTh1細胞の分化における可塑性とSLEにおけるヘルパーT細胞バランス異常
湯之上 直樹; 中山田 真吾; 久保 智史; 好川 真以子; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

P1-02  関節リウマチにおけるTh1/Th17様の形質を有する移行様濾胞性ヘルパーT細胞とその病原的役割
中山田 真吾; 久保 智史; 湯之上 直樹; 好川 真以子; Wang Sheau-Pey; 齋藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2013

Dopamine receptor signaling regulates human osteoclastogenesis
Kentaro Hanami; Kazuhisa Nakano; Yoshiya Tanaka
Japanese Journal of Clinical Immunology, 2013, Reviewed, No invitation

A case of multiple endocrine neoplasia 2B with probable ectopic adrenocorticotropic hormone-secreting liver metastasis from medullary thyroid carcinoma
Akira Kurozumi; Yosuke Okada; Tadashi Arao; Yuji Nakamoto; Kaori Togashi; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

Effect of metformin in elderly type 2 diabetes
Maiko Hajime; Yosuke Okada; Hiroko Mori; Tadashi Arao; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

Discontinuation of biologics in patients with rheumatoid arthritis
Yoshiya Tanaka; Shintaro Hirata; Benazir Saleem; Paul Emery
Clinical and Experimental Rheumatology, 2013, Reviewed, No invitation

Iatrogenic osteomalacia: Report of two cases
Sunao Yamamoto; Yosuke Okada; Hiroko Mori; Akira Kurozumi; Keiichi Torimoto; Tadashi Arao; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

Regulation of osteoclastogenesis by human mesenchymal stem cells leading to application of a novel treatment for rheumatoid arthritis
Koichi Oshita; Kunihiro Yamaoka; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension
Tadashi Arao; Yosuke Okada; Hiroko Mori; Keiko Nishida; Yoshiya Tanaka
Endocrine Journal, 2013, Reviewed, No invitation

A case of postural orthostatic tachycardia syndrome (POTS) with difficulties in differentiation from hypoglycemic attack
Akira Kurozumi; Yosuke Okada; Keiko Nishida; Sunao Yamamoto; Hiroko Mori; Tadashi Arao; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

Mutual interaction between vitamin d and lifestyle-related diseases in women
Hiroko Mori; Yosuke Okada; Yoshiya Tanaka
Journal of UOEH, 2013, Reviewed, No invitation

A case of multiple brown tumors with primary hyperparathyroidism
Hiroko Mori; Yosuke Okada; Tadashi Arao; Shohei Shimaziri; Yoshiya Tanaka
JOURNAL OF BONE AND MINERAL METABOLISM, Jan. 2013, Reviewed, No invitation

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus
Keiichi Torimoto; Yosuke Okada; Hiroko Mori; Yoshiya Tanaka
CARDIOVASCULAR DIABETOLOGY, Jan. 2013, Reviewed, No invitation

Juvenile-onset Hereditary Pheochromocytoma-paraganglioma Syndrome
Chiho Sugisawa; Yosuke Okada; Tadashi Arao; Hiroko Mori; Keiko Nishida; Kazumasa Isobe; Kazuhiro Takekoshi; Yoshiya Tanaka
INTERNAL MEDICINE, 2013, Reviewed, No invitation

Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes
Hiroko Mori; Yosuke Okada; Hirofumi Kishikawa; Nobuo Inokuchi; Hidekatsu Sugimoto; Yoshiya Tanaka
JOURNAL OF BONE AND MINERAL METABOLISM, Jan. 2013, Reviewed, No invitation

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
Shintaro Hirata; Kazuyoshi Saito; Satoshi Kubo; Shunsuke Fukuyo; Yasushi Mizuno; Shigeru Iwata; Masao Nawata; Norifumi Sawamukai; Kazuhisa Nakano; Kunihiro Yamaoka; Yoshiya Tanaka
ARTHRITIS RESEARCH & THERAPY, 2013, Not reviewed, No invitation

Extrapyramidal symptoms and advanced calcification of the basal ganglia in a patient with autosomal dominant hypocalcemia.
Kurozumi A; Okada Y; Arao T; Endou I; Matsumoto T; Tanaka Y
Internal medicine (Tokyo, Japan), 2013, Reviewed, No invitation

Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA (R) DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Hirata, Shintaro; Li, Wanying; Defranoux; Nadine A; Bolce, Rebecca; Sasso, Eric H; Kubo, Satoshi; Fukuyo, Shunsuke; Hanami, Kentaro; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya
ARTHRITIS AND RHEUMATISM, 2013, Not reviewed, No invitation

A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome
Keiichi Torimoto; Yosuke Okada; Tadashi Arao; Hiroko Mori; Yoshiya Tanaka
ENDOCRINE JOURNAL, Dec. 2012, Reviewed, No invitation

Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy
Shigeru Iwata; Kazuyoshi Saito; Shintaro Hirata; Yoshiya Tanaka
ANNALS OF THE RHEUMATIC DISEASES, Dec. 2012, Not reviewed, No invitation

Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
Modern rheumatology, Nov. 2012, Reviewed, No invitation

Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
Modern rheumatology, Nov. 2012, Reviewed, No invitation

Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
Michi Tanaka; Ryoko Sakai; Ryuji Koike; Yukiko Komano; Toshihiro Nanki; Fumikazu Sakai; Haruhito Sugiyama; Hidekazu Matsushima; Toshihisa Kojima; Shuji Ohta; Yoji Ishibe; Takuya Sawabe; Yasuhiro Ota; Kazuhisa Ohishi; Hajime Miyazato; Yoshinori Nonomura; Kazuyoshi Saito; Yoshiya Tanaka; Hayato Nagasawa; Tsutomu Takeuchi; Ayako Nakajima; Hideo Ohtsubo; Makoto Onishi; Yoshinori Goto; Hiroaki Dobashi; Nobuyuki Miyasaka; Masayoshi Harigai
Modern rheumatology, Nov. 2012, Reviewed, No invitation

Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
Michi Tanaka; Ryoko Sakai; Ryuji Koike; Yukiko Komano; Toshihiro Nanki; Fumikazu Sakai; Haruhito Sugiyama; Hidekazu Matsushima; Toshihisa Kojima; Shuji Ohta; Yoji Ishibe; Takuya Sawabe; Yasuhiro Ota; Kazuhisa Ohishi; Hajime Miyazato; Yoshinori Nonomura; Kazuyoshi Saito; Yoshiya Tanaka; Hayato Nagasawa; Tsutomu Takeuchi; Ayako Nakajima; Hideo Ohtsubo; Makoto Onishi; Yoshinori Goto; Hiroaki Dobashi; Nobuyuki Miyasaka; Masayoshi Harigai
Modern rheumatology, Nov. 2012, Reviewed, No invitation

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M; REAL Study Group
Annals of the rheumatic diseases, Nov. 2012, Reviewed, No invitation

Interleukin-1 beta induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway
Koshiro Sonomoto; Kunihiro Yamaoka; Koichi Oshita; Shunsuke Fukuyo; Xiangmei Zhang; Kazuhisa Nakano; Yosuke Okada; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2012, Reviewed, No invitation

Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results.
Yoshiya Tanaka; Shintaro Hirata; Shunsuke Fukuyo; Masao Nawata; Satoshi Kubo; Kunihiro Yamaoka; Kazuyoshi Saito
ARTHRITIS AND RHEUMATISM, Oct. 2012, Not reviewed, No invitation

Correlation of A Multi-Biomarker Disease Activity (VECTRA (TM) DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib.
Kunihiro Yamaoka; Satoshi Kubo; Koshiro Sonomoto; Shintaro Hirata; Guy Cavet; Rebecca Bolce; Michael W. Rowe; David Chernoff; Nadine Defranoux; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2012, Not reviewed, No invitation

A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Shintaro Hirata; Douglas J. Haney; Guy Cavet; Rebecca Bolce; Wanying Li; Nadine Defranoux; David Chernoff; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2012, Not reviewed, No invitation

[Diabetes mellitus and osteoporosis. Mutual interaction between bone and blood vessel in diabetes mellitus].
Mori H; Okada Y; Tanaka Y
Clinical calcium, Sep. 2012, Reviewed, No invitation

A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β₂ glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies.
Hirakawa E; Saito K; Hirata S; Atsumi T; Koike T; Tanaka Y
Modern rheumatology / the Japan Rheumatism Association, Sep. 2012, Reviewed, No invitation

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
Modern rheumatology, Aug. 2012, Reviewed, No invitation

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R; Komano Y; Tanaka M; Nanki T; Koike R; Nagasawa H; Amano K; Nakajima A; Atsumi T; Koike T; Ihata A; Ishigatsubo Y; Saito K; Tanaka Y; Ito S; Sumida T; Tohma S; Tamura N; Fujii T; Sugihara T; Kawakami A; Hagino N; Ueki Y; Hashiramoto A; Nagasaka K; Miyasaka N; Harigai M; Real Study Group
Arthritis care & research, Aug. 2012, Reviewed, No invitation

Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients
Hiroko Mori; Yosuke Okada; Tadashi Arao; Keiko Nishida; Yoshiya Tanaka
ADVANCES IN THERAPY, Jul. 2012, Reviewed, No invitation

Cell-autonomous role of TGF beta and IL-2 receptors in CD4(+) and CD8(+) inducible regulatory T-cell generation during GVHD
Norifumi Sawamukai; Atsushi Satake; Amanda M. Schmidt; Ian T. Lamborn; Priti Ojha; Yoshiya Tanaka; Taku Kambayashi
BLOOD, Jun. 2012, Reviewed, No invitation

Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation
Shigeru Iwata; Kunihiro Yamaoka; Hiroaki Niiro; Kazuhisa Nakano; Sheau-Pey Wang; Koichi Akashi; Yoshiya Tanaka
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Jun. 2012, Reviewed, No invitation

Thin-section chest CT findings in systemic lupus erythematosus with antiphospholipid syndrome: A comparison with systemic lupus erythematosus without antiphospholipid syndrome
Hodaka Oki; Takatoshi Aoki; Kazuyoshi Saito; Yoshiko Yamashita; Mai Hanamiya; Yoshiko Hayashida; Yoshiya Tanaka; Yukunori Korogi
EUROPEAN JOURNAL OF RADIOLOGY, Jun. 2012, Reviewed, No invitation

Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial
Nobuyuki Miyasaka; Masako Hara; Takao Koike; Eizo Saito; Masahito Yamada; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Jun. 2012, Reviewed, No invitation

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Yoshinaga T; Freundlich B; Suzukawa M
Rheumatology international, Jun. 2012, Reviewed, No invitation

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Yoshinaga T; Freundlich B; Suzukawa M
Rheumatology international, Jun. 2012, Reviewed, No invitation

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D; GO-FORTH Study Group
Annals of the rheumatic diseases, Jun. 2012, Reviewed, No invitation

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
Arthritis and rheumatism, Jun. 2012, Reviewed, No invitation

Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept
Yoshiya Tanaka; Hisashi Yamanaka; Kazuyoshi Saito; Shigeru Iwata; Ippei Miyagawa; Yohei Seto; Shigeki Momohara; Hayato Nagasawa; Hideto Kameda; Yuko Kaneko; Keisuke Izumi; Koichi Amano; Tsutomu Takeuchi
MODERN RHEUMATOLOGY, Apr. 2012, Reviewed, No invitation

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
Yoshiya Tanaka; Y. Maeshima; K. Yamaoka
Annals of the Rheumatic Diseases, Apr. 2012, Reviewed, No invitation

当科における甲状腺クリーゼ8症例の臨床的検討
新生 忠司; 岡田 洋右; 鳥本 桂一; 山本 直; 田中 良哉
内科, Mar. 2012

臨床経験 当科における甲状腺クリーゼ8症例の臨床的検討
新生 忠司; 岡田 洋右; 鳥本 桂一; 山本 直; 田中 良哉
内科, Mar. 2012

Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study.
Harigai M; Tanaka Y; Maisawa S; Study Group
The Journal of rheumatology, Mar. 2012, Reviewed, No invitation

Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
Hisanori Umehara; Kazuichi Okazaki; Yasufumi Masaki; Mitsuhiro Kawano; Motohisa Yamamoto; Takako Saeki; Shoko Matsui; Tadashi Yoshino; Shigeo Nakamura; Shigeyuki Kawa; Hideaki Hamano; Terumi Kamisawa; Toru Shimosegawa; Akira Shimatsu; Seiji Nakamura; Tetsuhide Ito; Kenji Notohara; Takayuki Sumida; Yoshiya Tanaka; Tsuneyo Mimori; Tsutomu Chiba; Michiaki Mishima; Toshifumi Hibi; Hirohito Tsubouchi; Kazuo Inui; Hirotaka Ohara
MODERN RHEUMATOLOGY, Feb. 2012, Reviewed, No invitation

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. Bingham; A. Ashrafzadeh; H. Travers; S. Safa-Leathers; S. Kumar; W. Dummer
Arthritis and Rheumatism, Feb. 2012, Reviewed, No invitation

A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Hisanori Umehara; Kazuichi Okazaki; Yasufumi Masaki; Mitsuhiro Kawano; Motohisa Yamamoto; Takako Saeki; Shoko Matsui; Takayuki Sumida; Tsuneyo Mimori; Yoshiya Tanaka; Kazuo Tsubota; Tadashi Yoshino; Shigeyuki Kawa; Ritsuro Suzuki; Tsutomu Takegami; Naohisa Tomosugi; Nozomu Kurose; Yasuhito Ishigaki; Atsushi Azumi; Masaru Kojima; Shigeo Nakamura; Dai Inoue
MODERN RHEUMATOLOGY, Feb. 2012, Reviewed, No invitation

P2-053  アバタセプト（ABT）の関節リウマチ（RA）疾患活動性制御および関節破壊防止効果（ALTAIR study）
久保 智史; 齋藤 和義; 平田 信太郎; 福與 俊介; 山岡 邦宏; 澤向 範文; 名和田 雅夫; 岩田 慈; 水野 泰志; 田中 良哉
日本臨床免疫学会会誌, 2012

P1-040  JAK阻害薬tofacitinibの樹状細胞を介した免疫応答調節機構
久保 智史; 山岡 邦宏; 岩田 慈; 田中 良哉
日本臨床免疫学会会誌, 2012

P1-010  RA患者のabatacept（ABT）治療によるT細胞およびB細胞への影響（ASET study）
福與 俊介; 岩田 慈; 山岡 邦宏; 斎藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2012

W8-5  Advanced delivery system of mesenchymal stem cells using nano-fiber scaffold for treatment of rheumatic arthritis models
張 香梅; 山岡 邦宏; 園本 格士朗; 近藤 真弘; 福興 俊介; 佐竹 真; 兼子 博章; 岡田 洋右; 中野 和久; 中山田 真吾; 田中 良哉
Jpn. J. Clin. Immunol., 2012

W9-4  濾胞性ヘルパーT細胞の分化における可塑性とエピゲノム制御機構
中山田 真吾; John O'Shea; 田中 良哉
日本臨床免疫学会会誌, 2012

MWS-2  B細胞活性化におけるSykの役割と自己免疫病態への関与
岩田 慈; 山岡 邦宏; 新納 宏昭; 中野 和久; ワン シャオペイ; 赤司 浩一; 田中 良哉
日本臨床免疫学会会誌, 2012

P2-093  関節リウマチにおけるB細胞上P糖蛋白質発現と薬剤抵抗性および組織侵襲性との関連
辻村 静代; 齋藤 和義; 田中 良哉; 笹栗 靖之
日本臨床免疫学会会誌, 2012

P2-077  ドパミン受容体シグナルによる破骨細胞の分化制御
花見 健太郎; 中野 和久; 山岡 邦宏; 斉藤 和義; 田中 良哉
日本臨床免疫学会会誌, 2012

Regulation of inflammation through JAK3-Stat6 pathway in dendritic cells
Kunihiro Yamaoka; Satoshi Kubo; Yoshiya Tanaka; Keisuke Maeshima
Japanese Journal of Clinical Immunology, 2012, Reviewed, No invitation

Involvement of Syk in pathology of systemic autoimmune disease
Shigeru Iwata; Kunihiro Yamaoka; Kazuhisa Nakano; Sheau-Pey Wang; Kazuyoshi Saito; Yoshiya Tanaka; Hiroaki Niiro; Koichi Akashi
Japanese Journal of Clinical Immunology, 2012, Reviewed, No invitation

antirheumatic effect of JAK-inhibitors
Kunihiro Yamaoka; Satoshi Kubo; Koshiro Sonomoto; Yoshiya Tanaka; Keisuke Maeshima
Japanese Journal of Clinical Immunology, 2012, Reviewed, No invitation

Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally
Reiji Yoshimura; Kosuke Saito; Tadanori Terada; Naoki Yunoue; Wakako Umene-Nakano; Shintaro Hirata; Kazuyoshi Saitoh; Yoshiya Tanaka; Jun Nakamura
ANNALS OF GENERAL PSYCHIATRY, Jan. 2012, Reviewed, No invitation

Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy
Hiroko Mori; Yosuke Okada; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
JOURNAL OF BONE AND MINERAL METABOLISM, Jan. 2012, Reviewed, No invitation

[Rheumatoid arthritis: progress in diagnosis and treatment. Topics: V. Evaluation; 2. Evaluation of joint destruction by plain X-ray in rheumatoid arthritis.
Hirata S; Tanaka Y
Nihon Naika Gakkai Zasshi, 2012, Not reviewed, No invitation

A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab.
Tanaka, Yoshiya; Hanami, Kentaro; Tasaka, Hisashi; Fukuyo, Shunsuke; Haney, Douglas J; Defranoux, Nadine; Bolce, Rebecca; Cavet, Guy; Chernoff, David; Yamaoka, Kunihiro; Saito, Kazuyoshi; Hirata, Shintaro
ARTHRITIS AND RHEUMATISM, 2012, Not reviewed, No invitation

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
Takeuchi, Tsutomu; Tanaka, Yoshiya; Kaneko, Yuko; Tanaka, Eiichi; Hirata, Shintaro; Kurasawa, Takahiko; Kubo, Satoshi; Saito, Kazuyoshi; Shidara, Kumi; Kimura, Noriko; Nagasawa, Hayato; Kameda, Hideto; Amano, Koichi; Yamanaka, Hisashi
MODERN RHEUMATOLOGY, 2012, Not reviewed, No invitation

Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
Internal medicine (Tokyo, Japan), 2012, Reviewed, No invitation

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Ito K; Yamanaka H
Annals of the rheumatic diseases, Dec. 2011, Reviewed, No invitation

Efficacy and Safety in Reducing the Dosage of Insulin Secretagogues with Addition of Pioglitazone in Patients with Type 2 Diabetes
MORI Hiroko; OKADA Yosuke; YOSHIMURA Akiko; ARAO Tadashi; NISHIDA Keiko; TANAKA Yoshiya
Journal of the Japan Diabetes Society, Oct. 2011

B cell targeting biologics for rheumatic diseases
SAITO Kazuyoshi; TANAKA Yoshiya
Nihon Naika Gakkai Kaishi, Oct. 2011

A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study
Cornelia F. Allaart; Linda Dirven; Shintaro Hirata; P. J. S. M. Kerstens; B. A. C. Dijkmans; David Chernoff; Guy Cavet; Michael Centola; Lyndal K. Hesterberg; Yoshiya Tanaka; T. W. J. Huizinga; Yijing Shen
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial
Shinichi Kawai; Tsutomu Takeuchi; Kazuhiko Yamamoto; Yoshiya Tanaka; Nobuyuki Miyasaka
MODERN RHEUMATOLOGY, Oct. 2011, Reviewed, No invitation

Discontinuation of Adalimumab Without Functional and Structural Progress After Attaining Remission in Patients with Rheumatoid Arthritis
Yoshiya Tanaka; Shintaro Hirata; Shunsuke Fukuyo; Masao Nawata; Satoshi Kubo; Kunihiro Yamaoka; Kazuyoshi Saito
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

A Multi-Biomarker Disease Activity Score (Vectra (TM) DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy
Shintaro Hirata; Douglas J. Haney; Guy Cavet; Lyndal K. Hesterberg; Norifumi Sawamukai; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

Tofacitinib Reduces Interferon-gamma and Interleukin-17 Production From CD4+T Cells in Patients with Rheumatoid Arthritis.
Satoshi Kubo; Kunihiro Yamaoka; Koshiro Sonomoto; Keisuke Maeshima; Shintaro Hirata; Kazuhisa Nakano; Norifumi Sawamukai; Masao Nawata; Shigeru Iwata; Kazuyoshi Saito; Yoshiya Tanaka
ARTHRITIS AND RHEUMATISM, Oct. 2011, Not reviewed, No invitation

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study
Takeuchi Tsutomu; Tanaka Yoshiya; Amano Koichi; Hoshi Daisuke; Nawata Masao; Nagasawa Hayato; Sato Eri; Saito Kazuyoshi; Kaneko Yuko; Fukuyo Shunsuke; Kurasawa Takahiko; Hanami Kentaro; Kameda Hideto; Yamanaka Hisashi
Rheumatology, Oct. 2011, Reviewed, No invitation

Remission Induction by Etanercept (ETN) Plus Methotrexate (MTX) Combination Therapy Versus ETN Monotherapy in Patients with Active Rheumatoid Arthritis Despite MTX Treatment
Kameda Hideto; Ueki Ukitaka; Saito Kazuyoshi; Nagaoka Shouhei; Hidaka Toshihiko; Atsumi Tatsuya; Tsukano Michishi; Kasama Tsuyoshi; Shiozawa Shunichi; Tanaka Yoshiya; Kanbe Katsuaki; Sato Eri; Yamanaka Hisashi; Takeuchi Tsutomu
ARTHRITIS AND RHEUMATISM, Oct. 2011, Reviewed, No invitation

Role of the MICA polymorphism in systemic lupus erythematosus.
Yoshida K; Komai K; Shiozawa K; Mashida A; Horiuchi T; Tanaka Y; Nose M; Hashiramoto A; Shiozawa S
Arthritis and rheumatism, Oct. 2011, Reviewed, No invitation

再生医学と免疫疾患 ヒト間葉系幹細胞による破骨細胞分化抑制作用の解析
尾下 浩一; 山岡 邦宏; 福與 俊介; 園本 格士朗; 岡田 洋右; 齋藤 和義; 宇田川 信之; 千葉 健治; 田中 良哉
日本臨床免疫学会会誌, Aug. 2011

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
Yoshiya Tanaka; Makoto Suzuki; Hiroyuki Nakamura; Shigeyuki Toyoizumi; Samuel H. Zwillich
Arthritis Care and Research, Aug. 2011, Reviewed, No invitation

Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study.
Kameda H; Kanbe K; Sato E; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Yamanaka H; Takeuchi T
The Journal of rheumatology, Aug. 2011, Reviewed, No invitation

Osteoprotegerin産生を介したヒト間葉系幹細胞の破骨細胞分化抑制作用
尾下 浩一; 山岡 邦宏; 宇田川 信之; 福與 俊介; 園本 格士朗; 岡田 洋右; 齋藤 和義; 千葉 健治; 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jul. 2011

Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method
Nobuo Morotomi; Kazumasa Fukuda; Masahiro Nakano; Sachiko Ichihara; Taichi Oono; Taiga Yamazaki; Noritada Kobayashi; Tatsuo Suzuki; Yoshiya Tanaka; Hatsumi Taniguchi
Biological and Pharmaceutical Bulletin, Jul. 2011, Reviewed, No invitation

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M; REAL Study Group
The Journal of rheumatology, Jul. 2011, Reviewed, No invitation

Effects of Combination Treatment of Alogliptin with Voglibose in Tipe 2 Diabetic Patients by Continuous Glucose Monitoring System
MORI H.; OKADA Y.; KUROZUMI A.; ARAO T.; NISHIDA K.; TANAKA Y.
Journal of the Japan Diabetes Society, Jun. 2011

ヒト間葉系幹細胞による破骨細胞分化抑制作用の解析
尾下 浩一; 山岡 邦宏; 宇田川 信之; 福與 俊介; 園本 格士朗; 岡田 洋右; 齋藤 和義; 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Jun. 2011

No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients
Atsuko Ikenouchi-Sugita; Reiji Yoshimura; Taro Kishi; Wakako Umene-Nakano; Hikaru Hori; Asuka Katsuki; Kazuyoshi Saito; Nakao Iwata; Yoshiya Tanaka; Jun Nakamura
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, Jun. 2011, Reviewed, No invitation

Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
Masaaki Hiura; Shintaro Abe; Akinari Tabaru; Shohei Shimajiri; Kentaro Hanami; Kazuyoshi Saito; Yoshiya Tanaka; Masaru Harada
HEPATOLOGY RESEARCH, May 2011, Reviewed, No invitation

Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Beh double dagger et's disease
Shigeru Iwata; Kazuyoshi Saito; Kunihiro Yamaoka; Shizuyo Tsujimura; Masao Nawata; Kentaro Hanami; Yoshiya Tanaka
MODERN RHEUMATOLOGY, Apr. 2011, Reviewed, No invitation

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan
Yamanaka Hisashi; Tanaka Yoshiya; Inoue Eisuke; Hoshi Daisuke; Momohara Shigeki; Hanami Kentaro; Yunoue Naoki; Saito Kazuyoshi; Amano Kouichi; Kameda Hideto; Takeuchi Tsutomu
Modern Rheumatology, Apr. 2011, Reviewed, No invitation

A Case of Severe Acute Pancreatitis Associated with Hypertriglyceridemia Caused by Soft Drink Ketoacidosis
YAMAMOTO S.; OKADA Y.; ARAO T.; NISHIDA K.; TANAKA Y.
Journal of the Japan Diabetes Society, Jan. 2011

S19-5 低分子量化合物を用いた治療の進歩(S19 関節リウマチの診療の革新的進歩,シンポジウム,第61回日本アレルギー学会秋季学術大会)
山岡 邦宏; 田中 良哉
アレルギー, 2011

Progress in b-cell targeting therapy for the treatment of systemic lupus erythematosus
Yoshiya Tanaka
Journal of UOEH, 2011, Reviewed, No invitation

Osteoprotegerin産生を介したヒト間葉系幹細胞の破骨細胞分化抑制作用
尾下 浩一; 山岡 邦宏; 福與 俊介; 園本 格士朗; 齋藤 和義; 岡田 洋右; 宇田川 信之; 田中 良哉
Inflammation and Regeneration, Jul. 2010

Osteoprotegerin産生を介したヒト間葉系幹細胞の破骨細胞分化抑制作用
尾下 浩一; 山岡 邦宏; 宇田川 信之; 福與 俊介; 園本 格士朗; 齋藤 和義; 岡田 洋右; 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jul. 2010

Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus.
Ikenouchi-Sugita A; Yoshimura R; Okamoto T; Umene-Nakano W; Ueda N; Hori H; Katsuki A; Saito K; Tanaka Y; Nakamura J
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, Mar. 2010, Reviewed, No invitation

EVS10-1 関節リウマチの治療の新展開 : インフリキシマブ治療による国内エビデンスから(EVS10 抗サイトカイン療法による炎症性疾患治療の進歩,イブニングシンポジウム,第60回日本アレルギー学会秋季学術大会)
田中 良哉
アレルギー, 2010

S5-5 膠原病における新規生物学的製剤治療戦略(S5 リウマチ性疾患の病態解明と新規治療法,シンポジウム,第60回日本アレルギー学会秋季学術大会)
齋藤 和義; 田中 良哉
アレルギー, 2010

[Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
Okada Y; Nawata M; Tanaka Y
Clinical calcium, Aug. 2009, Reviewed, No invitation

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Wolfgang Hueber; Beren H. Tomooka; Franak Batliwalla; Wentian Li; Paul A. Monach; Robert J. Tibshirani; Ronald F. Van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C. Genovese; Lars Klareskog; Peter K. Gregersen; William H. Robinson
Arthritis Research and Therapy, May 2009, Reviewed, No invitation

産業医と専門医との連携によるストレス過食性肥満への早期介入効果の検討
西田 啓子; 岡田 洋右; 児玉 直樹; 北村 拓朗; 梶木 繁之; 松永 京子; 田中 良哉
糖尿病, Apr. 2009

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients
Yukiko Komano; Masayoshi Harigai; Ryuji Koike; Haruhito Sugiyama; J. U.N. Ogawa; Kazuyoshi Saito; Naoya Sekiguchi; Masayuki Inoo; Ikuko Onishi; Hiroyuki Ohashi; Fujio Amamoto; Masayuki Miyata; Hideo Ohtsubo; Kazuko Hiramatsu; Masahiro Iwamoto; Seiji Minota; Naoki Matsuoka; Goichi Kageyama; Kazuyoshi Imaizumi; Hitoshi Tokuda; Yasumi Okochi; Koichiro Kudo; Yoshiya Tanaka; Tsutomu Takeuchi; Nobuyuki Miyasaka
Arthritis Care and Research, Mar. 2009, Reviewed, No invitation

The comparison of efficacy and safety between etanercept (ETN) plus methotrexate (MTX) combination therapy and ETN monotherapy in MTX-refractory Japanese patients with rheumatoid arthritis: 52-week clinical results from the JESMR study
Kameda Hideto; Ueki Yukitaka; Saito Kazuyoshi; Nagaoka Shouhei; Hidaka Toshihiko; Atsumi Tatsuya; Tsukano Michishi; Kasama Tsuyoshi; Shiozawa Shunichi; Tanaka Yoshiya; Takeuchi Tsutomu
ARTHRITIS AND RHEUMATISM, Sep. 2008, Reviewed, No invitation

TNF阻害治療で効果不十分の関節リウマチ患者に対するトシリズマブの有効性の検討
西本 憲弘; 美馬 亨; 田中 良哉; 齋藤 和義; 岩田 慈; 福與 俊介; 住田 孝之; 伊藤 聡; 佐伯 行彦; 大島 至郎; 佐伯 修; 宇田 裕史; 蓑田 清次; 岩本 雅弘; 藤原 弘士; 都留 智巳; 赤星 透; 遠藤 平仁
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2008

NPSLEにおける血中脳由来神経栄養因子(BDNF)の意義
杉田 篤子; 斎藤 和義; 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2008

S8-4 ループス腎炎の最近の治療戦略(膠原病の病態解明と新しい治療戦略,第58回日本アレルギー学会秋季学術大会)
齋藤 和義; 徳永 美貴子; 名和田 雅夫; 岩田 慈; 鈴木 克典; 辻村 静代; 田中 良哉
アレルギー, 2008

[Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
Okada Y; Nawata M; Tanaka Y
Clinical calcium, Nov. 2007, Reviewed, No invitation

A case of pulmonary infection with Mycobacterium chelonae in healthy breast-feeding woman
Katsunori Suzuki; Akihiro Matsuki; Kazuyoshi Saito; Yoshiya Tanaka
Kekkaku, Oct. 2007, Reviewed, No invitation

Erratum: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) (Modern Rheumatology (2007) vol. 17 (28-32) 10.1007/s10165-006-0532-0)
Hisashi Yamanaka; Yoshiya Tanaka; Naoya Sekiguchi; Eisuke Inoue; Kazuyoshi Saito; Hideto Kameda; Noriko Iikuni; Masao Nawata; Kouichi Amano; Mikiko Shinozaki; Tsutomu Takeuchi
Modern Rheumatology, Apr. 2007, Reviewed, No invitation

[Bisphosphonates for vascular calcification].
Tanaka Y; Okada Y
Clinical calcium, Mar. 2007, Reviewed, No invitation

[Erythropoietin resistant anemia and neutropenia due to copper deficiency during long-term enteral nutrition on maintained hemodialysis].
Shoichi Shimizu; Kohei Uriu; Ichiro Takagi; Shinichiro Mine; Shinichi Tounai; Masami Kuriyama; Etsuko Oda; Aya Tanaka; Yoshiya Tanaka; Junichi Tsukada
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, Jan. 2007

S5-2 抗CD20抗体による治療 : 基礎から臨床での新展開まで(B細胞をターゲットとした新しい自己免疫疾患の治療-基礎から臨床まで,シンポジウム,第57回日本アレルギー学会秋季学術大会)
田中 良哉
アレルギー, 2007

381 樹状細胞はドパミン合成・放出によりTh2分化偏向を誘導する(抗原提示細胞2・その他,一般演題(デジタルポスター),第57回日本アレルギー学会秋季学術大会)
中野 和久; 田中 良哉; 松下 祥
アレルギー, 2007

Treatment of inflammatory immunologic disease - 4. B cell targeting therapy using the Anti-CD20 antibody rituximab in inflammatory autoimmune diseases
Yoshiya Tanaka
INTERNAL MEDICINE, 2007, Reviewed, No invitation

[Diabetic vascular calcification and abnormal bone metabolism: the relation between bone and vascular].
Okada Y; Nishida K; Tanikawa T; Hashimoto O; Tanaka Y
Clinical calcium, Aug. 2006, Reviewed, No invitation

[Primary hyperparathyroidism complicated with flail chest due to severe osteoporosis].
Kanda K; Okada Y; Arao T; Tanaka Y; Kishikawa H
Clinical calcium, Apr. 2006, Reviewed, No invitation

S6-2 抗CD20抗体による全身性エリテマトーデスの治療の新展開(シンポジウム6 膠原病に対する治療法の新展開,第56回日本アレルギー学会秋季学術大会)
田中 良哉
アレルギー, 2006

3 神経精神SLEに対する抗CD20抗体リツキシマブの効果(イブニングシンポジウム9 膠原病について今知るべきこと,第18回日本アレルギー学会春季臨床大会)
田中 良哉
アレルギー, 2006

Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus
S Maeda; T Shuichi; A Kanazawa; A Sekine; T Tsunoda; D Koya; H Maegawa; A Kashiwagi; T Babazono; M Matsuda; Y Tanaka; T Fujioka; H Hirose; T Eguchi; Y Ohno; CJ Groves; AT Hattersley; GA Hitman; M Walker; K Kaku; Y Iwamoto; R Kawamori; R Kikkawa; N Kamatani; MI McCarthy; Y Nakamura
JOURNAL OF HUMAN GENETICS, 2005, Reviewed, No invitation

Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts.
Shingo Nakayamada; Hitoshi Kurose; Kazuyoshi Saito; Akira Mogami; Yoshiya Tanaka
Arthritis research & therapy, 2005

膠原病治療に於ける薬剤抵抗性の臨床と基礎
田中 良哉; 辻村 静代; 齋藤 和義
日本臨床免疫学会総会抄録集, 2005

4 SLEにおける抗CD20抗体療法(5 自己免疫疾患の新しい治療法, 第55回日本アレルギー学会秋季学術大会)
田中 良哉
アレルギー, 2005

Eosinophilic lung diseaseを合併したと考えられた血管免疫芽球型T細胞リンパ腫の1例
畠山 佳久; 渡辺 秀幸; 青木 隆敏; 川波 哲; 興梠 征典; 清水 少一; 塚田 順一; 田中 良哉
日本医学放射線学会雑誌, Nov. 2004

Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice
S Shimizu; H Nakashima; K Masutani; Y Inoue; K Miyake; M Akahoshi; Y Tanaka; K Egashira; H Hirakata; T Otsuka; M Harada
RHEUMATOLOGY, Sep. 2004, Reviewed, No invitation

関節リウマチ治療のこれからの流れ
田中 良哉
日本臨床免疫学会会誌 = Japanese journal of clinical immunology, Aug. 2004

Degenerate recognition and response of human CD4+ Th cell clones: implications for basic and applied immunology.
Nishimura Y; Chen YZ; Uemura Y; Tanaka Y; Tsukamoto H; Kanai T; Yokomizo H; Yun C; Matsuoka T; Irie A; Matsushita S
Molecular immunology, Feb. 2004, Reviewed, No invitation

RAに対するインフリキマブ療法の高反応群の分別化と骨代謝への影響
名和田 雅夫; 齋藤 和義; 藤井 幸一; 中山田 真吾; 中野 和久; 澤向 範文; 徳永 美貴子; 辻村 静代; 田中 良哉
日本臨床免疫学会総会抄録集, 2004

腎臓病医による長期腎不全治療が奏効すると腎不全進行を緩徐にするだけでなく晩期透析導入が可能となる―第４８回日本透析医学会コントラバシィより―:第48回日本透析医学会コントラバシィより
海津 嘉蔵; 瓜生 康平; 宮本 秀光; 高木 一郎; 稲田 良郁; 池田 匡儀; 伊藤 亜紀; 橋本 修; けき 月玲; 田中 良哉
日本透析医学会雑誌, 2004

1 全身性エリテマトーデス(SLE)の治療の進歩:新規生物学的製剤の可能性
田中 良哉
アレルギー, 2004

3 B細胞を標的とした治療(自己免疫疾患の新しい治療戦略)
田中 良哉
アレルギー, 2004

The International HapMap Project
RA Gibbs; JW Belmont; P Hardenbol; TD Willis; FL Yu; HM Yang; LY Ch'ang; W Huang; B Liu; Y Shen; PKH Tam; LC Tsui; MMY Waye; JTF Wong; CQ Zeng; QR Zhang; MS Chee; LM Galver; S Kruglyak; SS Murray; AR Oliphant; A Montpetit; TJ Hudson; F Chagnon; Ferretti, V; M Leboeuf; MS Phillips; A Verner; PY Kwok; SH Duan; DL Lind; RD Miller; JP Rice; NL Saccone; P Taillon-Miller; M Xiao; Y Nakamura; A Sekine; K Sorimachi; T Tanaka; Y Tanaka; T Tsunoda; E Yoshino; DR Bentley; P Deloukas; S Hunt; D Powell; D Altshuler; SB Gabriel; RZ Qiu; A Ken; GM Dunston; K Kato; N Niikawa; BM Knoppers; MW Foster; EW Clayton; VO Wang; J Watkin; RA Gibbs; JW Belmont; E Sodergren; GM Weinstock; RK Wilson; LL Fulton; J Rogers; BW Birren; H Han; HG Wang; M Godbout; JC Wallenburg; P L'Archeveque; G Bellemare; K Todani; T Fujita; S Tanaka; AL Holden; EH Lai; FS Collins; LD Brooks; JE McEwen; MS Guyer; E Jordan; JL Peterson; J Spiegel; LM Sung; LF Zacharia; K Kennedy; MG Dunn; R Seabrook; M Shillito; B Skene; JG Stewart; DL Valle; EW Clayton; LB Jorde; JW Belmont; A Chakravarti; MK Cho; T Duster; MW Foster; M Jasperse; BM Knoppers; PY Kwok; J Licinio; JC Long; PA Marshall; PN Ossorio; VO Wang; CN Rotimi; CDM Royal; P Spallone; SF Terry; ES Lander; EH Lai; DA Nickerson; GR Abecasis; D Altshuler; DR Bentley; M Boehnke; LR Cardon; MJ Daly; P Deloukas; JA Douglas; SB Gabriel; RR Hudson; TJ Hudson; L Kruglyak; PY Kwok; Y Nakamura; RL Nussbaum; CDM Royal; SF Schaffner; ST Sherry; LD Stein; T Tanaka
NATURE, Dec. 2003, Reviewed, No invitation

免疫学的ツールの臨床応用 : オーバービュー
田中 良哉
日本臨床免疫学会会誌 = Japanese journal of clinical immunology, Aug. 2003

[Prevention and treatment of glucocorticoid-induced osteoporosis].
Tanaka Y; Okada Y
Clinical calcium, Jun. 2003, Reviewed, No invitation

Hepatobiliary and pancreatic: Porcelain gallbladder
H Nakashima; Y Tanaka
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Nov. 2002, Reviewed, No invitation

Cell-to-cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1 alpha,25(OH)(2)D-3, PTH and IL-1 alpha-induced osteoclast differentiation and bone resorption
Y Okada; Morimoto, I; K Ura; K Watanabe; S Eto; M Kumegawa; L Raisz; C Pilbeam; Y Tanaka
ENDOCRINE JOURNAL, Aug. 2002, Reviewed, No invitation

[Not Available].
Tanaka Y; Okada Y; Tsukada J
Clinical calcium, Apr. 2002, Reviewed, No invitation

Association between IL-4 genotype and IL-4 production in the Japanese population
H. Nakashima; K. Miyake; Y. Inoue; S. Shimizu; M. Akahoshi; Y. Tanaka; T. Otsuka; M. Harada
Genes and Immunity, Apr. 2002, Reviewed, No invitation

Autocrine induction of the human pro-IL-1 beta gene promoter by IL-1 beta in monocytes
Y Toda; J Tsukada; M Misago; Y Kominato; PE Auron; Y Tanaka
JOURNAL OF IMMUNOLOGY, Feb. 2002, Reviewed, No invitation

Camurati-Engelmann disease type II: Progressive diaphyseal dysplasia with striations of the bones
G Nishimura; H Nishimura; Y Tanaka; Y Makita; S Ikegawa; M Ghadami; A Kinoshita; N Niikawa
AMERICAN JOURNAL OF MEDICAL GENETICS, Jan. 2002, Reviewed, No invitation

Role for adapter proteins in costimulatory signals of CD2 and IL-2 on NK cell activation
Hisanori Umehara; Hiroshi Inoue; Jianyong Huang; Takeshi Kono; Yasuhiro Minami; Yoshiya Tanaka; Toshiro Okazaki; Tsuneyo Mimori; Eda T Bloom; Naochika Domae
Molecular Immunology, 2002, Reviewed, No invitation

A case of rheumatoid arthritis with secondary amyloidosis in urinary bladder
Shingo Nakayamada; Kazuyoshi Saito; Keisuke Nakatsuka; Kazuhisa Nakano; Mikiko Tokunaga; Shizuyo Tsujimura; Toshiyuki Ota; Yoshiya Tanaka
Ryumachi, 2002, Reviewed, No invitation

アデノウィルスベクターを用いたDominant Negative Ras遺伝子の導入による炎症性骨関節破壊の抑制
山本愛一郎; 十字琢夫; 宮崎剛; 門野夕峰; 片桐秀樹; 田中良哉; 仲村一郎; 織田弘美; 中村耕三; 田中栄
日本整形外科学会雑誌, Aug. 2001, Reviewed, No invitation

Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8
Y Hirashima; H Kobayashi; M Suzuki; Y Tanaka; N Kanayama; M Fujie; T Nishida; M Takigawa; T Terao
JOURNAL OF BIOLOGICAL CHEMISTRY, Apr. 2001, Not reviewed, No invitation

Regulation of glucose transporter 1 expression by gliclazide in rat L6 myoblasts
H. Imamura; I. Morimoto; Y. Tanaka; O. Hashimoto; K. Kanda; S. Yamashita; S. Eto
Diabetes, Nutrition and Metabolism - Clinical and Experimental, 2001, Reviewed, No invitation

Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis - Involvement of cell cycle machinery
Y Tanaka; M Nomi; K Fujii; S Hubscher; A Maruo; S Matsumoto; Y Awazu; K Saito; S Eto; Y Minami
ARTHRITIS AND RHEUMATISM, Nov. 2000, Reviewed, No invitation

慢性関節リウマチ滑膜細胞の活性化及びサイトカイン産生におけるRas-MAPキナーゼ系の関与
山本愛一郎; 田中栄; 片桐秀樹; 宮崎剛; 高柳広; 門野夕峰; 仲村一郎; 田中良哉; 織田弘美; 中村耕三
日本整形外科学会雑誌, Aug. 2000, Reviewed, No invitation

A case of systemic lupus erythemotosus with pulmonary hypertension
K. Nakano; Y. Tanaka; M. Aso; K. Saito; K. Fujii; A. Takazawa; T. Ota
Ryumachi, 2000, Reviewed, No invitation

Thyrocyte proliferation by cellular adhesion to infiltrating lymphocytes through the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 pathway in Graves' disease
T Arao; Morimoto, I; A Kakinuma; O Ishida; K Zeki; Y Tanaka; N Ishikawa; K Ito; K Ito; S Eto
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Jan. 2000, Reviewed, No invitation

New classification of capsular block syndrome
K. Miyake; I. Ota; S. Ichihashi; S. Miyake; Y. Tanaka; H. Terasaki
Journal of Cataract and Refractive Surgery, 1998, Reviewed, No invitation

cell lines reactive with a self-K-ras-derived peptide in vitro, using a mAb to CD29
Tanaka, Y; Ogawa, M; Nishimura, Y; Matsushita,Sanaka, Y; Ogawa, M; Nishimura, Y; Matsushita,S
Human Immunol., 1998, Reviewed, No invitation

Rheumatoid synovial fibroblasts are stimulated by the cellular adhesion to T cells through lymphocyte function associated antigen-1 intercellular adhesion molecule-1
K Nakatsuka; Y Tanaka; S Hubscher; M Abe; A Wake; K Saito; Morimoto, I; S Eto
JOURNAL OF RHEUMATOLOGY, Mar. 1997, Reviewed, No invitation

The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis
K. Ohta; S. Sawamoto; M. Nakajima; S. Kubota; Y. Tanaka; T. Miyasaka; A. Nagai; K. Hirai; K. Mano; H. Miyashita
Clinical and Experimental Allergy, Supplement, Mar. 1996, Reviewed, No invitation

Activation of sympathetic outflow by recombinant human interleukin-1 beta in conscious rats
H Kannan; Y Tanaka; T Kunitake; Y Ueta; Y Hayashida; H Yamashita
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, Feb. 1996, Reviewed, No invitation

3. IL-1β遺伝子発現における転写開始調節機構の解析 (<シンポジウム>7 サイトカイン産生の遺伝子コントロール)
齊藤 和義; 白川 文彦; 塚田 順一; 田中 良哉; 江藤 澄哉
アレルギー, 1996

CYCLIC AMP-ELEVATING AGENTS NEGATIVELY REGULATE THE ACTIVATION OF P72(SYK) IN N-FORMYL-METHIONYL-LEUCYL-PHENYLALANINE RECEPTOR SIGNALING
M ASAHI; Y TANAKA; SF QIN; M TSUBOKAWA; K SADA; Y MINAMI; H YAMAMURA
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Jul. 1995, Reviewed, No invitation

EXPRESSION OF FOS-PROTEIN ACTIVATED BY TACTILE STIMULATION ON THE LARYNGEAL VESTIBULUM IN THE CATS LOWER BRAIN-STEM
Y TANAKA; Y YOSHIDA; M HIRANO
JOURNAL OF LARYNGOLOGY AND OTOLOGY, Jan. 1995, Reviewed, No invitation

PROADHESIVE CYTOKINE IMMOBILIZED ON ENDOTHELIAL PROTEOGLYCAN - A NEW PARADIGM FOR RECRUITMENT OF T-CELLS
Y TANAKA; DH ADAMS; S SHAW
CELLULAR ADHESION, 1994, Reviewed, No invitation

REGULATION OF T-CELL ADHESION WITH T-CELL DIFFERENTIATION AND WITH ACUTE ACTIVATION BY MIP-1-BETA CYTOKINE IMMOBILIZED ON CD44 PROTEOGLYCAN
Y TANAKA; DH ADAMS; T SCHWEIGHOFFER; S SHAW
CELL ADHESION MOLECULES, 1993, Reviewed, No invitation

T-CELL ADHESION CASCADES - GENERAL-CONSIDERATIONS AND ILLUSTRATION WITH CD31
Y TANAKA; S SHAW
MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION IV, 1992, Reviewed, No invitation

Production of B cell stimulating factors (BSF) by B cells in SLE patients
Y. Tanaka; K. Saito; T. Ota; S. Eto; U. Yamashita
International Journal of Immunopharmacology, 1988, Reviewed, No invitation

Effect of interleukin 1 (IL 1) on T cell activation in vivo
U. Yamashita; Y. Tanaka
International Journal of Immunopharmacology, 1988, Reviewed, No invitation

Relationship between extraluminal oxyhemoglobin and endothelium-dependent vasodilatation in isolated perfused canine internal carotid arteries
Y. Tanaka; S. Chiba
Neurosurgery, 1988, Reviewed, No invitation

Potentiating effects of extraluminal oxyhemoglobin to intraluminal 5-hydroxytryptamine in isolated canine internal carotid arteries
Y. Tanaka; S. Chiba
Journal of Neurosurgery, 1988, Reviewed, No invitation

A ganglioside of rat ascites hepatoma AH 7974F cells. Occurrence of a novel disialoganglioside (G(D1α)) with a unique N-acetylneuraminosyl(α2-6)-N-acetylgalactosamine structure
T. Taki; Y. Hirabayashi; H. Ishikawa; S. Ando; K. Kon; Y. Tanaka; M. Matsumoto
Journal of Biological Chemistry, 1986, Reviewed, No invitation

A comparative anatomical study of 3 different intestinal spleens and their significances in vertebrate hematopoiesis
Y. Tanaka; Y. Saito
Acta Haematologica Japonica, 1982, Reviewed, No invitation

リウマチ性疾患の諸症状に対する新たな試み　RAにおけるビスフォスフォネート製剤
田中 良哉
Arthritis-運動器疾患と炎症-, Dec. 2005, Reviewed, Null
Lead

【膠原病診療と分子標的薬update】全身性エリテマトーデスの分子標的薬
中山田 真吾, 田中 良哉
BIO Clinica, Feb. 2024, Reviewed, No invitation
Last

【骨代謝マーカーIV】骨代謝マーカー(骨代謝関連検査を含む)にいま求められていること　関節リウマチ診療における骨代謝マーカーの意義
田中 良哉
THE BONE, Jan. 2020, Reviewed, No invitation
Lead

【Treat to Targetと最新の骨粗鬆症診断・治療】Treat to Targetの基本的な考え方
田中 良哉
THE BONE, Feb. 2019, Reviewed, No invitation
Lead

骨ミネラル代謝研究・臨床における国内外の動向
田中 良哉, 遠藤 直人, 杉本 利嗣, 伊東 昌子
THE BONE, Apr. 2018, Reviewed, No invitation
Lead

骨ミネラル代謝研究・臨床における国内外の動向
田中良哉, 遠藤直人, 杉本利嗣, 伊東昌子
THE BONE, Apr. 2018, Reviewed, No invitation
Lead

【骨免疫学の進歩が変える骨関節疾患アプローチ】 骨免疫学と新たな治療への展望　骨髄由来間葉系幹細胞を用いた骨関節疾患治療
田中 良哉
THE BONE, Jul. 2017, Not reviewed, Null
Lead

【骨粗鬆症関連ガイドラインと日常診療】 続発性骨粗鬆症の診断、治療　治療関連骨粗鬆症　ステロイド性骨粗鬆症
田中 良哉
THE BONE, Mar. 2016, Null, Null
Lead

【中枢神経の自己免疫性・炎症性疾患ハンドブック】(第1章)治療法概論　分子標的薬の使い方
田中 良哉
BRAIN and NERVE: 神経研究の進歩, May 2021, Reviewed, No invitation
Lead

【NPSLE】NPSLEの臨床　膠原病内科の立場から
田中 良哉
BRAIN and NERVE: 神経研究の進歩, May 2019, Reviewed, No invitation
Lead

【自己免疫性脳炎・脳症】 SLE脳症
田中 良哉
BRAIN and NERVE: 神経研究の進歩, Sep. 2016, Null, Null
Lead

【骨粗鬆症の診断と治療update】 ステロイド性骨粗鬆症
田中 良哉
Bone Joint Nerve, Jan. 2016, Null, Null
Lead

シタグリプチン50mgからミチグリニド/ボグリボース配合錠への変更が有用であった2型糖尿病の1例
新生 忠司, 岡田 洋右, 須貝 慧, 鳥本 桂一, 田中 良哉
Calm, Jul. 2017, Not reviewed, Null
Last

Case Study　ビルダグリプチンとミチグリニド/ボグリボース配合錠の併用による食後の血糖改善効果をCGMにより確認した一例
久能 芙美, 岡田 洋右, 鳥本 桂一, 田中 良哉
Calm, Jan. 2016, Null, Null
Corresponding

【関節リウマチの診断・治療法の進歩:ベストプラクティスを目指して】 関節リウマチ治療に伴う免疫フェノタイプの変化
中山田 真吾, 田中 良哉
Clinical Calcium, Apr. 2018, Reviewed, Null
Corresponding

【運動器系の制御機構と破綻】関節リウマチの治療法の進歩
田中良哉
Clinical Calcium, Apr. 2018, Reviewed, No invitation
Lead

【続発性骨粗鬆症】 関節リウマチにおける骨代謝異常
中野 和久, 岡田 洋右, 田中 良哉
Clinical Calcium, Nov. 2018, Reviewed, Null
Corresponding

【骨リモデリング制御と疾患】 不動化と骨リモデリング異常
塚本 学, 酒井 昭典
Clinical Calcium, Nov. 2017, Reviewed, Invited

【糖尿病と骨疾患】　糖尿病性血管石灰化と骨代謝異常　骨血管相関
岡田 洋右, 西田 啓子, 谷川 隆久, 橋本 修, 田中 良哉
Clinical Calcium, Jul. 2006, Reviewed, Null
Last, Corresponding

【骨代謝疾患の成因と治療　基礎と臨床をつなぐもの】　関節リウマチの発症メカニズムと治療の新展開
田中 良哉
Clinical Calcium, Jul. 2005, Reviewed, No invitation
Lead

重症成人成長ホルモン分泌不全症における成長ホルモン補充療法による治療1年後の糖代謝への影響に関する検討
新生 忠司, 岡田 洋右, 成澤 学, 鳥本 桂一, 田中 良哉
Diabetes Frontier, Oct. 2017, Reviewed, Null
Last

リラグルチドのインスリン併用療法における有効性および安全性の検討
五嶋 由紀子, 岡田 洋右, 鳥本 桂一, 田中 良哉
Diabetes Frontier, Aug. 2017, Reviewed, Null
Last

精神疾患を合併した病的肥満症に対する認知行動療法の有用性とその適応
新生 忠司, 岡田 洋右, 成澤 学, 西田 啓子, 田中 良哉
Diabetes Frontier, Feb. 2016, Null, Null
Corresponding

糖尿病合併高血圧患者の外来随時血圧,早朝家庭血圧およびインスリン抵抗性の改善に関するテルミサルタンの効果の検討
新生 忠司, 岡田 洋右, 廣瀬 暁子, 神田 加壽子, 森田 恵美子, 森山 裕之, 田中 良哉
Diabetes Frontier, Jun. 2006, Reviewed, No invitation
Last

糖尿病患者の総胆管結石に伴う胆管炎にMRCPが早期診断に有用であった1例
新生 忠司, 岡田 洋右, 鳥本 桂一, 西田 啓子, 田中 良哉
Diabetes Journal: 糖尿病と代謝, Dec. 2016, Null, Null
Corresponding

【高齢者におけるリウマチと膠原病】関節リウマチの治療と管理
田中 良哉
Geriatric Medicine, Dec. 2019, Reviewed, No invitation
Lead

【高齢者とリウマチ性疾患】　関節リウマチの薬物療法
田中 良哉
Geriatric Medicine, Jun. 2005, Null, Null

生物学的製剤による関節リウマチ治療のパラダイムシフト
田中 良哉
Inflammation and Regeneration, Jul. 2006, Null, Null

マスト細胞由来トリプターゼによる関節リウマチ滑膜組織の炎症病態遷延化機構
澤向 範文, 齋藤 和義, 山岡 邦宏, 中山田 真吾, 田中 良哉
Inflammation and Regeneration, Jul. 2006, Null, Null

免疫抑制薬による炎症性疾患の治療　治療抵抗性SLEの免疫抑制薬療法
田中 良哉
Inflammation and Regeneration, Jul. 2006, Null, Null

生物学的製剤による炎症制御の現状と展望　全身性エリテマトーデス
田中 良哉
Inflammation and Regeneration, Jul. 2006, Null, Null

手の関節リウマチ診断におけるトモシンセシスの有用性
青木 隆敏, 山下 慶子, 大木 穂高, 林田 佳子, 高橋 広行, 興梠 征典, 齋藤 和義, 田中 良哉
Japanese Journal of Radiology, Feb. 2013, Null, Null

JAK阻害薬の最新研究：　2年間の関節破壊抑制効果からみた適正使用
田中良哉
Joint and Kinase Frontier, May 2020, Reviewed, No invitation
Lead

JAK阻害薬の安全性
田中良哉
Joint and Kinase Frontier, May 2019, Reviewed, No invitation
Lead

JAK阻害薬は新たなパラダイムシフトをもたらすか？
田中良哉
Joint and Kinase Frontier, Apr. 2018, Reviewed, Null
Lead

【関節リウマチのプレクリニカルステージ】 エピジェネティクスからみたRAの発症要因
河邊 明男, 中野 和久, 田中 良哉
Keynote R・A, Apr. 2017, Not reviewed, Null
Last

【関節リウマチ滑膜のbiology update】 関節リウマチ滑膜におけるDNAメチル化とTET分子
中野 和久, 田中 良哉
Keynote R・A, Jan. 2017, Reviewed, Null
Corresponding

【『グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン2023』を読み解く】クリニカルクエスチョン　骨粗鬆症薬剤間で有用性に相違は認められるか?
岡田 洋右, 田中 良哉
Loco Cure, Nov. 2024, Reviewed, No invitation
Last

【『グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン2023』を読み解く】
田中 良哉, 平田 信太郎, 宗圓 聰
Loco Cure, Nov. 2024, Reviewed, No invitation
Lead

GVHD発症における炎症性サイトカインパラダイム　マクロファージにおける炎症性サイトカイン産生の意義
塚田 順一, 田中 良哉
MHC: Major Histocompatibility Complex, May 2005, Null, Null

【関節リウマチ診療のup to date 2017】 バイオシミラーの現状
田中 良哉
Mebio, Apr. 2017, Not reviewed, Null
Lead

【リウマチ　最新治療のトピックス】　全身性エリテマトーデスを抗CD20抗体で治療する
田中 良哉
Mebio, Apr. 2005, Null, Null

グルココルチコイド誘発性骨粗鬆症の特徴とその診療
田中良哉
Medical Practice, Jul. 2024, Reviewed, No invitation
Lead

【骨粗鬆症　内科医に求められる骨粗鬆症診療】骨粗鬆症患者の発見・鑑別・診療科間の連携をめぐる話題　グルココルチコイド誘発性骨粗鬆症の特徴とその診療
田中 良哉
Medical Practice, Jul. 2024, Reviewed, No invitation
Lead

【関節リウマチ「真の寛解」と「安全性」を目指す治療】実地医家が知っておくべき関節リウマチの最新治療　T細胞選択的共刺激調整薬(CTLA4-Ig)
久保 智史, 田中 良哉
Medical Practice, Jul. 2019, Reviewed, No invitation

【膠原病　膠原病診療のPearls and Myths】 治療　実地医家が知っておくべき膠原病治療のPearls and Myths　膠原病に対する新規分子標的療法
中山田 真吾, 田中 良哉
Medical Practice, Jun. 2018, Reviewed, Null
Corresponding

【骨粗鬆症　最新の知見をもとにした骨折予防と先制医療への応用】最新の実地診療のポイントの整理と活用　ステロイド性骨粗鬆症の診断と治療
田中良哉
Medical Practice, Nov. 2018, Reviewed, No invitation
Lead

【最新のガイドラインを生かした日常内科診療-その充実とレベルアップを目指して-】 免疫・膠原病　関節リウマチの薬物治療
田中 良哉
Medical Practice, Apr. 2016, Null, Null
Lead

【膠原病　膠原病の新たな治療戦略とその実際】　膠原病へのアプローチその3　全身性エリテマトーデスの最新治療とその有用性
田中 良哉
Medical Practice, Apr. 2006, Null, Null

【自己免疫疾患Up to Date】 自己免疫疾患の分子標的治療Up to date
田中 良哉
Medical Science Digest, Nov. 2017, Not reviewed, Null
Lead

【抗体療法の現状と展望】　膠原病に対する抗TNF,抗CD20抗体療法
田中 良哉
Medical Science Digest, Dec. 2005, Null, Null

【膠原病・自己免疫疾患を「見える化」する】臨床から見える化する　強皮症　強皮症における微小血管障害を見える化する
久保 智史, 田中 良哉
Medicina, Nov. 2020, Reviewed, No invitation
Last

【ベッドサイドの免疫学　免疫疾患に強くなるために】　知っておきたい免疫疾患のトピックス　薬物療法のトピックス　生物学的製剤による抗細胞表面分子療法
田中 良哉
Medicina, Jun. 2006, Null, Null

内科疾患における生物学的製剤の使い分け
田中良哉
Modern Physician, Sep. 2018, Reviewed, No invitation
Lead

【内科疾患における生物学的製剤の使い分け】 《生物学的製剤を極める》　ベリムマブ
久保 智史, 田中 良哉
Modern Physician, Sep. 2018, Reviewed, Null
Corresponding

【内科疾患における生物学的製剤の使い分け】《生物学的製剤を極める》　リツキシマブ
岩田慈, 田中良哉
Modern Physician, Sep. 2018, Reviewed, No invitation

私の処方　抗リウマチ薬抵抗性関節リウマチの治療
齋藤 和義, 田中 良哉
Modern Physician, Jan. 2006, Null, Null

【管理不良関節リウマチのコントロール　生物学的製剤時代のアプローチ】　管理不良関節リウマチのコントロール　薬物療法からのアプローチ　わが国初の生物学的製剤インフリキシマブの有効性と注意点
齋藤 和義, 田中 良哉
Modern Physician, Jun. 2005, Null, Null

診療の秘訣　CD20抗体(rituximab)療法の奇跡　難治性全身性エリテマトーデスに対するCD20抗体の著効例の経験より
齋藤 和義, 田中 良哉
Modern Physician, Dec. 2005, Null, Null

Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
Tanaka Y,Yamazaki K,Nakajima R,Komatsu S,Igarashi A,Tango T,Takeuchi T.
Modern Rheumatology, Apr. 2018, Reviewed, No invitation
Lead

大量ステロイド投与による骨粗鬆症に対するアレンドロネートの一次予防効果
岡田 洋右, 斉藤 和義, 中山田 真吾, 名和田 雅夫, 田中 良哉
Osteoporosis Japan, Jan. 2006, Null, Null

大量ステロイド投与による骨粗鬆症に対するアレンドロネートの一次予防効果
岡田 洋右, 斎藤 和義, 中山田 真吾, 名和田 雅夫, 田中 良哉
Osteoporosis Japan, Sep. 2005, Null, Null

関節リウマチに対する抗TNFα抗体の骨代謝調節機序
名和田 雅夫, 岡田 洋右, 中山田 真吾, 齋藤 和義, 田中 良哉
Osteoporosis Japan, May 2005, Null, Null

【ステロイド性骨粗鬆症　病態と治療のUpdate】　ステロイド性骨粗鬆症における一次予防
岡田 洋右, 田中 良哉
Osteoporosis Japan, May 2005, Null, Null

【免疫疾患治療を変える新たな治療標的】全身性エリテマトーデス
中山田 真吾, 田中 良哉
Pharma Medica, Mar. 2025, Reviewed, No invitation
Last

病気について知りたい!　臨床講座　関節リウマチ
田中良哉
PharmaTribune, Apr. 2018, Reviewed, No invitation
Lead

【自己免疫疾患の個別化医療】全身性エリテマトーデスのprecision medicine
中山田 真吾, 田中 良哉
Precision Medicine, Jan. 2019, Reviewed, No invitation
Last

膠原病・リウマチ科
中山田真吾、田中良哉
RP.＋, 2023, Reviewed, No invitation
Last

Rheumatology Q&A　画像が明かす診断と治療のポイント(第11回)　鑑別すべき肺疾患について
平田 信太郎, 田中 宏明, 中野 和久, 田中 良哉
Rheumatology Clinical Research, Apr. 2016, Null, Null
Corresponding

【膠原病疾患の治療の最新情報】 B細胞標的治療
中山田 真吾, 田中 良哉
Rheumatology Clinical Research, Apr. 2016, Null, Null
Corresponding

【飲むステロイド　最強の切り札にする「はじめの一歩」】投与方法イロイロ!　経口グルココルチコイドの投与設計　膠原病・リウマチ科
中山田 真吾, 田中 良哉
Rp.+, Jul. 2023, Reviewed, No invitation
Last

膠原病に対する治療法の新展開 抗CD20抗体による全身性エリテマトーデスの治療の新展開
田中 良哉
アレルギー, Sep. 2006, Null, Null

膠原病について今知るべきこと　神経精神SLEに対する抗CD20抗体リツキシマブの効果
田中 良哉
アレルギー, Apr. 2006, Null, Null

自己免疫疾患の新しい治療法　SLEにおける抗CD20抗体療法
田中 良哉
アレルギー, Sep. 2005, Null, Null

ヒトB細胞分化におけるアミノ酸を介した免疫代謝機構の解明　SLE新規治療の創出
岩田 慈, 田中 良哉
アレルギーの臨床, Feb. 2021, Reviewed, No invitation
Last

【アレルギー・自己免疫疾患の治療と生物学的製剤】　抗CD20抗体
田中 良哉
アレルギーの臨床, Jul. 2005, Null, Null

自己免疫疾患の抗体治療の現況
田中 良哉
アレルギー科, May 2006, Null, Null

【IgG4関連疾患-診断と治療の最新動向】Key words　IgG4関連疾患の末梢血リンパ球フェノタイプ
中山田 真吾, 田中 良哉
カレントテラピー, Jul. 2020, Reviewed, No invitation

【リウマチ・膠原病-病態に基づいた治療戦略】末梢血リンパ球サブセットによる病態解析と臨床応用
中山田 真吾, 宮川 一平, 久保 智史, 田中 良哉
カレントテラピー, May 2020, Reviewed, No invitation
Last

【新時代を切り拓く自己免疫疾患治療〜平成から令和へ〜】関節リウマチ治療update
田中 良哉
クリニシアン, Dec. 2020, Reviewed, No invitation
Lead

【令和新時代の医療トピックス】関節リウマチの早期治療
田中 良哉
クリニシアン, Jan. 2020, Reviewed, No invitation
Lead

【Immunology〜領域を超えた挑戦〜】RA領域　リウマチ医から見た乾癬性関節炎と生物学的製剤を用いたprecision medicine
宮川一平, 田中良哉
クリニシアン, Oct. 2018, Reviewed, No invitation

関節リウマチへの早期積極的治療介入とtreatment holiday
田中 良哉
クリニシアン, Jan. 2017, Reviewed, Null
Lead

【免疫疾患Update】 関節リウマチ治療のパラダイムシフト　RA治療「寛解」の次なる目標　バイオフリーの可能性について
田中 良哉
クリニシアン, Feb. 2016, Null, Null
Lead

【関節リウマチの新たなる展開】　関節リウマチの先端医療
田中 良哉
クリニシアン, Oct. 2005, Null, Null

血糖管理不十分な2型糖尿病患者におけるアナグリプチン増量の有用性に関する検討
新生 忠司, 岡田 洋右, 黒住 旭, 田中 良哉
プラクティス, Nov. 2019, Reviewed, No invitation
Last

躁うつ病に伴う食行動異常により著明な高脂血症および高血糖をきたしたと考えられた1例
新生 忠司, 岡田 洋右, 廣瀬 暁子, 森田 恵美子, 田中 良哉
プラクティス, Jul. 2006, Null, Null

高浸透圧性糖尿病性昏睡,急性膵炎,急性腎不全に急性動脈閉塞症を合併し急速な経過を辿った1例
廣瀬 暁子, 岡田 洋右, 福島 あゆみ, 谷川 隆久, 神田 加壽子, 森田 恵美子, 田中 良哉
プラクティス, Nov. 2005, Null, Null

ダンピング症候群に持続性インスリン過剰分泌症を合併した低血糖症の1例
神田 加壽子, 岡田 洋右, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 森田 恵美子, 田中 良哉
プラクティス, Sep. 2005, Null, Null

【骨免疫学　osteoimmunologyとは何か】 生物学的製剤による関節リウマチ治療と関節破壊の改善
田中 良哉
ホルモンと臨床, Sep. 2006, Null, Null

【日本人の骨を守る】　骨を守る治療　関節リウマチ,内分泌疾患,糖尿病,ステロイド治療などから骨を守る
岡田 洋右, 田中 良哉
ホルモンと臨床, May 2005, Null, Null

混合性結合組織病における新規バイオマーカー　抗SMN complex抗体
轟 泰幸, 久保 智史, 田中 良哉
リウマチ科, Mar. 2025, Reviewed, No invitation
Last

【病態を考慮した治療選択-ガイドラインからプレシジョンメディシンへ-】免疫学的背景を考慮したSLEの治療選択
久保 智史, 田中 良哉
リウマチ科, Dec. 2024, Reviewed, No invitation
Last

SLEにおけるリツキシマブ療法
上野 匡庸, 中山田 真吾, 田中 良哉
リウマチ科, Aug. 2024, Reviewed, No invitation
Last

【リウマチ性疾患における分子標的療法の現在と未来-主に生物学的製剤を用いて-】脊椎関節炎
宮川 一平, 田中 良哉
リウマチ科, Jun. 2024, Reviewed, No invitation
Last

【リウマチ性疾患診療における自己抗体アップデート】混合性結合組織病に関連した自己抗体
久保 智史, 田中 良哉
リウマチ科, Apr. 2024, Reviewed, No invitation
Last

JAK阻害薬休薬の可能性　XANADU study
久保 智史, 田中 良哉
リウマチ科, Jan. 2024, Reviewed, No invitation
Last

【JAK阻害薬の効果・安全性と展望】全身性エリテマトーデス
中山田 真吾, 田中 良哉
リウマチ科, Dec. 2023, Reviewed, No invitation
Last

FREE-J studyにおける患者とのshared decision makingによるRA寛解時の治療選択
山口 絢子, 田中 良哉
リウマチ科, Oct. 2023, Reviewed, No invitation
Last

新規抗TNFα多価ナノボディ製剤オゾラリズマブの有効性と安全性
田中 良哉
リウマチ科, Jun. 2023, Reviewed, No invitation
Lead

高疾患活動性のSLE患者に対するustekinumabの有効性と安全性　全身性エリテマトーデス患者を対象としたustekinumabの有効性と安全性を評価する第III相多施設共同無作為化プラセボ比較試験(LOTUS試験)から
宮崎 佑介, 田中 良哉
リウマチ科, Apr. 2023, Reviewed, No invitation
Last

SLEの形質芽細胞分化におけるグルタミン代謝を介したミトコンドリア機能増強
隅川 舞子[元], 岩田 慈, 田中 良哉
リウマチ科, Mar. 2023, Reviewed, No invitation
Last

【SLE診療の進歩】SLEにおけるB細胞を標的とした治療の作用機序と有用性
上野 匡庸, 中山田 真吾, 田中 良哉
リウマチ科, Feb. 2023, Reviewed, No invitation
Last

巨細胞性動脈炎および高安動脈炎のマネジメントに関するACR/VFガイドライン
中山田真吾, 田中良哉
リウマチ科, Oct. 2022, Reviewed, No invitation
Last

実臨床下においてヤヌスキナーゼ阻害薬ごとの有効性と安全性に差はあるのか?　実臨床下における関節リウマチ患者に対するtofacitinibとbaricitinibの有効性と安全性の比較　傾向スコアに基づく逆確率重み付け法による解析から
宮﨑佑介, 田中良哉
リウマチ科, Sep. 2022, Reviewed, No invitation
Last

【混合性結合組織病(MCTD)診療のupdate】MCTDの疾患概念、疫学
田中良哉
リウマチ科, Jun. 2022, Reviewed, No invitation
Lead

【関節リウマチの治療の現状と問題点】治療薬剤の減量と休薬
山口絢子, 田中良哉
リウマチ科, Apr. 2022, Reviewed, No invitation
Last

【生物学的製剤による免疫性炎症性疾患の治療】Tocilizumabによる大型血管炎(高安動脈炎、巨細胞性動脈炎)の治療
中山田 真吾, 田中 良哉
リウマチ科, Feb. 2022, Reviewed, No invitation
Last

シェーグレン症候群におけるTfh細胞とTph細胞の関与
神田 友梨恵, 中山田 真吾, 田中 良哉
リウマチ科, Aug. 2021, Reviewed, No invitation
Last

全身性エリテマトーデスの治療における抗I型IFN受容体モノクローナル抗体anifrolumab
田中 良哉
リウマチ科, Jul. 2021, Reviewed, No invitation
Lead

ループス腎炎のマネジメント　2019年EULAR/ERA-EDTAリコメンデーション
中山田 真吾, 田中 良哉
リウマチ科, Feb. 2021, Reviewed, No invitation
Last

【リウマチ性疾患の病態における適応免疫と治療への展望】全身性エリテマトーデスにおける適応免疫と治療への展望
岩田 慈, 田中 良哉
リウマチ科, Nov. 2020, Reviewed, No invitation
Last

【IgG4関連疾患の基礎と臨床】IgG4関連疾患の治療
田中 良哉
リウマチ科, Mar. 2020, Reviewed, No invitation
Lead

【リウマチ性疾患の病因・病態研究の進歩】SLEにおける濾胞性ヘルパーT細胞の分化と機能
中山田 真吾, 田中 良哉
リウマチ科, Feb. 2020, Reviewed, No invitation

関節リウマチ患者におけるバリシチニブ治療による末梢血リンパ球サブセットの変化
田中 良哉
リウマチ科, Jan. 2020, Reviewed, No invitation
Lead

末梢血T細胞フェノタイプによる乾癬性関節炎のprecision medicine
宮川 一平, 田中 良哉
リウマチ科, Dec. 2019, Reviewed, No invitation

SLE末梢血で増殖するCD4陽性T細胞集団はIL-10とコハク酸によりB細胞をヘルプする
岩田 慈, 田中 良哉
リウマチ科, Oct. 2019, Reviewed, No invitation

【SLEの診断と治療の進歩-2019 update】SLEに対するJAK阻害療法
佐藤 友梨恵, 中山田 真吾, 田中 良哉
リウマチ科, Sep. 2019, Reviewed, No invitation
Last

【SLEの診断と治療の進歩-2019 update】SLEに対するアニフロルマブ(anifrolumab)
轟 泰幸, 中野 和久, 田中 良哉
リウマチ科, Sep. 2019, Reviewed, No invitation
Last

【JAK阻害薬の基礎と臨床】JAK阻害薬による自然免疫および適応免疫に対する作用
久保 智史, 田中 良哉
リウマチ科, Jul. 2019, Reviewed, No invitation

【JAK阻害薬の基礎と臨床】バリシチニブの有効性と安全性
田中 良哉
リウマチ科, Jul. 2019, Reviewed, No invitation
Lead

生物学的抗リウマチ薬の末梢血免疫細胞プロファイルに対する影響
中山田 真吾, 久保 智史, 田中 良哉
リウマチ科, Mar. 2019, Reviewed, No invitation
Last

IL-21はSLEにおける自己反応性CD11c高発現T-bet陽性B細胞の増殖と形質細胞分化を促進する
久保 智史, 中山田 真吾, 田中 良哉
リウマチ科, Feb. 2019, Reviewed, No invitation
Last

【リウマチ性疾患における遺伝素因と環境要因】関節リウマチとエピゲノム修飾
大久保 直紀, 河邊 明男, 中野 和久, 田中 良哉
リウマチ科, Feb. 2019, Reviewed, No invitation
Last

RA疾患活動性制御後のトファシチニブ休薬について
久保 智史, 田中 良哉
リウマチ科, Sep. 2018, Reviewed, Null

米国リウマチ学会のステロイド性骨粗鬆症の予防と治療のガイドライン(2017年版)
田中良哉
リウマチ科, Aug. 2018, Reviewed, No invitation
Lead

RAに対するバイオシミラーの進歩
福與 俊介, 中野 和久, 田中 良哉
リウマチ科, Jul. 2018, Reviewed, Null
Corresponding

強皮症
久保智史，田中良哉
リウマチ科, Apr. 2018, Reviewed, No invitation

【関節リウマチ治療における生物学的製剤を使いこなすためには】バイオシミラーの使い方
田中良哉
リウマチ科, Jun. 2018, Reviewed, No invitation
Lead

【医療経済をかんがみた関節リウマチの診療】 バイオシミラーの開発の現状と未来
田中 良哉
リウマチ科, Dec. 2017, Not reviewed, Null
Lead

JAK阻害薬の開発の現状と今後の展望
中山田 真吾, 田中 良哉
リウマチ科, Oct. 2017, Reviewed, Null
Last

CORRONAレジストリーのアバタセプトとトシリズマブのcomparative effectiveness study
久保 智史, 田中 良哉
リウマチ科, Oct. 2017, Not reviewed, Null
Last

Multi-biomarker disease activity(MBDA)は関節リウマチの疾患活動性を正確に反映するか
田中 良哉
リウマチ科, Jul. 2017, Not reviewed, Null
Lead

関節リウマチ治療におけるバリシチニブの有用性
久保 智史, 中山田 真吾, 田中 良哉
リウマチ科, Apr. 2017, Not reviewed, Null
Last

関節リウマチに対するbaricitinibの有効性と安全性
田中 良哉
リウマチ科, Nov. 2016, Null, Null
Lead

自己免疫疾患におけるリンパ球サブセット解析の新展開
中山田 真吾, 久保 智史, 田中 良哉
リウマチ科, Sep. 2016, Null, Null
Corresponding

【関節リウマチ治療における生物学的製剤を使いこなすためには】 バイオフリー寛解の導入と維持
田中 良哉
リウマチ科, Jul. 2016, Null, Null
Lead

【リウマチ診療に必要な骨代謝マーカーの知識】 1型プロコラーゲン-N-プロペプチド(P1NP)
岡田 洋右, 田中 良哉
リウマチ科, Jun. 2016, Null, Null
Corresponding

【関節リウマチ診療における新たな課題】 バイオフリー寛解・ドラッグフリー寛解の現状
平田 信太郎, 田中 良哉
リウマチ科, May 2016, Null, Null
Corresponding

ヒト間葉系幹細胞の軟骨分化におけるシグナル伝達機構
近藤 真弘, 山岡 邦宏, 田中 良哉
リウマチ科, Jan. 2016, Null, Null
Corresponding

【Non-biologic(synthetic)DMARDの現状と将来】 トファシチニブ(CP690、550)
山岡 邦宏, 田中 良哉
リウマチ科, Sep. 2012, Null, Null

【生物学的製剤update2006】　リツキシマブの概要と欧米におけるエビデンス
田中 良哉
リウマチ科, May 2006, Null, Null

【生物学的製剤update2006】　関節リウマチに対するインフリキシマブ使用の実際
名和田 雅夫, 齋藤 和義, 田中 良哉
リウマチ科, May 2006, Null, Null

膠原病に合併するニューモシスチス肺炎の早期診断,早期治療
齋藤 和義, 田中 良哉
リウマチ科, Jan. 2006, Null, Null

【SLE　基礎と臨床の最前線】　SLEに対する抗CD20抗体リツキシマブの効果
岩田 慈, 田中 良哉
リウマチ科, Jan. 2006, Null, Null

【リウマチ・膠原病の治療における免疫抑制薬のEBM】　SLEの精神神経症状に対するIVCY療法
徳永 美貴子, 田中 良哉
リウマチ科, Nov. 2005, Null, Null

【関節リウマチの早期診断と早期治療】　関節リウマチ早期例における抗リウマチ薬の選択　メトトレキサート単独療法はもはやゴールドスタンダードではない
田中 良哉
リウマチ科, Sep. 2005, Null, Null

難治性SLEに対するリツキシマブの治療成績
田中 良哉
リウマチ科, May 2005, Null, Null

TNF阻害療法による関節リウマチ治療の新展開
田中 良哉
中部日本整形外科災害外科学会雑誌, Mar. 2006, Null, Null

COVID-19罹患後に発症した重症心筋炎の一例
日下 勝秀, 大久保 直紀, 中山田 真吾, 宮崎 佑介, 松永 五月, 田中 良哉
九州リウマチ, Sep. 2024, Reviewed, No invitation
Last

リウマチ医が知っておきたいシリーズ　最新の経口血糖降下薬の使い方
岡田 洋右, 田中 良哉
九州リウマチ, Sep. 2023, Reviewed, No invitation
Last

巨細胞性動脈炎と好酸球性多発血管炎性肉芽腫症を合併した多発血管炎重複症候群の一例
有冨 貴史, 中野 和久, 河邊 明男, 今林 慶祐, 名和田 彩, 宮崎 佑介, 中山田 真吾, 田中 良哉
九州リウマチ, Sep. 2021, Reviewed, No invitation
Last

乾癬性関節炎を合併した全身性エリテマトーデスに対してセクキヌマブが奏功した一例
藤田 悠哉, 中野 和久, 玉城 泰太郎, 吉成 紘子, 岩田 慈, 福與 俊介, 宮川 一平, 中山田 真吾, 田中 良哉
九州リウマチ, Mar. 2021, Reviewed, No invitation
Last

トシリズマブに対するInfusion Reaction後に再投与により寛解導入・維持が可能であった成人スチル病の1症例
有冨 貴史, 名和田 雅夫, 船田 将史, 齋藤 和義, 田中 良哉
九州リウマチ, Mar. 2021, Reviewed, No invitation
Last

滑膜研究の進歩
中野 和久, 田中 良哉
九州リウマチ, Mar. 2021, Reviewed, No invitation
Last

当院における分子標的療法中の関節リウマチ患者の現状と課題
小柳徳子, 中野和久, 田中良哉
九州リウマチ, Sep. 2020, Reviewed, No invitation
Last

家族性地中海熱(FMF)非典型例としてカナキヌマブ治療中に、ベーチェット病の症状が顕在化し、アダリムマブが奏功した一例
小坂 峻平, 中野 和久, 宮崎 佑介, 中山田 真吾, 岩田 慈, 河邊 明男, 吉成 紘子, 田中 良哉
九州リウマチ, Sep. 2020, Reviewed, No invitation
Last

強直性脊椎炎に対してTNF-α阻害薬で加療中に発症した掌蹠膿疱症の2症例
有冨 貴史, 中野 和久, 吉成 紘子, 中山田 真吾, 岩田 慈, 福與 俊介, 宮川 一平, 河邊 明男, 宮崎 佑介, 上野 匡庸, 田中 良哉
九州リウマチ, Mar. 2020, Reviewed, No invitation
Last

無症候性IgG4関連胆嚢炎を伴ったIgG4関連疾患の一例
日下 勝秀, 中野 和久, 吉成 紘子, 岩田 慈, 福與 俊介, 花見 健太郎, 久保 智史, 宮川 一平, 河邊 明男, 宮崎 佑介, 名和田 彩, 井上 嘉乃, 上野 匡庸, 有冨 貴史, 中山田 真吾, 田中 良哉
九州リウマチ, Mar. 2019, Reviewed, No invitation
Last

JAK阻害薬UPDATE
田中 良哉
九州リウマチ, Mar. 2019, Reviewed, No invitation
Last, Corresponding

消化管潰瘍を反復した骨髄異形成症候群関連結節性多発動脈炎の1例
有冨 貴史, 中野 和久, 宮川 一平, 玉城 泰太郎, 宮田 寛子, 岩田 慈, 福與 俊介, 中山田 真吾, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null
Corresponding

外転神経麻痺で発症した好酸球性多発血管炎性肉芽腫症の一例
永安 敦, 中野 和久, 宮川 一平, 中山田 真吾, 岩田 慈, 福與 俊介, 久保 智史, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null
Corresponding

上大静脈症候群を呈した血管型ベーチェット病の1例
上野 匡庸, 中野 和久, 宮川 一平, 中山田 真吾, 岩田 慈, 福與 俊介, 久保 智史, 宮崎 佑介, 河邊 明男, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null
Corresponding

リツキシマブが奏効したオーバーラップ症候群(全身性エリテマトーデス・関節リウマチ・全身性強皮症)の一例
轟 泰幸, 久保 智史, 中野 和久, 中山田 真吾, 岩田 慈, 福與 俊介, 宮川 一平, 名和田 彩, 田中 良哉
九州リウマチ, Sep. 2018, Reviewed, Null
Last, Corresponding

MPO-ANCA陽性を呈した抗GBM抗体型腎炎の1例
上野 匡庸, 中野 和久, 吉成 紘子, 中山田 真吾, 久保 智史, 宮川 一平, 好川 真以子, 田村 雅仁, 宮本 哲, 齋藤 和義, 田中 良哉
九州リウマチ, Apr. 2018, Reviewed, Null
Corresponding

治療抵抗性の関節リウマチ(RA)と全身性エリテマトーデス(SLE)の併発に対しリツキシマブ(RTX)投与にて疾患活動性を制御できた1例
井上 嘉乃, 中野 和久, 宮崎 佑介, 中山田 真吾, 福與 俊介, 久保 智史, 宮川 一平, 齋藤 和義, 田中 良哉
九州リウマチ, Sep. 2017, Reviewed, Null
Last

アバタセプトの作用機序の新知見
中山田 真吾, 久保 智史, 田中 良哉
九州リウマチ, Mar. 2016, Null, Null
Corresponding

関節リウマチ(RA)に対する有効なセカンドバイオ選択に関する検討　当科の生物学的製剤導入2191例の解析による報告
齋藤 和義, 中野 和久, 大久保 直紀, 井上 嘉乃, 中山田 真吾, 平田 信太郎, 福與 俊介, 久保 智史, 宮川 一平, 湯之上 直樹, 田中 良哉
九州リウマチ, Sep. 2015, Reviewed, Null
Last, Corresponding

関節リウマチ関連間質性肺疾患(RA-ILD)に対するタクロリムス(TAC)の効果についての検討
平田 信太郎, 齋藤 和義, 園本 格士朗, 福與 俊介, 花見 健太郎, 水野 泰志, 岩田 慈, 名和田 雅夫, 澤向 範文, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
九州リウマチ, Sep. 2013, Reviewed, No invitation
Last

関節リウマチ(RA)におけるTNF阻害薬(IFX)導入前の免疫抑制薬(MTX)の意義　関節破壊を軸とした解析結果からの報告
名和田 雅夫, 齋藤 和義, 福與 俊介, 水野 泰志, 平田 信太郎, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
九州リウマチ, Sep. 2013, Reviewed, No invitation
Last

関節リウマチ(RA)に対するアダリムマブ治療におけるMTX増量と疾患活動性改善効果
平田 信太郎, 齋藤 和義, 園本 格士朗, 福與 俊介, 花見 健太郎, 水野 泰志, 岩田 慈, 名和田 雅夫, 澤向 範文, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

関節リウマチ(RA)のIFX療法における併用MTX増量の有効性の検証
名和田 雅夫, 齋藤 和義, 福與 俊介, 花見 健太郎, 久保 智史, 水野 泰志, 平田 信太郎, 山岡 邦宏, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

早期関節リウマチ(RA)におけるメトトレキサート(MTX)の短期増量の重要性
齋藤 和義, 山岡 邦宏, 中山田 真吾, 中野 和久, 名和田 雅夫, 澤向 範文, 水野 泰志, 平田 信太郎, 福與 俊介, 園本 格士朗, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

関節リウマチ(RA)に対するトシリズマブ(TCZ)療法におけるMTX併用量の有効性の検討
花見 健太郎, 田坂 文一, 平田 信太郎, 福與 俊介, 久保 智史, 水野 泰志, 齋藤 和義, 田中 良哉
九州リウマチ, Mar. 2013, Null, Null

生物学的製剤投与者におけるB型肝炎ウイルス感染の検討
水野 泰志, 齋藤 和義, 石崎 淳, 岩田 慈, 名和田 雅夫, 澤向 範文, 徳永 美貴子, 平田 信太郎, 山岡 邦宏, 田中 良哉
九州リウマチ, Sep. 2012, Null, Null

生物学的製剤におけるPCP一次予防策定後にPCPを発症した症例の検討
湯之上 直樹, 齋藤 和義, 名和田 雅夫, 澤向 範文, 山岡 邦宏, 田中 良哉
九州リウマチ, Sep. 2012, Null, Null

インフリキシマブ療法によるニューモシスチス肺炎発症例の検討
鈴木 克典, 齋藤 和義, 中山田 真吾, 山岡 邦宏, 名和田 雅夫, 岩田 慈, 吾妻 妙子, 田中 良哉
九州リウマチ, Sep. 2006, Null, Null

難治性精神神経SLEに対する抗CD20抗体療法の効果
徳永 美貴子, 齋藤 和義, 中山田 真吾, 辻村 静代, 名和田 雅夫, 岩田 慈, 吾妻 妙子, 田中 良哉
九州リウマチ, Sep. 2006, Null, Null

生物学的製剤のリウマチ骨粗鬆症や近縁の炎症性疾患への有効性　腸管ベーチェットに対しTNF阻害療法が奏効した2症例
岩田 慈, 齋藤 和義, 辻村 静代, 中山田 真吾, 名和田 雅夫, 吾妻 妙子, 鈴木 克典, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

生物学的製剤のリウマチ骨粗鬆症や近縁の炎症性疾患への有効性　抗TNFa抗体infliximab投与の抗動脈硬化作用の検討
西田 啓子, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 岡田 洋右, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

生物学的製剤のリウマチ骨粗鬆症や近縁の炎症性疾患への有効性　抗TNFα抗体infliximab投与の骨粗鬆症化・骨破壊抑制効果
名和田 雅夫, 齋藤 和義, 中山田 真吾, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

RAにおけるステロイドの功罪　抗TNFα抗体infliximabの臨床効果と併用ステロイドに関する検討　infliximabのステロイド投与量による層別解析
名和田 雅夫, 齋藤 和義, 中山田 真吾, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

RAにおけるステロイドの功罪　関節リウマチにおけるinfliximabによるステロイド治療抵抗性克服
辻村 静代, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 岩田 慈, 鈴木 克典, 吾妻 妙子, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

RAにおけるステロイドの功罪　抗TNFα抗体infliximab投与時に見られた感染症　重篤な感染症発症はステロイド投与が関与する
鈴木 克典, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 吾妻 妙子, 岩田 慈, 田中 良哉
九州リウマチ, Mar. 2006, Null, Null

関節リウマチに対するシクロスポリン療法の短期効果
辻村 静代, 齋藤 和義, 中山田 真吾, 名和田 雅夫, 岩田 慈, 鈴木 克典, 吾妻 妙子, 田中 良哉
九州リウマチ, Sep. 2005, Null, Null

レフルノミドの有用性と使用における留意事項　当科での投与1年後の111例の解析結果より
澤向 範文, 齋藤 和義, 中山田 真吾, 名和田 雅夫, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
九州リウマチ, Sep. 2005, Null, Null

関節リウマチ(RA)の骨障害に対する抗TNFα抗体(Infliximab)の効果
名和田 雅夫, 齋藤 和義, 中山田 真吾, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
九州リウマチ, Sep. 2005, Null, Null

RAにおけるInfliximabの投与1年後の効果解析　約100症例における層別化解析による治療反応性予測と適正使用の検討
齋藤 和義, 名和田 雅夫, 中山田 真吾, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
九州リウマチ, Sep. 2005, Null, Null

【内科疾患最新の治療　専門家からのアドバイス】　膠原病・免疫・アレルギー　混合性結合組織病
田中 良哉
内科, Jun. 2006, Null, Null

【膠原病診療ピットフォール　知っておきたい基礎知識】　治療におけるリスクマネージメント　ステロイド誘発骨粗鬆症
齋藤 和義, 田中 良哉
内科, Apr. 2006, Null, Null

目でみるバイオサイエンス　抗リウマチ薬抵抗性の作用機序
田中 良哉, 辻村 静代
内科, Aug. 2005, Null, Null

【内科疾患の診断基準病型分類・重症度】　診断メモ　成人発症Still病
田中 良哉
内科, Jun. 2005, Null, Null

【内科疾患の診断基準病型分類・重症度】　膠原病　関節リウマチの診断基準・病型分類・重症度
田中 良哉
内科, Jun. 2005, Null, Null

【全身性強皮症-皮膚だけではなく全身性の自己免疫疾患】[Chapter 4]新規治療戦略　免疫フェノタイプによる層別化　精密医療への挑戦
久保 智史, 田中 良哉
内科, Jan. 2025, Reviewed, No invitation
Last

腹痛を契機に甲状腺クリーゼを発見できた高齢者Basedow病の1例
大塚 隆史, 岡田 洋右, 新生 忠司, 田中 健一, 田中 良哉
内科, Oct. 2017, Reviewed, Null
Last

心アミロイドーシスを合併した甲状腺アミロイドーシスによる粘液水腫性昏睡の1例
新生 忠司, 岡田 洋右, 鳥本 桂一, 瓜生 康平, 田中 良哉
内科, Feb. 2017, Reviewed, Null
Last, Corresponding

胃切除術後の2型糖尿病症例における著明な血糖変動に対してCGMが有用であった1例
園田 里美, 岡田 洋右, 森 博子, 鳥本 桂一, 田中 良哉
内科, Jul. 2016, Null, Null
Last, Corresponding

妊娠中期に発症し出産後も遷延した中枢性尿崩症の1例
松下 幸司, 岡田 洋右, 森 博子, 田中 良哉
内科, Jul. 2016, Null, Null
Corresponding

【プライマリケア医もできる!　関節リウマチ診療】 バイオシミラー・バイオフリーについて　治療費軽減対策
平田 信太郎, 田中 良哉
内科, May 2016, Null, Null

治療自己中断による血糖コントロール増悪にて発症した糖尿病性舞踏病の1例
大塚 隆史, 岡田 洋右, 新生 忠司, 元 舞子, 田中 良哉
内科, Jan. 2016, Null, Null
Corresponding

抗甲状腺薬長期内服中に生じた無顆粒球症の2例
成澤 学, 岡田 洋右, 新生 忠司, 杉澤 千穂, 田中 良哉
内科, Sep. 2012, Null, Null

生物学的製剤の新しいTrial　RAに対する抗CD20抗体療法　寛解導入は可能か
田中 良哉
分子リウマチ, Aug. 2006, Null, Null

【自己免疫疾患に関与する役者たち】　自己反応性B細胞による病態形成
野島 崇樹, 田中 良哉
分子リウマチ, Aug. 2006, Null, Null

【生物学的製剤のPMS後の臨床】　インフリキシマブとニューモシスチス肺炎
田中 良哉, 齋藤 和義
分子リウマチ, Nov. 2005, Null, Null

【次世代の膠原病治療】 間葉系幹細胞の応用により関節リウマチ患者の関節の再生は可能か?
田中 良哉
分子リウマチ治療, Jul. 2016, Null, Null
Lead

【SLEの新しい治療戦略】ベリムマブ
中山田 真吾, 田中 良哉
分子リウマチ治療, Apr. 2019, Reviewed, No invitation

骨代謝　骨免疫(第19回)　ステロイド性骨粗鬆症のメカニズム
田中 良哉
分子リウマチ治療, Jan. 2019, Reviewed, No invitation
Lead

【関節リウマチと骨粗鬆症　今後の展開】関節リウマチにおける骨障害と骨粗鬆症の病態
田中 良哉
分子リウマチ治療, Jan. 2018, Reviewed, No invitation
Lead

【既存の生物学的製剤を総括する】 セルトリズマブペゴル
宮崎 佑介, 中野 和久, 田中 良哉
分子リウマチ治療, Jul. 2018, Reviewed, Null
Corresponding

【経口抗リウマチ薬を総括する】 バリシチニブ
中山田 真吾, 田中 良哉
分子リウマチ治療, Oct. 2017, Reviewed, Null
Last

リツキシマブと新たな臨床応用展開
田中 良哉
分子呼吸器病, May 2006, Null, Null

【膠原病と慢性炎症】 膠原病に於ける再生医学へのアプローチ
田中 良哉
別冊Bio Clinica: 慢性炎症と疾患, Aug. 2016, Null, Null
Lead

【膠原病】全身性エリテマトーデスの免疫フェノタイピング
中山田 真吾, 田中 良哉
別冊Bio Clinica: 慢性炎症と疾患, Oct. 2023, Reviewed, No invitation
Last

【骨壊死　最新の診断と治療】　基礎的アプローチ　原因に関する基礎研究　特発性大腿骨頭壊死症におけるhypoxia-inducible factor(HIF)-1αの関与　血管内皮細胞におけるHIF-1α遺伝子導入および糖質コルチコイド投与によるアポトーシスの誘導
飯田 武, 岡田 洋右, 峯 信一郎, 田中 良哉
別冊整形外科, Oct. 2005, Null, Null

序文―治療の新たな潮流
田中良哉
医学と薬学, Aug. 2022, Reviewed, No invitation
Lead

【膠原病の最前線】関節リウマチ
田中 良哉
医学と薬学, Sep. 2019, Reviewed, No invitation
Lead

【関節リウマチ治療の検査・診断・治療】 関節リウマチの薬物療法
田中 良哉
医学と薬学, Dec. 2016, Null, Null
Lead

【膠原病のすべて】膠原病の治療の進歩　膠原病治療における新規治療法の開発
中山田 真吾, 田中 良哉
医学のあゆみ, Feb. 2024, Reviewed, No invitation
Last

【膠原病のすべて】膠原病の病態解明　免疫サブセット解析の最前線
久保 智史, 田中 良哉
医学のあゆみ, Feb. 2024, Reviewed, No invitation
Last

【骨粗鬆症-予防と治療の将来展望】カルシウム製剤、活性型ビタミンD製剤
田中 健一, 岡田 洋右, 田中 良哉
医学のあゆみ, Jan. 2022, Reviewed, No invitation
Last

骨粗鬆症―予防と治療の将来展望
田中良哉
医学のあゆみ, Jan. 2022, Reviewed, No invitation
Lead

【難治性免疫疾患-病態解明と新規治療戦略】疾患　全身性エリテマトーデスの病態と新規治療戦略
中山田 真吾, 田中 良哉
医学のあゆみ, May 2021, Reviewed, No invitation
Last

【難治性免疫疾患-病態解明と新規治療戦略】免疫疾患の病態へのアプローチ　自己免疫疾患におけるB細胞の役割と新規治療戦略
岩田 慈, 田中 良哉
医学のあゆみ, May 2021, Reviewed, No invitation
Last

【マクロファージのすべて】 マクロファージのかかわる臨床疾患　関節リウマチの病態・治療とマクロファージ
田中 良哉
医学のあゆみ, Oct. 2016, Null, Null
Lead

【血管炎の基礎と臨床】　基礎　血管炎とリンパ球,接着分子
田中 良哉
医学のあゆみ, Jul. 2005, Null, Null

【自己免疫疾患研究の最先端】　病態　B細胞と自己免疫疾患
田中 良哉
医学のあゆみ, Apr. 2005, Null, Null

【膠原病と呼吸器疾患】混合性結合組織病
田中 良哉
呼吸器内科, Aug. 2024, Reviewed, No invitation
Lead

期待される血管炎の新規治療
田中 良哉
呼吸器内科, Oct. 2017, Not reviewed, Null
Lead

【自己免疫疾患　層別化する新時代へ　臨床検体のマルチオミクス解析、腸内細菌によって見えてきた免疫経路の全容】(第1章)精密医療を目指したマルチオミクス解析によるアプローチ　イムノフェノタイピングによる自己免疫疾患の層別化医療
田中 良哉, 宮川 一平, 久保 智史, 中山田 真吾
実験医学, Sep. 2022, Reviewed, No invitation
Lead

【分子標的薬を極める】膠原病・自己炎症症候群　ベーチェット病
田中良哉
小児内科, Feb. 2023, Reviewed, No invitation
Lead

侵襲性カンジダ症に抗真菌剤投与開始までの時間が予後に与える影響について
鈴木 克典, 迎 寛, 楠原 浩一, 田中 良哉, 松本 哲朗
感染症学雑誌, May 2013, Null, Null

【関節痛をどう診るか】 関節のMRIの診かた
久保 智史, 田中 良哉
成人病と生活習慣病, Sep. 2017, Not reviewed, Null
Last

【脊椎関節炎の診断と治療update】乾癬性関節炎update　骨関節専門医の立場から
宮川 一平, 田中 良哉
整形・災害外科, Oct. 2024, Reviewed, No invitation
Last

【関節リウマチに対する新しい治療戦略-新分類基準・ガイドラインに基づいて】 関節リウマチの治療戦略update
田中 良哉
整形・災害外科, Sep. 2012, Null, Null

【関節リウマチに対する生物学的製剤の効果と問題点】　インフリキシマブ
齋藤 和義, 田中 良哉
整形・災害外科, May 2006, Null, Null

関節リウマチ患者でのバリシチニブ投与開始12および24週時の寛解達成に対する負の予測因子としての投与開始4週時の臨床的疾患活動性における反応性欠如　第3相2試験(RA-BEAMおよびRA-BEGIN)の結果
田中 良哉, Weinblatt Michael, Taylor Peter C., Fleischmann Roy, 石塚 智子, 田中 大, 多喜田 保志, Schlichting Douglas, 竹内 勤
新薬と臨牀, Jul. 2021, Reviewed, No invitation
Lead

肺炎球菌性肺炎患者に対するガレノキサシンの解熱効果の検討
鈴木 克典, 真弓 俊彦, 矢寺 和博, 田中 良哉, 迎 寛
新薬と臨牀, Jul. 2014, Not reviewed, Null

整形外科医のためのエタネルセプト(エンブレル)の使い方　TNF阻害療法によるリウマチ治療の新展開
田中 良哉
日本リウマチ・関節外科学会雑誌, Oct. 2005, Null, Null

関節リウマチに対するTNF阻害薬による強化療法とバイオフリー寛解の可能性
田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチに於ける長期予後を見据えた早期治療介入
田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチ治療に於ける生物学的製剤ゴリムマブの真価　寛解導入と寛解維持のためのベストユースに迫る
田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

多彩な臓器障害(心膜炎、胸膜炎、ループス腎炎)に加え無石性胆嚢炎を合併し、ステロイド+IV-CYが奏功したSLEの一例
吉成 紘子, 名和田 雅夫, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

Tofacitinib投与関節リウマチ患者における治療反応予測因子の検討
山岡 邦宏, 園本 格士朗, 久保 智史, 平田 信太郎, 福與 俊介, 前島 圭佑, 中野 和久, 澤向 範文, 名和田 雅夫, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

Tofacitinib治療による感染症発症とその予測因子
園本 格士朗, 山岡 邦宏, 前島 圭佑, 久保 智史, 中野 和久, 鈴木 克典, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

ループス腎炎におけるCD4+cell上P糖蛋白質/CXCR3の腎臓侵襲性への関与
辻村 静代, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

IL-17によるヒト間葉系幹細胞の軟骨細胞分化抑制作用の解析
近藤 真弘, 山岡 邦宏, 園本 格士朗, 福與 俊介, 尾下 浩一, 岡田 洋右, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチ患者における生物学的製剤導入前スクリーニングCTにて発見された胸部異常陰影の検討
水野 泰志, 齋藤 和義, 岩田 滋, 澤向 範文, 園本 格士朗, 中野 和久, 中山田 真吾, 名和田 雅夫, 平田 信太郎, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬以外) 関節リウマチにおけるトシリズマブ療法の脱落例に関する検討
花見 健太郎, 齋藤 和義, 田坂 文一, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) 関節リウマチ(RA)の骨破壊と軟骨破壊に対するインフリキシマブ(IFX)の異なる効果
松浦 広学, 齋藤 和義, 名和田 雅夫, 平田 信太郎, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬以外) 関節リウマチに対するトシリズマブによる2年間の関節破壊抑制効果の検討
花見 健太郎, 齋藤 和義, 田坂 文一, 平田 信太郎, 水野 泰志, 福與 俊介, 久保 智史, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) 血清MMP-3はTNF阻害療法下の関節リウマチにおける関節裂隙狭小化スコアと相関性が高い
平田 信太郎, 齋藤 和義, 久保 智史, 福與 俊介, 水野 泰志, 園本 格士朗, 花見 健太郎, 岩田 慈, 名和田 雅夫, 澤向 範文, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

サイトカイン・ケモカイン Tofacitinib投与中関節リウマチ患者におけるMulti-Biomarker Disease Activity(VECTRA DA)と骨破壊との関連性
山岡 邦宏, 久保 智史, 園本 格士朗, Voinov Alexander, Rowe Michael, Cavet Guy, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

SLE/NPSLE 当科におけるステロイド・免疫抑制薬に治療抵抗性難治性SLEに対するAbatacept治療の早期有効性の検証
山田 彩, 齋藤 和義, 名和田 雅夫, 岩田 慈, 吉成 紘子, 宮川 一平, 水野 泰志, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬以外) 関節リウマチにおけるヘルパーT細胞の病原性とアバタセプト治療反応性への関与
福與 俊介, 中山田 真吾, 岩田 慈, 久保 智史, 山岡 邦宏, 中野 和久, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬以外) 関節リウマチ患者におけるアバタセプト治療の位置づけ　臨床的、機能的、構造的寛解に寄与する因子の検討
久保 智史, 齋藤 和義, 平田 信太郎, 福與 俊介, 山岡 邦宏, 中山田 真吾, 中野 和久, 澤向 範文, 名和田 雅夫, 岩田 慈, 水野 泰志, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

臨床(内科) 関節リウマチ(RA)における炎症と血管内皮機能障害の関係　エンドパットを用いた検討
好川 真以子, 齋藤 和義, 岩田 慈, 山岡 邦宏, 中山田 真吾, 中野 和久, 澤向 範文, 名和田 雅夫, 水野 泰志, 花見 健太郎, 福與 俊介, 園本 格士朗, 岡田 洋右, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) 関節リウマチ(RA)のInfliximab(IFX)療法における寛解休薬後の戦略　T2Tを実践した寛解休薬後の治療体系の構築を目指した取り組み
名和田 雅夫, 齋藤 和義, 松浦 広学, 福與 俊介, 平田 信太郎, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの予後予測因子 Multi-biomarker disease activity(MBDA)スコアは関節リウマチにおけるTNF阻害薬による構造的寛解を最も鋭敏に予測、反映する疾患活動性マーカーである
平田 信太郎, 齋藤 和義, 久保 智史, 福與 俊介, 水野 泰志, Li Wanying, Haney Douglas J., Defranoux Nadine, Bolce Rebecca, Cavet Guy, 園本 格士朗, 花見 健太郎, 岩田 慈, 名和田 雅夫, 澤向 範文, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　新しい治療薬 JAK阻害薬tofacitinibはIRF7の発現抑制を介してtolerogenic DCを誘導する
久保 智史, 山岡 邦宏, 岩田 慈, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　新しい治療薬 トファシチニブは生体内でT細胞に作用しIL-17産生を抑制して骨破壊抑制をもたらす
久保 智史, 山岡 邦宏, 園本 格士朗, 平田 信太郎, 福與 俊介, 中山田 真吾, 中野 和久, 澤向 範文, 名和田 雅夫, 岩田 慈, 水野 泰志, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの病因・病態 炎症性サイトカインによる滑膜のDNAメチル化異常の誘発機構
中野 和久, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの病因・病態 濾胞性ヘルパーT細胞の可塑性と関節リウマチ病態形成における役割
中山田 真吾, 福與 俊介, 久保 智史, 岩田 慈, 湯之上 直樹, 山岡 邦宏, 中野 和久, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) メトトレキサートを投与できない日本人関節リウマチ患者に対するCertolizumab Pegolの長期安全性、有効性および患者報告アウトカム　HIKARI継続投与試験(52週)
田中 良哉, 山本 一彦, 竹内 勤, 山中 寿, 石黒 直樹, 江口 勝美, 小路 利治, 宮坂 信之, 小池 隆夫
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) ゴリムマブ(GLM;ヒト抗TNFαモノクローナル抗体)MTX併用療法の長期投与における有効性・安全性の検討
田中 良哉, 針谷 正祥, 竹内 勤, 山中 寿, 石黒 直樹, 山本 一彦, 宮坂 信之, 小池 隆夫, Golimumab-Japan Clinical Study Group
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) 関節リウマチに対するゴリムマブの国内臨床試験成績のサブ解析　ACR/EULAR新寛解基準による評価
田中 良哉, 針谷 正祥, 竹内 勤, 山中 寿, 石黒 直樹, 山本 一彦, 石井 豊, 宮坂 信之, 小池 隆夫, Golimumab-Japan Clinical Study Group
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

骨・軟骨・滑膜 ナノファイバーによる間葉系幹細胞を用いた関節リウマチ骨再生の検討
園本 格士朗, 山岡 邦宏, 兼子 博章, 佐竹 真, 山本 由香, 張 香梅, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

ベーチェット病 治療抵抗性腸管ベーチェット病(BD)20例に対するInfliximab(IFX)療法の継続率、有効性、安全性の検討
宮川 一平, 齋藤 和義, 岩田 慈, 山岡 邦宏, 中山田 真吾, 中野 和久, 名和田 雅夫, 水野 泰志, 園本 格士朗, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

関節リウマチの治療　生物学的製剤(TNF阻害薬) 関節リウマチ(RA)のInfliximab(IFX)療法におけるMTX適正用量の検討および有効性・安全性の検証
名和田 雅夫, 齋藤 和義, 福與 俊介, 水野 泰志, 平田 信太郎, 中野 和久, 中山田 真吾, 山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

RA関節のレントゲン評価とスコアリング
平田 信太郎, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

低分子化合物　新しい経口抗リウマチ薬 細胞内シグナル伝達について
山岡 邦宏, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2013, Null, Null

シェーグレン症候群の臨床　小唾液腺組織分類からみたシェーグレン症候群に対するミゾリビン有効症例の分別化
中山田 真吾, 藤本 隆, 野々村 昭孝, 中村 忍, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

全身性エリテマトーデスの臨床　難治性neuropsychiatric SLE(NPSLE)に対する抗CD20抗体療法の効果
徳永 美貴子, 齋藤 和義, 川端 大介, 井村 嘉孝, 藤井 隆夫, 中山田 真吾, 辻村 静代, 名和田 雅夫, 岩田 慈, 吾妻 妙子, 三森 経世, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

機能分子を標的にしたリウマチ性疾患の治療　B細胞のCD20をターゲットとしたリウマチ性疾患の治療戦略
田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

続発性骨粗鬆症の病態と治療　RAにおける骨粗鬆症・関節破壊と抗サイトカイン療法
岡田 洋右, 斉藤 和義, 中山田 真吾, 名和田 雅夫, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

生物学的製剤　有用性,治療反応性の予測,副作用　抗TNFα抗体infliximabの治療効果予測および寛解導入へ向けての適正使用
齋藤 和義, 名和田 雅夫, 中山田 真吾, 岩田 慈, 鈴木 克典, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

関節リウマチの関節破壊機序　インフリキシマブによるRAの関節破壊抑制機序の解析
名和田 雅夫, 齋藤 和義, 中山田 真吾, 山岡 邦宏, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

全身性エリテマトーデス　発症の分子機序と新たな治療法　全身性エリテマトーデスを対象とした抗CD20モノクローナル抗体リツキシマブの臨床第I/II相試験(中間報告)
田中 良哉, 山本 一彦, 竹内 勤, 西本 憲弘, 宮坂 信之, 住田 孝之, 三森 経世, 小池 隆夫
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

関節リウマチの治療　インフリキシマブ　RA患者における抗TNFalpha抗体Infliximabによる抗動脈硬化作用
西田 啓子, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 岡田 洋右, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

関節リウマチの治療　インフリキシマブ　抗TNFα抗体infliximab投与時にみられた感染症発症の危険因子の検索　重篤な感染症発症はステロイド投与が関与する
鈴木 克典, 齋藤 和義, 名和田 雅夫, 山岡 邦宏, 中山田 真吾, 吾妻 妙子, 岩田 慈, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

関節リウマチの治療　エタネルセプト　Etanerceptによる短期臨床効果とInfliximabからのスイッチによる再疾患制御の可能性
岩田 慈, 齋藤 和義, 中山田 真吾, 山岡 邦宏, 吾妻 妙子, 鈴木 克典, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

RAに対するインフリキシマブの治療反応性症例の層別化　当科158症例による解析と再疾患制御の試み
名和田 雅夫, 齋藤 和義, 中山田 真吾, 山岡 邦宏, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

滑膜増殖と制御　マスト細胞由来tryptaseによるRA滑膜細胞不死化機構の解析
澤向 範文, 齋藤 和義, 山岡 邦宏, 中山田 真吾, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

関節リウマチの臨床　関節リウマチ(RA)におけるリンパ球上P糖蛋白質発現に伴う治療抵抗性とその克服
辻村 静代, 齋藤 和義, 名和田 雅夫, 鈴木 克典, 中山田 真吾, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

骨粗鬆症・骨代謝　大量ステロイド投与における骨粗鬆症および骨折に対するアレンドロネートの予防効果
岡田 洋右, 斉藤 和義, 中山田 真吾, 名和田 雅夫, 岩田 慈, 鈴木 克典, 吾妻 妙子, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Mar. 2006, Null, Null

β1インテグリン/FAKシグナルを標的としたSLE患者T細胞活性化の制御
中山田 真吾, 齋藤 和義, 藤井 幸一, 中野 和久, 藤井 裕子, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

抗CD20抗体療法が著効した重症SLE患者B細胞上のCD40,CD80発現抑制
徳永 美貴子, 齋藤 和義, 藤井 幸一, 中山田 真吾, 辻村 静代, 名和田 雅夫, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

RAにおけるInfliximabの投与1年後の効果解析　層別化解析による治療反応性予測と適正使用の検討
名和田 雅夫, 齋藤 和義, 藤井 幸一, 中山田 真吾, 吾妻 妙子, 岩田 慈, 鈴木 克典, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

RA滑膜における新生血管はM-CSFを産生し破骨細胞分化を支持する
中野 和久, 岡田 洋右, 谷川 令奈, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

PDK1/Akt経路伝達阻害というレフルノミドの新規作用機序　関節リウマチ治療の新しい視点となるマスト細胞制御
澤向 範文, 齋藤 和義, 藤井 幸一, 中山田 真吾, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

抗CD20抗体療法による長期寛解後に再燃したSLEへの再投与　抗ヒトキメラ抗体(HACA)産生抑制の重要性
岩田 慈, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 徳永 美貴子, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

低分子量Gタンパク質Rhoシグナルを標的とする骨粗鬆症の制御
平井 文彦, 中山田 真吾, 齋藤 和義, 藤井 幸一, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

リウマチ治療の新機軸　CCR5拮抗薬による関節リウマチでの骨破壊抑制
徳永 美貴子, 岡田 洋右, 藤井 幸一, 中山田 真吾, 中野 和久, 齋藤 和義, 田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

全身性エリテマトーデス　最近の研究の進歩　B細胞を標的としたSLEの治療
田中 良哉
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Apr. 2005, Null, Null

全身性自己免疫疾患に対する生物学的製剤を用いた治療のパラダイムシフト
田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2012, Null, Null

関節リウマチ治療のトレンド　T細胞標的治療を中心に
田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2012, Null, Null

T細胞の多剤抵抗性遺伝子発現誘導におけるTNF-αの関与
鈴木 克典, 齋藤 和義, 辻村 静代, 中山田 真吾, 田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2005, Null, Null

関節リウマチ(RA)におけるリンパ球上P糖蛋白質発現に伴う治療抵抗性とその克服
辻村 静代, 齋藤 和義, 中山田 真吾, 田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2005, Null, Null

C5a受容体拮抗薬による関節リウマチ(RA)の骨破壊抑制
徳永 美貴子, 齋藤 和義, 中山田 真吾, 澤向 範文, 田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2005, Null, Null

関節リウマチ(RA)治療の新たな標的としてのマスト細胞〜tryptase/PAR2を介したマスト細胞によるRA滑膜細胞不死化
澤向 範文, 齋藤 和義, 中山田 真吾, 田中 良哉
日本免疫学会総会・学術集会記録, Nov. 2005, Null, Null

CKDにおけるアレンドロネートの有用性および安全性の検討
元 舞子, 岡田 洋右, 森 博子, 田中 健一, 黒住 旭, 成澤 学, 鳥本 桂一, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

シタグリプチン常用量で血糖コントロール不十分な2型糖尿病患者でのシタグリプチン増量とミチグリニド/ボグリボースの有用性に関する検討
新生 忠司, 岡田 洋右, 須貝 慧, 黒住 旭, 鳥本 桂一, 森 博子, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

バセドウ病眼症に対するステロイドパルス療法中の食後高血糖に対するミチグリニドとレパグリニドの有効性についてCGMで比較検討
田中 健一, 岡田 洋右, 森 博子, 鳥本 桂一, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

無痛性甲状腺炎後にPlummer病を発症して心不全を繰り返した無表情型甲状腺機能亢進症の一例
成澤 学, 岡田 洋右, 久能 芙美, 鳥本 桂一, 森 博子, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

無痛性甲状腺炎寛解後に発症したバセドウ病の2例
須貝 慧, 岡田 洋右, 鳥本 桂一, 森 博子, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

抗甲状腺薬治療前後での糖新生亢進の改善をCGMで確認しえたバセドウ病の2例
久能 芙美, 岡田 洋右, 鳥本 桂一, 森 博子, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

2型糖尿病患者におけるシタグリプチンの骨代謝へ及ぼす影響
森 博子, 岡田 洋右, 元 舞子, 田中 健一, 黒住 旭, 成澤 学, 鳥本 桂一, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

2型糖尿病患者における血糖コントロールと血管内皮機能の関係　エンドパットを用いた検討
鳥本 桂一, 岡田 洋右, 久能 芙美, 須貝 慧, 園田 里美, 元 舞子, 田中 健一, 黒住 旭, 成澤 学, 森 博子, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

関節リウマチに伴う既存骨折を有する骨粗鬆症に対するテリパラチド治療効果の検討
園田 里美, 岡田 洋右, 森 博子, 田中 健一, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

2型糖尿病患者における高脂肪食負荷が血管内皮機能に与える影響および薬剤介入による血管内皮機能改善作用の検討
黒住 旭, 岡田 洋右, 森 博子, 田中 良哉
日本内分泌学会雑誌, Apr. 2013, Null, Null

ステロイド糖尿病におけるオーダーメイド治療　3例のCGMを通して
元 舞子, 岡田 洋右, 森 博子, 新生 忠司, 田中 良哉
日本内分泌学会雑誌, Dec. 2012, Null, Null

無痛性甲状腺炎の寛解期に発症したバセドウ病の一例
鳥本 桂一, 岡田 洋右, 新生 忠司, 山本 直, 田中 良哉
日本内分泌学会雑誌, Sep. 2012, Null, Null

ステロイド骨粗鬆症の診断・治療指針　ステロイド骨粗鬆症の治療戦略
岡田 洋右, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

CNPは高濃度ステロイドによる血管内皮細胞障害を抑制する
谷川 隆久, 岡田 洋右, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

エチドロネートによる透析患者における血管石灰化抑制効果の検討
廣瀬 暁子, 岡田 洋右, 谷川 隆久, 西田 啓子, 橋本 修, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

ガレクチン9によるlipid raftを介した骨芽細胞増殖機構の解明
谷川 令奈, 岡田 洋右, 中野 和久, 細川 隆司, 山内 清明, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

抗TNFα抗体は炎症制御状態にかかわらずアディポネクチンを増加させる
西田 啓子, 岡田 洋右, 名和田 雅夫, 中山田 真吾, 齋藤 和義, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

多様な異所性石灰化症に対するエチドロネートの効果
森 博子, 岡田 洋右, 廣瀬 暁子, 谷川 隆久, 新生 忠志, 西田 啓子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

大量ステロイド開始時にはアレンドロネート同時投与が骨折予防に重要である
岡田 洋右, 名和田 雅夫, 齋藤 和義, 田中 良哉
日本内分泌学会雑誌, Apr. 2006, Null, Null

ランゲルハンス細胞組織球症へのビスホスホネートの長期治療効果
岡田 洋右, 神薗 淳司, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 神田 加壽子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Jun. 2005, Null, Null

飲酒との関連が推測された多発性対称性脂肪腫症の1例
廣瀬 暁子, 岡田 洋右, 谷川 隆久, 新生 忠司, 神田 加壽子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Jun. 2005, Null, Null

無痛性甲状腺炎を契機に診断されたHajdu-Cheney syndromeの一例
新生 忠司, 岡田 洋右, 森 博子, 廣瀬 暁子, 谷川 隆久, 西田 啓子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Dec. 2005, Null, Null

インスリン抗体陽性例に反応性低血糖を合併した一例
森 博子, 岡田 洋右, 西田 啓子, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Dec. 2005, Null, Null

グルココルチコイドと骨粗鬆症　ステロイド性骨粗鬆症における一次予防の有用性
岡田 洋右, 斉藤 和義, 中山田 真吾, 名和田 雅夫, 田中 良哉
日本内分泌学会雑誌, Apr. 2005, Null, Null

多量の胸腹水貯留がステロイド投与により著減した多腺性自己免疫症候群II型(Schmidt症候群)の一例
河原 哲也, 岡田 洋右, 岸川 博文, 広瀬 暁子, 谷川 隆久, 神田 加寿子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Apr. 2005, Null, Null

喫煙により急性好酸球性肺炎を発症した汎下垂体機能低下症の一例
廣瀬 暁子, 岡田 洋右, 谷川 隆久, 新生 忠司, 神田 加壽子, 森田 恵美子, 田中 良哉
日本内分泌学会雑誌, Apr. 2005, Null, Null

抗TNFα抗体Infliximabの関節リウマチにおける骨代謝調節機序の解明
名和田 雅夫, 岡田 洋右, 斉藤 和義, 中山田 真吾, 田中 良哉
日本内分泌学会雑誌, Apr. 2005, Null, Null

炎症性免疫疾患の治療　炎症性免疫疾患に対する抗CD20抗体療法
田中 良哉
日本内科学会雑誌, Feb. 2006, Null, Null

炎症性免疫疾患の治療　炎症性免疫疾患に対する抗CD20抗体
田中 良哉
日本内科学会雑誌, Sep. 2006, Null, Null

関節リウマチ治療の新展開
田中 良哉
日本内科学会雑誌, Mar. 2006, Null, Null

生物学的製剤と膠原病の臨床　治療のブレークスルーを目指して
田中 良哉
日本内科学会雑誌, Sep. 2005, Null, Null

【膠原病リウマチ診療の新展開】　最新のトピックス　全身性エリテマトーデスの新しい治療
田中 良哉
日本内科学会雑誌, Oct. 2005, Null, Null

医学と医療の最前線　グルココルチコイド誘発性骨粗鬆症
田中 良哉
日本内科学会雑誌, Feb. 2025, Reviewed, No invitation
Lead

医学と医療の最前線　関節リウマチの最新の治療戦略
中山田 真吾, 田中 良哉
日本内科学会雑誌, Feb. 2025, Reviewed, No invitation
Last

シンポジウム3 分子標的薬が変える内科学
田中良哉, 竹内勤
日本内科学会雑誌, 2022, Reviewed, No invitation
Lead

【慢性疾患としての骨粗鬆症-内科的管理と多職種連携-】骨粗鬆症の薬物療法
岡田洋右, 田中健一, 田中良哉
日本内科学会雑誌, Apr. 2022, Reviewed, No invitation
Last

難治性免疫疾患治療の最前線　難治性リウマチ・免疫疾患治療の最前線
田中 良哉
日本内科学会雑誌, Sep. 2020, Reviewed, No invitation
Lead

骨と関節の内科学
田中 良哉
日本内科学会雑誌, Sep. 2019, Reviewed, No invitation
Lead

第46回内科学の展望　内科医、general physicianに必要な免疫・炎症学update　アレルギーと自己免疫での抗サイトカイン療法　膠原病・リウマチ疾患における抗サイトカイン療法　update
田中 良哉
日本内科学会雑誌, Mar. 2019, Reviewed, No invitation
Last

TNF阻害療法を導入した関節リウマチ患者におけるmulti-biomarkerによる客観的疾患活動性評価の検討
平田 信太郎, 齋藤 和義, 久保 智史, 福與 俊介, 水野 泰志, 岩田 慈, 名和田 雅夫, 山岡 邦宏, 田中 良哉
日本内科学会雑誌, Feb. 2013, Null, Null

2型糖尿病患者に於けるエンドパットを用いた血糖変動と血管内皮機能の関連性に関する検討
鳥本 桂一, 岡田 洋右, 森 博子, 元 舞子, 田中 健一, 黒住 旭, 成澤 学, 新生 忠司, 田中 良哉
日本内科学会雑誌, Feb. 2013, Null, Null

関節リウマチ疑い患者への検索事項　診断確定後、速やかに合成抗リウマチ薬で治療し、臨床的寛解に導入する
田中 良哉
日本医事新報, Jul. 2019, Reviewed, No invitation
Lead

治療法の再整理とアップデートのために　専門家による私の治療　関節リウマチ(内科的治療)
田中 良哉
日本医事新報, Jul. 2019, Reviewed, No invitation
Lead

【乾癬性関節炎診療の最適化】乾癬性関節炎に対する生物学的製剤の使いわけ
宮川 一平, 田中 良哉
日本医事新報, Mar. 2019, Reviewed, No invitation

【最近のループス腎炎治療】生物学的製剤による新規治療の展望
田中 良哉
日本医事新報, Feb. 2019, Reviewed, No invitation
Lead

ここまできた分子標的薬・抗体製剤の最新情報from A to Z(No.17)　全身性エリテマトーデスの分子標的薬
田中 良哉
日本医師会雑誌, Jan. 2023, Reviewed, No invitation
Lead

【免疫・炎症疾患のすべて】免疫・炎症疾患で用いられる主な治療法　生物学的製剤を含めた分子標的療法
田中 良哉
日本医師会雑誌, Oct. 2020, Reviewed, No invitation
Lead

【指定難病ペディア2019】個別の指定難病　免疫系　悪性関節リウマチ[指定難病46]
田中 良哉
日本医師会雑誌, Jun. 2019, Reviewed, No invitation
Lead

【骨粗鬆症の診断と治療update】ステロイド性骨粗鬆症
田中良哉
日本医師会雑誌, Apr. 2018, Reviewed, No invitation
Lead

【関節リウマチ診療の進歩】　ステロイド薬の選び方と使用法のコツ
田中 良哉
日本医師会雑誌, Aug. 2006, Null, Null

【わかりやすい免疫疾患】　免疫学的治療法　免疫抑制薬
田中 良哉
日本医師会雑誌, Jun. 2005, Null, Null

グルココルチコイド誘発性骨粗鬆症の病態と管理
田中良哉
日本整形外科学会雑誌, 2025, Reviewed, No invitation
Lead

アルコール性肝硬変の経過中に化膿性脊椎炎と腸腰筋膿瘍を合併した1例
太幡 敬洋, 峯 信一郎, 飯田 武, 岸川 博文, 田中 良哉
日本消化器病学会雑誌, Jan. 2006, Null, Null

【内分泌症候群(第2版)　その他の内分泌疾患を含めて】　副甲状腺・骨・ミネラル代謝　カルシウム,マグネシウム代謝異常　原発性低マグネシウム血症
岡田 洋右, 田中 良哉
日本臨床, Jun. 2006, Null, Null

【動脈・静脈の疾患2024(下)-最新の診断・治療動向-】血管炎　単一臓器血管炎
宮川 一平, 田中 良哉
日本臨床, Jul. 2024, Reviewed, No invitation
Last

【膠原病診療の進歩2024-世界最新のガイドライン,リコメンデーション-】プレシジョンメディシン
久保 智史, 田中 良哉
日本臨床, Aug. 2024, Reviewed, No invitation
Last

【膠原病診療の進歩2024-世界最新のガイドライン,リコメンデーション-】世界最新のガイドライン,リコメンデーション　乾癬性関節炎
宮川 一平, 田中 良哉
日本臨床, Aug. 2024, Reviewed, No invitation
Last

【膠原病診療の進歩2024-世界最新のガイドライン,リコメンデーション-】世界最新のガイドライン,リコメンデーション　全身性エリテマトーデス
田中 良哉
日本臨床, Aug. 2024, Reviewed, No invitation
Lead

【IgG4関連疾患-診断と治療の最近の考え方-】特論　開発中の治療
宮川 一平, 田中 良哉
日本臨床, Mar. 2024, Reviewed, No invitation
Last

【IgG4関連疾患-診断と治療の最近の考え方-】各論(診断と治療)　疾患活動性,重症度評価
中山田 真吾, 田中 良哉
日本臨床, Mar. 2024, Reviewed, No invitation
Last

【混合性結合組織病(MCTD)-診断と治療の最近の考え方-】臨床　MCTDに有用な臨床検査,生理機能検査
久保智史, 田中良哉
日本臨床, Mar. 2023, Reviewed, No invitation
Last

【混合性結合組織病(MCTD)-診断と治療の最近の考え方-】臨床　MCTDの特徴的な臨床症候,共通する症候
宮川一平, 田中良哉
日本臨床, Mar. 2023, Reviewed, No invitation
Last

【混合性結合組織病(MCTD)-診断と治療の最近の考え方-】病態　MCTDにおける抗U1-RNP抗体の臨床的意義
佐藤 実, 田中 晋, 長谷川 智子, 田中 良哉
日本臨床, Mar. 2023, Reviewed, No invitation
Last

MCTDの疫学、予後
中山田真吾, 田中良哉
日本臨床, Mar. 2023, Reviewed, No invitation

MCTDの疾患概念
田中良哉
日本臨床, Mar. 2023, Reviewed, No invitation
Lead

【全身性エリテマトーデス-診断・治療の最新動向-】SLEの治療に用いられる薬剤　抗インターフェロン療法
田中 良哉
日本臨床, May 2022, Reviewed, No invitation
Lead

【全身性エリテマトーデス-診断・治療の最新動向-】総論とSLEの発症メカニズム　SLEの治療目標と活動性指標
中山田真吾, 田中良哉
日本臨床, May 2022, Reviewed, No invitation
Last

【シェーグレン症候群-診断・治療の最新動向-】診断　鑑別診断　関節リウマチ
田中 良哉
日本臨床, Oct. 2022, Reviewed, No invitation
Lead

【関節リウマチの診療update-最新の診断と治療-】関節リウマチ治療薬の最新情報　JAK阻害薬
中山田 真吾, 田中 良哉
日本臨床, Sep. 2021, Reviewed, No invitation

【ベーチェット病-基礎と臨床の最新知見-】ベーチェット病治療における生物学的製剤　現況と将来展望
田中 良哉
日本臨床, Jun. 2021, Reviewed, No invitation
Lead

【乾癬性関節炎-診断と治療における最新知見-】治療　薬物療法　生物学的製剤の使い分け
中山田 真吾, 宮川 一平, 田中 良哉
日本臨床, Apr. 2021, Reviewed, No invitation
Last

【骨粗鬆症診療update-最新の診断と治療-】続発性骨粗鬆症の診断・治療　ステロイド性骨粗鬆症
田中 良哉
日本臨床, Dec. 2020, Reviewed, No invitation
Lead

【医薬品副作用学(第3版)上-薬剤の安全使用アップデート-】薬効群別副作用　副腎皮質ステロイド
田中 良哉
日本臨床, Jun. 2019, Reviewed, No invitation
Lead

【膠原病診療update-診断・治療の最新知見-】主要疾患の診断・治療の進歩　全身性エリテマトーデス　成人全身性エリテマトーデス
田中 良哉
日本臨床, Mar. 2019, Reviewed, No invitation
Lead

【関節リウマチupdate-基礎・臨床の最新情報-】 関節リウマチ薬物治療の最新知見　トファシチニブ
田中 良哉
日本臨床, Jun. 2016, Null, Null
Lead

【関節リウマチupdate-基礎・臨床の最新情報-】 関節リウマチ画像診断と評価　関節リウマチの新しい評価法　MBDAスコアによるRAの活動性評価
平田 信太郎, 田中 良哉
日本臨床, Jun. 2016, Null, Null
Lead

【広範囲血液・尿化学検査　免疫学的検査　その数値をどう読むか】　プロスタノイド,サイトカイン,増殖因子,ケモカイン　MIP-1
田中 良哉
日本臨床, Aug. 2005, Null, Null

【広範囲血液・尿化学検査　免疫学的検査　その数値をどう読むか】　プロスタノイド,サイトカイン,増殖因子,ケモカイン　MCP-1
田中 良哉
日本臨床, Aug. 2005, Null, Null

【臨床免疫学　基礎研究の進歩と最新の臨床】　臨床編　免疫抑制剤　抗CD20抗体
田中 良哉
日本臨床, May 2005, Null, Null

【臨床免疫学　基礎研究の進歩と最新の臨床】　臨床編　膠原病の臨床免疫学　膠原病研究の進歩　膠原病におけるシクロスポリン療法
田中 良哉
日本臨床, May 2005, Null, Null

【関節リウマチの最新動向　骨免疫学的視点からの病因論・治療学】　破骨細胞分化機構　炎症性サイトカインによる破骨細胞分化制御
田中 良哉
日本臨床, Sep. 2005, Null, Null

Multi-biomarker disease activity(MBDA)scoreによる関節リウマチの活動性評価
平田 信太郎, 田中 良哉
日本臨床免疫学会会誌, Feb. 2016, Null, Null
Corresponding

自己免疫疾患における濾胞性ヘルパーT(Tfh)細胞
中山田 真吾, 田中 良哉
日本臨床免疫学会会誌, Feb. 2016, Null, Null
Corresponding

【B細胞と自己免疫】 自己免疫疾患におけるT細胞-B細胞相互作用の重要性
岩田 慈, 田中 良哉
日本臨床免疫学会会誌, Oct. 2015, Null, Null

全身性エリテマトーデス(SLE)患者B細胞におけるケモカイン受容体発現異常
好川 真以子, 中山田 真吾, 岩田 慈, 久保 智史, 湯之上 直樹, 汪 曉珮, 田中 良哉
日本臨床免疫学会会誌, Feb. 2015, Null, Null

中枢神経病変を伴った難治性SLEに対する抗CD20抗体療法の効果
徳永 美貴子, 齋藤 和義, 川端 大介, 井村 嘉孝, 藤井 隆夫, 中山田 真吾, 辻村 静代, 名和田 雅夫, 岩田 慈, 吾妻 妙子, 三森 経世, 田中 良哉
日本臨床免疫学会会誌, Aug. 2006, Null, Null

免疫吸着療法の併用はSLEの1年後の臨床的予後を改善させる
鈴木 克典, 齋藤 和義, 中山田 真吾, 田中 良哉
日本臨床免疫学会会誌, Aug. 2006, Null, Null

関節リウマチ(RA)におけるリンパ球上P糖蛋白質発現に伴う治療抵抗性のステロイド投与による増強と生物学的製剤による克服
辻村 静代, 名和田 雅夫, 齋藤 和義, 中山田 真吾, 田中 良哉
日本臨床免疫学会会誌, Aug. 2006, Null, Null

TNF阻害薬の新展開 関節リウマチに於ける寛解を目指した新しい治療戦略
田中 良哉
日本臨床免疫学会会誌, Aug. 2006, Null, Null

自己免疫疾患に伴う全身の臓器障害とその克服
田中 良哉
日本臨床免疫学会会誌, Aug. 2006, Null, Null

関節リウマチ(RA)に於ける抗TNFα抗体infliximabへの反応性層別化の試み<当科130症例における検討からの報告>
名和田 雅夫, 齋藤 和義, 中山田 真吾, 田中 良哉
日本臨床免疫学会会誌, Aug. 2005, Null, Null

中枢神経病変を伴った難治性SLEに対する抗CD20抗体療法の効果
徳永 美貴子, 齋藤 和義, 中山田 真吾, 辻村 静代, 名和田 雅夫, 岩田 慈, 吾妻 妙子, 田中 良哉
日本臨床免疫学会会誌, Aug. 2005, Null, Null

関節リウマチ(RA)におけるリンパ球上P糖蛋白質発現に伴う治療抵抗性とその克服
辻村 静代, 齋藤 和義, 名和田 雅夫, 中山田 真吾, 田中 良哉
日本臨床免疫学会会誌, Aug. 2005, Null, Null

From Bedside to Bench　臨床が基礎医学・生物学に与えたインパクト　膠原病治療に於ける薬剤抵抗性の臨床と基礎
田中 良哉, 辻村 静代, 齋藤 和義
日本臨床免疫学会会誌, Aug. 2005, Null, Null

臨床免疫領域におけるバイオマーカーの臨床的意義　混合性結合組織病(MCTD)における抗survival of motor neuron(SMN)complex抗体の臨床的意義
轟 泰幸, 佐藤 実, 久保 智史, 田中 晋, 中山田 真吾, 田中 良哉
日本臨床免疫学会総会プログラム・抄録集, Oct. 2022, Reviewed, Null
Last

疾患活動性、重症度評価
中山田真吾、田中良哉
日本臨牀, Mar. 2024, Reviewed, No invitation
Last

IgG4関連疾患における獲得免疫の役割
久保智史、田中良哉
日本臨牀, Mar. 2024, Reviewed, No invitation
Last

Perspectives on IgG4-related disease
田中良哉
日本臨牀, Mar. 2024, Reviewed, No invitation
Lead

寛解導入不応性骨髄線維症合併急性骨髄性白血病にフルダラビン,L-PAM,TBIに加え脾照射を用いた同種骨髄移植
大中 貴史, 河野 一郎, 森本 浩章, 窪田 歩, 松浦 愛, 溝部 貴光, 毛利 文彦, 東 丈裕, 塚田 順一, 田中 良哉
日本血液学会・日本臨床血液学会総会プログラム・抄録集, Sep. 2005, Null, Null

非寛解血液腫瘍に対する骨髄非破壊的前処置フルダラビン+メルファラン+全身放射線照射による同種骨髄移植
森本 浩章, 塚田 順一, 大中 貴史, 松浦 愛, 杉藤 素子, 太田 貴徳, 河野 一郎, 窪田 歩, 東 丈裕, 溝部 貴光, 毛利 文彦, 中田 浩一, 田中 良哉
日本血液学会・日本臨床血液学会総会プログラム・抄録集, Sep. 2005, Null, Null

成人T細胞白血病株化細胞におけるMyD88-Toll/IL-1 receptorシグナルの恒常的活性化
溝部 貴光, 塚田 順一, 東 丈裕, 毛利 文彦, 松浦 愛, 森本 浩章, 田中 良哉
日本血液学会・日本臨床血液学会総会プログラム・抄録集, Sep. 2005, Null, Null

成人T細胞白血病における恒常的チロシン・セリンリン酸化STAT4のSTAT3とのヘテロダイマー形成
東 丈裕, 塚田 順一, 溝部 貴光, 毛利 文彦, 松浦 愛, 森本 浩章, 田中 良哉
日本血液学会・日本臨床血液学会総会プログラム・抄録集, Sep. 2005, Null, Null

骨代謝異常から見た血管障害　ビスホスホネートによる血管石灰化の制御　基礎および臨床的検討から
岡田 洋右, 谷川 隆久, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

骨代謝から見た関節リウマチの診断と治療　RAの骨代謝異常とTNFα
田中 良哉, 岡田 洋右, 名和田 雅夫, 中山田 真吾, 齋藤 和義
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

ガレクチン9の骨代謝調節機序の解明
谷川 令奈, 岡田 洋右, 中野 和久, 谷川 隆久, 細川 隆司, 山内 清明, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

ステロイド性骨粗鬆症におけるビスホスホネートによる一次予防効果
岡田 洋右, 斉藤 和義, 中山田 真吾, 名和田 雅夫, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

RA滑膜由来血管内皮細胞はM-CSFを産生し破骨細胞分化形成を誘導する
中野 和久, 岡田 洋右, 谷川 令奈, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

Advanced glycation end productによる血管平滑筋細胞の石灰化機序とエチドロネートによる予防効果の検討
谷川 隆久, 岡田 洋右, 谷川 令奈, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

Rhoシグナルを標的とする骨芽細胞機能の人為的制御
中山田 真吾, 平井 文彦, 岡田 洋右, 齋藤 和義, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

関節リウマチ(RA)に対する抗TNFα抗体(infliximab)の骨代謝調節機序　当科72症例における1年後の解析
名和田 雅夫, 岡田 洋右, 中山田 真吾, 齋藤 和義, 田中 良哉
日本骨代謝学会学術集会プログラム抄録集, Jun. 2005, Null, Null

ステロイド性骨粗鬆症
田中良哉
日本骨粗鬆症学会雑誌, May 2022, Reviewed, No invitation
Lead

グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン2023
田中 良哉
日本骨粗鬆症学会雑誌, Feb. 2024, Reviewed, No invitation
Lead

【慢性炎症性疾患の新たな展開】 慢性炎症と疾患　自己免疫疾患と慢性炎症Tfh細胞の病的意義
中山田 真吾, 田中 良哉
最新医学, Nov. 2016, Null, Null
Corresponding

【自己免疫疾患の新しい治療法　生物学的製剤を中心に】　抗CD20抗体
齋藤 和義, 徳永 美貴子, 田中 良哉
最新医学, May 2006, Null, Null

【免疫と疾患(後篇)　自己免疫と疾患】　自己免疫疾患の概念と知見　全身性エリテマトーデス
田中 良哉
最新医学, Jun. 2005, Null, Null

糖尿病に合併する感染症(第33回)　膠原病と感染症
田中 良哉
月刊糖尿病, Oct. 2012, Null, Null

【関節リウマチ　積極的な治療へのパラダイム転換】　生物学的製剤の現状と展望
田中 良哉
治療学, Jul. 2006, Null, Null

リウマチ医療の変遷
田中良哉
流, Jan. 2023, Reviewed, No invitation
Lead

【SLE診療up to date】BAFF標的治療の位置づけ
中山田 真吾, 田中 良哉
炎症と免疫, Feb. 2025, Reviewed, No invitation
Last

リウマチ性疾患の臓器障害　リウマチ性疾患における多臓器障害のメカニズム
久保 智史, 田中 良哉
炎症と免疫, Jun. 2024, Reviewed, No invitation
Last

【アンメットニーズに対するJAK阻害薬の可能性】膠原病・リウマチ性疾患治療の実際と今後の展望
田中 良哉
炎症と免疫, Feb. 2024, Reviewed, No invitation
Lead

【膠原病に合併する進行性線維化を伴う間質性肺疾患】PF-ILDの臨床像　膠原病リウマチ内科の視点から
田中 良哉
炎症と免疫, Dec. 2021, Reviewed, No invitation
Lead

【膠原病で期待される標的療法〜効果と今後への展望〜】BAFF阻害薬の作用機序、使い方と今後の展望
宮崎 佑介, 中山田 真吾, 田中 良哉
炎症と免疫, Jun. 2021, Reviewed, No invitation
Last

関節リウマチの鑑別診断(No.5)　乾癬性関節炎
宮川 一平, 田中 良哉
炎症と免疫, Feb. 2021, Reviewed, No invitation
Last

ヒト免疫細胞の新しい解析手法(第2回)　ヒト免疫細胞のマルチカラーフローサイトメトリー解析
中山田 真吾, 宮崎 佑介, 田中 良哉
炎症と免疫, Aug. 2020, Reviewed, No invitation
Last

【IgG4関連疾患の新展開】IgG4関連疾患における免疫細胞とサイトカイン
田中 良哉, 久保 智史, 井上 嘉乃, 中山田 真吾
炎症と免疫, Jun. 2020, Reviewed, No invitation
Lead

炎症性サイトカインの基礎と臨床　IL-6を中心に(第5回)　サリルマブのRA治療
田中 良哉
炎症と免疫, Aug. 2019, Reviewed, No invitation
Lead

【自己免疫性疾患・炎症性疾患における治療最適化の試み】全身性エリテマトーデス
中山田 真吾, 田中 良哉
炎症と免疫, Jun. 2019, Reviewed, No invitation

【話題のリウマチ・膠原病治療薬:その基礎と臨床評価】バリシチニブ
田中 良哉
炎症と免疫, Jan. 2018, Reviewed, No invitation
Lead

【全身性エリテマトーデス:病態解明の進歩】 全身性エリテマトーデスにおける免疫異常のオーバービュー
中山田 真吾, 田中 良哉
炎症と免疫, Feb. 2017, Reviewed, No invitation

【Human immunology:基礎から臨床まで】 濾胞性ヘルパーT細胞
中山田 真吾, 田中 良哉
炎症と免疫, Oct. 2016, Null, Null
Corresponding

医学用語解説　プロペンシティスコア(Propensity score)
久保 智史, 田中 良哉
炎症と免疫, Jun. 2016, Null, Null
Corresponding

B細胞内のシグナル伝達機構(第8回)　ヒトB細胞シグナルにおけるSykの役割
岩田 慈, 田中 良哉
炎症と免疫, Jun. 2016, Null, Null
Corresponding

抗CD20抗体によるSLEの治療
田中 良哉
炎症と免疫, Aug. 2006, Null, Null

【マスト細胞を軸としたアレルギー・感染・炎症】　マスト細胞からみた自己免疫疾患の病態と治療の新展開
澤向 範文, 田中 良哉
炎症と免疫, Aug. 2006, Null, Null

ステロイド治療抵抗性と生物学的製剤による克服
田中 良哉, 辻村 静代
炎症と免疫, Jun. 2006, Null, Null

【TNFと病態】　TNFと動脈硬化
田中 良哉, 西田 啓子, 岡田 洋右
炎症と免疫, Jun. 2006, Null, Null

T細胞内のシグナル伝達分子機構　免疫シグナル研究の展望
田中 良哉
炎症と免疫, Oct. 2005, Null, Null

【骨破壊の分子細胞機能学】　サイトカインと骨破壊
田中 良哉
炎症と免疫, Jun. 2005, Null, Null

炎症性疾患の分子標的治療の実際と課題　B細胞
田中 良哉
炎症・再生, Jul. 2005, Null, Null

免疫制御　移植/リウマチ治療/医薬開発の現状と将来　膠原病における免疫抑制　生物学的製剤によるパラダイムシフト
田中 良哉
炎症・再生, Jul. 2005, Null, Null

血糖持続モニタリングを用いて月経前に増悪する反応性低血糖が改善した1例
齋藤桃, 岡田洋右, 鳥本桂一, 田中良哉
産業医科大学雑誌, Sep. 2022, Reviewed, No invitation
Last

悪性黒色腫に対するニボルマブ投与後に破壊性甲状腺炎とACTH単独欠損症を来した1例
西尾 公佑, 岡田 洋右, 黒住 旭, 田中 良哉
産業医科大学雑誌, Mar. 2021, Reviewed, No invitation
Last

Flash Glucose MonitoringでSGLT2阻害薬の短期的血糖改善効果が確認できた外来通院中1型糖尿病の2症例
羽生 桃子, 岡田 洋右, 黒住 旭, 田中 良哉
産業医科大学雑誌, Dec. 2020, Reviewed, No invitation
Last

末梢血リンパ球の多様性が推測された劇症1型糖尿病の1症例(Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report)
黒住 旭, 岡田 洋右, 宮崎 佑介, 中山田 真吾, 田中 良哉
産業医科大学雑誌, Mar. 2020, Null, Null
Last

2型糖尿病と血管内皮機能障害
鳥本桂一, 岡田洋右, 田中良哉
産業医科大学雑誌, Apr. 2018, Reviewed, No invitation
Last

オクトレオチドLong Acting Release(LAR)投与により下垂体腫瘍が著明に縮小し治癒切除し得た先端巨大症の1例
新生 忠司, 岡田 洋右, 上村 芙美, 西澤 茂, 田中 良哉
産業医科大学雑誌, Sep. 2017, Reviewed, Null
Last

2型糖尿病患者におけるシタグリプチン50mgから100mgへの増量とミチグリニドカルシウム水和物・ボグリボースへの切り替えにおける有用性に関する比較検討(Comparison Between Effectiveness of 100mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50mg/day Sitagliptin in Patients with Type 2 Diabetes)
新生 忠司, 岡田 洋右, 鳥本 桂一, 須貝 慧, 大塚 隆史, 黒住 旭, 田中 良哉
産業医科大学雑誌, Mar. 2017, Not reviewed, Null
Last

骨粗鬆症など生活習慣病を中心とした就労女性におけるヘルスケアの実態調査　女性が健康的な就労者であり続けることを目指して
森 博子, 卜部 理恵, 永田 昌子, 岡田 洋右, 田中 良哉
産業医科大学雑誌, Mar. 2013, Null, Null

難治性線維化病態に対するイマチニブ少量療法の効果
澤向 範文, 久保 智史, 齋藤 和義, 山岡 邦宏, 田中 良哉
産業医科大学雑誌, Mar. 2013, Null, Null

単球系細胞のチロシンキナーゼJAKを介した職業性アレルギー病態調整機構
山岡 邦宏, 久保 智史, 尾下 浩一, 田中 良哉
産業医科大学雑誌, Mar. 2013, Null, Null

行動療法と環境整備により著明な減量とその後の体重維持を成し得たPrader-Willi症候群の2例
西田 啓子, 岡田 洋右, 森 博子, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 森田 恵美子, 田中 良哉
産業医科大学雑誌, Mar. 2006, Null, Null

簡易血糖測定器(アキュチェックアクティブ)の基本的性能評価の検討　メディセーフミニとの比較
矢野 百合子, 岡田 洋右, 永松 京子, 廣瀬 暁子, 新生 忠司, 西田 啓子, 森田 恵美子, 田中 良哉
産業医科大学雑誌, Mar. 2006, Null, Null

糖尿病就労者における療養上の問題点および早期生活習慣への介入による一次・二次予防効果の検討
岡田 洋右, 神田 加寿子, 西田 啓子, 森田 恵美子, 山下 和仁, 太崎 博美, 日野 義之, 柴田 弘子, 矢野 百合子, 永松 京子, 杉本 英克, 田中 良哉
産業医科大学雑誌, Mar. 2006, Null, Null

炎症性サイトカイン遺伝子転写活性化機構と遺伝子異変の影響
塚田 順一, 長田 良雄, 森本 浩幸, 吉田 安宏, 田中 良哉
産業医科大学雑誌, Mar. 2006, Null, Null

【ステロイド性骨粗鬆症の治療】　ステロイド性骨粗鬆症の一次予防
田中 良哉
痛みと臨床, Mar. 2006, Null, Null

Streptococcus agalactiaeによる両側腸腰筋膿瘍を呈した糖尿病の1例
大塚 隆史, 岡田 洋右, 鳥本 桂一, 稲田 良郁, 鈴鹿 佳南子, 瓜生 康平, 田中 良哉
糖尿病, Oct. 2019, Reviewed, No invitation
Last

イプラグリフロジンを含めた総合的治療が血糖、NASHによる肝機能障害の改善につながった2型糖尿病の1例
森 博子, 岡田 洋右, 川口 真悠子, 日浦 政明, 阿部 慎太郎, 柴 瑛介, 島尻 正平, 原田 大, 田中 良哉
糖尿病, Apr. 2015, Null, Null
Last, Corresponding

2型糖尿病合併高血圧患者に対するオルメサルタンとテルミサルタン高用量による糖代謝、脂質代謝、降圧に関する検討
新生 忠司, 岡田 洋右, 森 博子, 鳥本 桂一, 田中 良哉
糖尿病, Apr. 2013, Reviewed, No invitation
Last

CKD合併2型糖尿病患者におけるテネリグリプチンとリナグリプチンのCGMにおける血糖動態の比較検討
田中健一, 岡田洋右, 森博子, 稲田良郁, 鈴鹿佳南子, 瓜生康平, 田中良哉
糖尿病, Apr. 2013, Reviewed, No invitation
Last

外来インスリン治療糖尿病患者における日差変動に影響を及ぼす因子の検討
森博子, 岡田洋右, 黒住旭, 田中良哉
糖尿病, Apr. 2013, Reviewed, No invitation
Last

外来インスリン使用患者における24時間持続血糖装置(iPro2)を用いた血糖変動と血糖コントロール指標との関係
黒住旭, 岡田洋右, 森博子, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

CGMによる日本人2型糖尿病患者におけるHbA1cに応じた血糖変動の検討
元舞子, 岡田洋右, 森博子, 久能芙美, 須貝慧, 園田里美, 田中健一, 黒住旭, 成澤学, 鳥本桂一, 新生忠司, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

2型糖尿病患者に於けるエクセナチドの食後血管内皮機能に関するエンドパットを用いた検討
鳥本桂一, 岡田洋右, 元舞子, 田中健一, 黒住旭, 成澤学, 森博子, 新生忠司, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

2型糖尿病患者におけるエキセナチドの糖代謝・膵外作用の検討
須貝慧, 岡田洋右, 鳥本桂一, 久能芙美, 園田里美, 元舞子, 田中健一, 黒住旭, 成澤学, 森博子, 新生忠司, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

2型糖尿病における25(OH)ビタミンDの充足状態と骨・糖・脂質代謝との関係
久能芙美, 岡田洋右, 森博子, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

2型糖尿病患者に於けるCGMを用いた糖尿病合併症への影響因子に関する検討
園田里美, 岡田洋右, 森博子, 久能芙美, 須貝慧, 元舞子, 田中健一, 黒住旭, 成澤学, 鳥本桂一, 新生忠司, 田中良哉
糖尿病, Apr. 2013, Null, Null
Last

外来通院中に持続血糖モニター(iPro2)を利用し血糖コントロール改善につながったインスリン治療中の4例
周田智美, 高橋利香, 守田幸代, 幸野恵美, 森博子, 岡田洋右, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

インスリン療法中の2型糖尿病患者におけるビルダグリプチンとシタグリプチンの併用効果の比較検討
成澤学, 岡田洋右, 森博子, 田中良哉
糖尿病, Apr. 2013, Reviewed, Null
Last

強化インスリン療法中2型糖尿病患者におけるCGMを用いた食後血糖値の評価
久能 芙美, 鳥本 桂一, 岡田 洋右, 須貝 慧, 園田 里美, 元 舞子, 田中 健一, 黒住 旭, 成澤 学, 山本 直, 森 博子, 新生 忠司, 田中 良哉
糖尿病, Sep. 2013, Reviewed, No invitation
Last

シタグリプチン追加時のスルフォニル尿素薬の適正減量量に関する検討
元舞子, 岡田洋右, 森博子, 田中健一, 黒住旭, 成澤学, 鳥本桂一, 新生忠司, 田中良哉
糖尿病, Sep. 2013, Reviewed, Null
Last

シタグリプチンからミチグリニド/ボグリボース配合錠への変更が有用であった2型糖尿病の1例
須貝 慧, 新生 忠司, 岡田 洋右, 久能 芙美, 園田 里美, 元 舞子, 田中 健一, 島本 桂一, 田中 良哉
糖尿病, Oct. 2013, Not reviewed, Null
Last

糖尿病患者の歯周病罹患状況と保健行動に関しての現状調査
入江 めぐみ, 山下 美里, 田中 絵美, 森 博子, 鳥本 桂一, 元 舞子, 黒住 旭, 岡田 洋右, 田中 良哉
糖尿病, Oct. 2013, Reviewed, No invitation
Last

ダンピング症候群症例におけるオーダーメイド治療　4症例のCGMを通して
園田 里美, 岡田 洋右, 森 博子, 元 舞子, 黒住 旭, 鳥本 桂一, 田中 良哉
糖尿病, Oct. 2013, Reviewed, No invitation
Last

2型糖尿病患者における高脂肪食負荷が血管内皮機能に与える影響
黒住 旭, 岡田 洋右, 森 博子, 新生 忠司, 田中 良哉
糖尿病, Oct. 2013, Reviewed, No invitation
Last

抗TNFα抗体投与による糖代謝,動脈硬化抑制効果の検討
西田 啓子, 岡田 洋右, 名和田 雅夫, 齋藤 和義, 田中 良哉
糖尿病, Apr. 2006, Null, Null

他のARBからのテルミサルタンへの切り替えによる高血圧合併2型糖尿病患者の降圧およびインスリン抵抗性改善効果の検討
新生 忠司, 岡田 洋右, 森 博子, 廣瀬 暁子, 谷川 隆久, 西田 啓子, 森田 恵美子, 神田 加壽子, 田中 良哉
糖尿病, Apr. 2006, Null, Null

糖尿病および血液透析による血管石灰化に対するエチドロネートの抑制効果
岡田 洋右, 橋本 修, 西田 啓子, 谷川 隆久, 廣瀬 暁子, 瓜生 康平, 田中 良哉
糖尿病, Apr. 2006, Null, Null

糖尿病性動脈硬化病変形成におけるCD31の関与についての検討
廣瀬 暁子, 岡田 洋右, 峯 信一郎, 田中 良哉
糖尿病, Apr. 2006, Null, Null

AGEによる血管平滑筋細胞の石灰化誘導機構およびエチドロネートによる予防機序の解明
谷川 隆久, 岡田 洋右, 田中 良哉
糖尿病, Apr. 2006, Null, Null

インスリン分泌促進薬投与中の2型糖尿病患者におけるピオグリタゾン追加投与の有効性に関する検討
森 博子, 岡田 洋右, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 西田 啓子, 森田 恵美子, 田中 良哉
糖尿病, Apr. 2006, Null, Null

インスリンリスプロにより硬性浮腫,好酸球増多,胸水をきたしたと考えられた2型糖尿病の1例
新生 忠司, 岡田 洋右, 廣瀬 暁子, 神田 加壽子, 森田 恵美子, 田中 良哉
糖尿病, Mar. 2006, Null, Null

著明な高血糖で発症し腎盂癌術直後よりインスリン治療が不要となった2型糖尿病の1例
西田 啓子, 岡田 洋右, 廣瀬 暁子, 森 博子, 新生 忠司, 森田 恵美子, 田中 良哉
糖尿病, Jan. 2006, Null, Null

テルミサルタン投与下における2型糖尿病患者のインスリン抵抗性改善効果の検討
神田 加壽子, 岡田 洋右, 新生 忠司, 谷川 隆久, 廣瀬 暁子, 岸川 博文, 村上 敦子, 森田 恵美子, 田中 良哉
糖尿病, Apr. 2005, Null, Null

AGEによる血管平滑筋細胞の石灰化誘導とエチドロネートによる予防の検討
谷川 隆久, 岡田 洋右, 廣瀬 暁子, 新生 忠司, 神田 加壽子, 森田 恵美子, 田中 良哉
糖尿病, Apr. 2005, Null, Null

ASVS陽性で膵切除術を施行したびまん性膵病変による低血糖症2症例の検討
廣瀬 暁子, 岡田 洋右, 谷川 隆久, 新生 忠司, 神田 加壽子, 森田 恵美子, 田中 良哉
糖尿病, Apr. 2005, Null, Null

ダンピング症候群にびまん性インスリン過剰分泌症を合併した低血糖症の1例
神田 加壽子, 岡田 洋右, 廣瀬 暁子, 岸川 博文, 谷川 隆久, 河原 哲也, 森田 恵美子, 田中 良哉
糖尿病, May 2005, Null, Null

就労中の糖尿病患者における療養上の問題点の検討
神田 加壽子, 岡田 洋右, 森田 恵美子, 杉本 英克, 田中 良哉
糖尿病, May 2005, Null, Null

2型糖尿病患者における週末2泊3日糖尿病短期教育パス入院による血糖コントロール改善効果に関する検討
新生 忠司, 岡田 洋右, 黒住 旭, 財津 日奈子, 五島 麻里子, 浦野 美紀, 豊福 律子, 亀田 敬子, 末松 直子, 田中 良哉
糖尿病プラクティス, Mar. 2021, Reviewed, No invitation
Last

【骨粗鬆症のすべて】(第11章)関節リウマチと骨粗鬆症　抗リウマチ薬と骨粗鬆症
田中 良哉
糖尿病・内分泌代謝科, Jul. 2020, Reviewed, No invitation
Lead

【骨粗鬆症のすべて】(第10章)特殊な病態と関連する骨粗鬆症　ステロイド性骨粗鬆症
岡田 洋右, 田中 良哉
糖尿病・内分泌代謝科, Jul. 2020, Reviewed, No invitation

血糖コントロールと血管内皮機能の関係　エンドバットを用いた検討
鳥本 桂一, 岡田 洋右, 森 博子, 元 舞子, 田中 健一, 黒住 旭, 成澤 学, 山本 直, 新生 忠司, 田中 良哉
糖尿病合併症, Oct. 2012, Null, Null

2型糖尿病患者におけるビタミンD充足状態およびその骨代謝、PTHに及ぼす影響
森 博子, 岡田 洋右, 新生 忠司, 田中 良哉
糖尿病合併症, Oct. 2012, Null, Null

免疫と糖尿病　オーバービュー
田中 良哉
糖尿病合併症, Jul. 2006, Null, Null

免疫と糖尿病　免疫と糖尿病　オーバービュー(基調講演)
田中 良哉
糖尿病合併症, Sep. 2005, Null, Null

【骨粗鬆症の診療Up Date】　続発性骨粗鬆症とその対策　移植療法
田中 良哉, 塚田 順一
綜合臨床, Nov. 2005, Null, Null

リハビリテーション医療に必要な薬物治療(第5回)　関節リウマチ
田中 良哉
総合リハビリテーション, May 2019, Reviewed, No invitation
Lead

【知っておくべき!モノクロな薬たち(注:モノクローナル抗体の話ですよ〜)】(第1部)あなたもよく使うモノクロな薬たち(非腫瘍性疾患)　骨粗鬆症・骨軟化症に使用するモノクローナル抗体　デノスマブ、ロモソズマブ、ブロスマブ
田中健一, 岡田洋右, 田中良哉
総合診療, Jun. 2023, Reviewed, No invitation
Last

【高齢者の転倒骨折予防に向けて-最新の骨粗鬆症-】ステロイド性骨粗鬆症の診断と治療
田中 良哉
老年内科, Apr. 2020, Reviewed, No invitation
Lead

【高齢者の骨系疾患】ステロイド性骨粗鬆症
田中良哉
老年科, Oct. 2022, Reviewed, No invitation
Lead

【SLEとAAVの新展開】現在治験中のSLEの新規薬剤(rozibafusp alfa, cenerimod)
久保 智史, 田中 良哉
腎と透析, Jun. 2023, Reviewed, No invitation
Last

【SLEとAAVの新展開】自己免疫疾患における濾胞性ヘルパーT細胞
中山田 真吾, 田中 良哉
腎と透析, Jun. 2023, Reviewed, No invitation
Last

【急速進行性腎炎症候群-Up date】ループス腎炎に対する治療法開発の現況
田中 良哉
腎と透析, Sep. 2021, Reviewed, No invitation
Lead

【全身性疾患と腎update】(第1章)膠原病、血管炎、自己免疫疾患　関節リウマチ・リウマチ専門医の視点より
田中 良哉
腎と透析, Jun. 2019, Reviewed, No invitation
Lead

【骨粗鬆症マネジメントupdate】 続発性骨粗鬆症　ステロイド性骨粗鬆症
田中 良哉
腎と骨代謝, Apr. 2017, Not reviewed, Null
Lead

【ステロイドと骨代謝】　ステロイド性骨粗鬆症の治療のエビデンス
田中 良哉
腎と骨代謝, Apr. 2006, Null, Null

【新たなるビタミンDの側面】　ビタミンDと免疫調節
田中 良哉
腎と骨代謝, Jul. 2005, Null, Null

関節リウマチ治療における寛解の先
久保 智史, 田中 良哉
臨床リウマチ, Jun. 2024, Reviewed, No invitation
Last

【バリシチニブ】
中山田 真吾, 田中 良哉
臨床リウマチ, Sep. 2023, Reviewed, No invitation
Last

【JAK阻害薬総論】
田中 良哉
臨床リウマチ, Sep. 2023, Reviewed, No invitation
Lead

関節リウマチ　precision medicineの可能性　免疫フェノタイプによるリウマチ性疾患のプレシジョン・メディシン
田中 良哉
臨床リウマチ, Dec. 2020, Reviewed, No invitation
Lead

関節リウマチの新規治療　関節リウマチ治療におけるJAK阻害薬
中山田 真吾, 田中 良哉
臨床リウマチ, Jun. 2019, Reviewed, No invitation

アクセプトされやすい英文論文の書き方
田中良哉
臨床リウマチ, Apr. 2018, Reviewed, Null
Lead

メトトレキサート未治療早期関節リウマチ患者に対する予後不良因子の検討とセルトリズマブペゴルの有効性の検討　無作為化、プラセボ対照第三相、C-OPERA試験のサブグループ解析
田中良哉, 渥美達也, 山本一彦, 竹内勤, 山中寿, 石黒直樹, 江口勝美, 渡辺彰, 折笠秀樹, 小路利治, Ralston P., 宮坂信之, 小池隆夫
臨床リウマチ, Jun. 2018, Reviewed, No invitation
Lead

日本のリウマチ学が世界に評価されつづけるには
田中 良哉
臨床リウマチ, Mar. 2017, Not reviewed, Null
Lead

膠原病治療Update:BIOLOGICSを中心に 関節リウマチ合併二次性シェーグレン症候群に対するアバタセプトによる新規治療戦略
坪井 洋人, 松本 功, 萩原 晋也, 廣田 智哉, 高橋 広行, 江辺 広志, 横澤 将宏, 柳下 瑞希, 高橋 秀典, 藏田 泉, 大山 綾子, 本田 文香, 浅島 弘充, 三木 春香, 梅田 直人, 近藤 裕也, 住田 孝之, 平田 信太郎, 齋藤 和義, 田中 良哉, 寳來 吉朗, 中村 英樹, 川上 純
臨床リウマチ, Dec. 2016, Null, Null

重症RAに対する新規生物学的製剤　適応とリスクマネージメント
田中 良哉
臨床リウマチ, Sep. 2006, Null, Null

【関節リウマチ研究における新たな視点】　関節リウマチの病態形成におけるマスト細胞の役割とその意義
澤向 範文, 田中 良哉
臨床免疫, Mar. 2006, Null, Null

【自己免疫疾患発症機序における最近の展望】　SLE患者T細胞におけるβ1インテグリンの意義
中山田 真吾, 田中 良哉
臨床免疫, Jan. 2006, Null, Null

【免疫と骨破壊の新たな接点】　骨芽細胞におけるRho発現制御と骨吸収
平井 文彦, 中山田 真吾, 田中 良哉
臨床免疫, Dec. 2005, Null, Null

【自己免疫疾患における遺伝子探索の現状と将来展望】　全身性自己免疫疾患患者における多剤抵抗性遺伝子発現異常
辻村 静代, 齋藤 和義, 河野 公俊, 田中 良哉
臨床免疫, Oct. 2005, Null, Null

自己免疫疾患のプレシジョンメディシン
中山田 真吾, 田中 良哉
臨床免疫・アレルギー科, Apr. 2025, Reviewed, No invitation
Last

【腎臓と免疫学】ループス腎炎治療の新知見
田中 良哉
臨床免疫・アレルギー科, Jul. 2024, Reviewed, No invitation
Lead

【免疫疾患の層別化】全身性エリテマトーデス患者の層別化
中山田 真吾, 田中 良哉
臨床免疫・アレルギー科, Apr. 2024, Reviewed, No invitation
Last

Tfh細胞/Tfr細胞と自己免疫疾患
中山田真吾, 田中良哉
臨床免疫・アレルギー科, Oct. 2022, Reviewed, No invitation
Last

【自己免疫疾患の病態と治療】自己免疫疾患における免疫代謝機構を介したリンパ球の分化・機能
岩田慈, 田中良哉
臨床免疫・アレルギー科, Jul. 2022, Reviewed, No invitation
Last

アニフロルマブ
中山田真吾, 田中良哉
臨床免疫・アレルギー科, Apr. 2022, Reviewed, No invitation
Last

【濾胞ヘルパーT細胞と疾患】SLEにおける濾胞性ヘルパーT細胞のエピゲノム制御
中山田 真吾, 田中 良哉
臨床免疫・アレルギー科, Mar. 2020, Reviewed, No invitation

【抗体医薬・生物学的製剤療法の現状と課題】リウマチ性疾患の生物学的製剤療法
田中 良哉
臨床免疫・アレルギー科, Sep. 2019, Reviewed, No invitation
Lead

【自己免疫疾患】 強皮症
久保 智史, 田中 良哉
臨床免疫・アレルギー科, Apr. 2018, Reviewed, Null
Last, Corresponding

関節リウマチに対する分子標的薬の新展開
田中 良哉
臨床免疫・アレルギー科, Jul. 2017, Not reviewed, Null
Lead

リツキシマブ抵抗性を示した重症血栓性血小板減少性紫斑病
岩重 淳司, 葛城 武文, 東 丈裕, 毛利 文彦, 森本 浩章, 松浦 愛, 田中 綾, 溝部 貴光, 塚田 順一, 田中 良哉, 松本 雅則, 加藤 誠司, 藤村 吉博
臨床血液, Sep. 2006, Null, Null

マクロファージにおける細胞内HMGB1とPU.1による炎症性サイトカイン遺伝子の相乗的活性化
毛利 文彦, 塚田 順一, 溝部 貴光, 東 丈裕, 松浦 愛, 田中 綾, 葛城 武文, 岩重 淳司, 森本 浩章, 田中 良哉
臨床血液, Sep. 2006, Null, Null

成人T細胞白血病(ATL)におけるTaxを介するToll like receptorシグナルの恒常的活性化
溝部 貴光, 塚田 順一, 森本 浩章, 岩重 淳司, 田中 綾, 葛城 武文, 東 丈裕, 毛利 文彦, 松浦 愛, 田中 良哉
臨床血液, Sep. 2006, Null, Null

成人T細胞白血病におけるSTAT4・STAT3ヘテロダイマーの形成
東 丈裕, 塚田 順一, 毛利 文彦, 森本 浩章, 岩重 淳司, 松浦 愛, 葛城 武文, 田中 綾, 溝部 貴光, 田中 良哉
臨床血液, Sep. 2006, Null, Null

[Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia].
Mizobe Takamitsu, Tsukada Junichi, Higashi Takehiro, Iwashige Atsushi, Ota Takanori, Kawano Ichiro, Kubota Ayumu, Matsuura Ai, Morimoto Hiroaki, Ogawa Ryosuke, Toda Yoko, Tanaka Yoshiya
[Rinsho ketsueki] The Japanese journal of clinical hematology, Mar. 2005, Reviewed, No invitation
Last

メシル酸イマチニブによる急激な好塩基球減少を契機に全身性紅斑を呈した慢性骨髄性白血病
Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib
臨床血液, Nov. 2005, Reviewed, No invitation
Last

[Remission induction of refractory diffuse large B-cell lymphoma with allogeneic peripheral blood stem cell transplantation followed by interferon-alpha and donor lymphocyte infusion].
Kawano Ichiro, Tsukada Junichi, Toda Yoko, Ogawa Ryosuke, Higashi Takehiro, Iwashige Atsushi, Ota Takanori, Kubota Ayumu, Mizobe Takamitsu, Morimoto Hiroaki, Machida Shinichiro, Tanaka Yoshiya
[Rinsho ketsueki] The Japanese journal of clinical hematology, Feb. 2004, Reviewed, No invitation
Last

【大きく変わった?ステロイドの使い方】各種疾患におけるステロイドの使い方　膠原病・リウマチ
田中 良哉
臨牀と研究, Oct. 2022, Reviewed, No invitation
Lead

膠原病治療薬の上手な使い方
田中 良哉, 大石 了三
臨牀と研究, Jul. 2021, Reviewed, No invitation
Lead

【最新の膠原病診療】診療の実際　全身性エリテマトーデス
田中 良哉
臨牀と研究, Jun. 2021, Reviewed, No invitation
Lead

【検診データの適正な解釈と患者指導】データの解釈と指導の実際　骨粗鬆症関連検査
田中 良哉
臨牀と研究, Aug. 2019, Reviewed, No invitation
Lead

【安全で効果的なステロイド療法】 ステロイドの副作用管理のポイント
田中 良哉
臨牀と研究, Jul. 2017, Not reviewed, Null
Lead

ループス様症状を示したHIV感染症の1例
鈴木 克典, 齋藤 和義, 田中 良哉
臨牀と研究, Nov. 2012, Null, Null

北九州地区における2型糖尿病患者の合併症調査
新生 忠司, 岡田 洋右, 岸川 博文, 村上 敦子, 神田 加壽子, 井口 信夫, 杉本 英克, 森田 恵美子, 田中 良哉
臨牀と研究, Apr. 2006, Null, Null

甲状腺癌術後に高カルシウム血症を来たした多発性肺転移を伴う高齢者の1例
森 博子, 岡田 洋右, 西田 啓子, 廣瀬 暁子, 谷川 隆久, 新生 忠司, 森田 恵美子, 田中 良哉
臨牀と研究, Jan. 2006, Null, Null

治療の実際　関節リウマチの最新の治療戦略
中山田 真吾, 田中 良哉
臨牀と研究, Jan. 2025, Reviewed, No invitation
Last

【今こそ知りたい! JAK阻害薬　適応の拡大を追いかける&免疫系に強くなる】JAK阻害薬の効きどころ,使いどころ　関節リウマチ
田中 良哉
薬局, Feb. 2025, Reviewed, No invitation
Lead

治療薬剤を重点的に更新！『グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン 2023』
田中良哉
薬局, 2023, Reviewed, No invitation
Lead

【2023年なにあった?　今年注目の診療ガイドライン&新薬・新規効能・新剤形】Pick Up!診療ガイドライン　治療薬剤を重点的に更新!『グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン2023』
田中 良哉
薬局, Dec. 2023, Reviewed, No invitation
Lead

【ここが変わった! 関節リウマチの治療】リウマチ患者さんの「困った!」「大丈夫?」に対処する　リウマチ治療中でもワクチンは打って大丈夫?
中山田 真吾, 田中 良哉
薬局, Mar. 2023, Reviewed, No invitation
Last

【ここが変わった! 関節リウマチの治療】リウマチ患者さんの「困った!」「大丈夫?」に対処する　薬は減らせないの?　疾患活動性と希望に応じて減薬を処方医に相談する
久保智史, 田中良哉
薬局, Mar. 2023, Reviewed, No invitation
Last

ここが変わった！ 関節リウマチの治療―特集にあたって―
田中良哉
薬局, Mar. 2023, Reviewed, No invitation
Lead

【2021年なにあった?-くすり・ガイドライン・社会etc…-】Catch Up!診療ガイドライン　ガイドラインTOPICS　混合性結合組織病(MCTD)診療ガイドライン2021が完成
田中 良哉
薬局, Dec. 2021, Reviewed, No invitation
Lead

【骨粗鬆症　最新の知見に基づいた治療薬の考え方・使い方】合併症・併存症をもつ骨粗鬆症患者における予防・治療の実践ポイント　関節リウマチ×骨粗鬆症
中野 和久, 田中 良哉
薬局, Oct. 2020, Reviewed, No invitation
Last

【骨粗鬆症　最新の知見に基づいた治療薬の考え方・使い方】徹底解説!治療薬を使いこなす"知識"と"ノウハウ"　副甲状腺ホルモン・PTHrPアナログ(テリパラチド、abaloparatide)
田中 健一, 岡田 洋右, 田中 良哉
薬局, Oct. 2020, Reviewed, No invitation
Last

【関節リウマチ　治療薬を使いこなす"ワザ"と"知恵"】関節リウマチにおける治療費軽減対策　バイオシミラーとドラッグホリデー
田中 良哉
薬局, Apr. 2019, Reviewed, No invitation
Lead

【関節リウマチ　治療薬を使いこなす"ワザ"と"知恵"】新たに登場した関節リウマチ治療薬を使いこなす勘所　JAK阻害薬
中山田 真吾, 田中 良哉
薬局, Apr. 2019, Reviewed, No invitation

【骨髄間質と造血】　各種病態での骨髄間質の異常　骨粗鬆症
田中 良哉, 塚田 順一
血液フロンティア, Jun. 2006, Null, Null

【マクロファージ研究の新展開】IgG4関連疾患におけるM2マクロファージの役割
大久保 直紀, 中山田 真吾, 田中 良哉
血液内科, Jul. 2021, Reviewed, No invitation
Last

【血管炎の診断と治療:エッセンスと今後の展望】各種血管炎の診断・鑑別診断と治療　リウマトイド血管炎
田中 良哉
診断と治療, Oct. 2021, Reviewed, No invitation
Lead

【コモンディジーズとしての骨粗鬆症診療】骨粗鬆症の新たな知見と生活指導　ステロイド性骨粗鬆症
田中 良哉
診断と治療, Sep. 2020, Reviewed, No invitation
Lead

【知っておきたい関節リウマチの診断から治療まで】 治療の考え方と実際　生物学的製剤の使い方と今後の動向
中野 和久, 田中 良哉
診断と治療, Dec. 2016, Null, Null
Corresponding

日本臨床「関節リウマチの診療戦略のさらなる進化を目指して」
田中 良哉
関節リウマチの診療update, Aug. 2021, Reviewed, No invitation
Lead

ビタミンDが免疫機能に与える影響
田中良哉
食と医療, Apr. 2018, Reviewed, Null
Lead

関節リウマチの研究と治療の最前線
田中良哉、小林泰浩、田中栄、塚崎雅之
骨・軟骨・筋科学Update, Apr. 2025, Reviewed, No invitation

関節リウマチの研究と治療の最前線
田中良哉
骨・軟骨・筋科学Update, 2022, Reviewed, No invitation
Lead

【ステロイド性骨粗鬆症の治療戦略　ガイドラインとエビデンス】　ステロイド性骨粗鬆症の病態
田中 良哉, 岡田 洋右
骨粗鬆症治療, Jan. 2006, Null, Null

Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort.
Hao Yanjie, Hansen Dylan, Louthrenoo Worawit, Chen Yi-Hsing, Cho Jiacai, Lateef Aisha, Hamijoyo Laniyati, Luo Shue Fen, Wu Yeong-Jian, Navarra Sandra, Zamora Leonid, Li Zhanguo, Sockalingam Sargunan, Katsumata Yasuhiro, Harigai Masayoshi, Ji Lanlan, Zhang Zhuoli, Chan Madelynn, Kikuchi Jun, Takeuchi Tsutomu, Bae Sang-Cheol, Goldblatt Fiona, O'Neill Sean, Ng Kristine Pek Ling, Basnayake B M D B, Tugnet Nicola, Ohkubo Naoaki, Tanaka Yoshiya, Tee Cherica, Tee Michael, Lau C S, Li Ning, Golder Vera, Hoi Alberta, Kandane-Rathnayake Rangi, Morand Eric, Oon Shereen, Nikpour Mandana,
ACR open rheumatology, Mar. 2025, Reviewed, No invitation

Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
McInnes Iain B, Mease Philip J, Tanaka Yoshiya, Gossec Laure, Husni M Elaine, Kristensen Lars Erik, Warren Richard B, Ink Barbara, Bajracharya Rajan, Coarse Jason, Gottlieb Alice B
ACR open rheumatology, Nov. 2024, Reviewed, No invitation

Tomosynthesis of the wrist and hand in patients with rheumatoid arthritis: comparison with radiography and MRI.
Aoki Takatoshi, Fujii Masami, Yamashita Yoshiko, Takahashi Hiroyuki, Oki Hodaka, Hayashida Yoshiko, Saito Kazuyoshi, Tanaka Yoshiya, Korogi Yukunori
AJR. American journal of roentgenology, Feb. 2014, Reviewed, Null

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients With Psoriatic Arthritis
Hidemi Nakagawa, Yoshiya Tanaka, Shigetoshi Sano , Hideto Kameda , Atsuo Taniguchi , Tomoko Kashiwagi , Takeshi Kawaberi , Junko Kimura , Akimichi Morita
Advances in Therapy, Jan. 2019, Reviewed, No invitation

Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
Takeuchi Tsutomu, Nakajima Ryo, Komatsu Shuichi, Yamazaki Kiyotaka, Nakamura Tomohiro, Agata Naoki, Igarashi Ataru, Tango Toshiro, Tanaka Yoshiya
Advances in therapy, Mar. 2017, Reviewed, Null
Last

Reduced expression of human mismatch repair genes in adult T-cell leukemia.
Morimoto Hiroaki, Tsukada Junichi, Kominato Yoshihiko, Tanaka Yoshiya
American journal of hematology, Feb. 2005, Reviewed, No invitation
Last

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi Takehiro, Tsukada Junichi, Kato Chiaki, Iwashige Atsushi, Mizobe Takamitsu, Machida Shinichiro, Morimoto Hiroaki, Ogawa Ryosuke, Toda Yoko, Tanaka Yoshiya
American journal of hematology, Jul. 2004, Reviewed, No invitation
Last

The first external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.
Jinnin M, Ohta A, Ishihara S, Amano H, Atusmi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori A, Mimori T, Mimura T, Muro Y, Saon H, Shumizu J, Takeuchi T, Yanaka Y, Yamamoto K, Sumida T, Kohsaka H
Ann Rheum Dis, Nov. 2019, Reviewed, No invitation

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying anti-rheumatic drugs (DESIRABLE study): a randomized, double-blind, placebo-controlled phase 3 trial.
Tanaka Y
Ann Rheum Dis, Jul. 2019, Reviewed, No invitation

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko K, Shiomi T, Yamada E, van der Heijde D
Ann Rheum Dis, Jul. 2019, Reviewed, No invitation

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.
Ann Rheum Dis, Sep. 2019, Reviewed, No invitation

Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally.
Yoshimura Reiji, Saito Kosuke, Terada Tadanori, Yunoue Naoki, Umene-Nakano Wakako, Hirata Shintaro, Saitoh Kazuyoshi, Tanaka Yoshiya, Nakamura Jun
Annals of general psychiatry, Jan. 2012, Reviewed, Null

Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: A propensity score analysis of the real-world nationwide database.
Ishikawa Y, Tokutsu K, Nakayamada S. Kuchiba A, Fushimi K, Matsuda S, Tanaka Y.
Annals of the Rheumatic Diseases, Jan. 2024, Reviewed, No invitation
Last

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
Tanaka H, Okada Y, Nakayamada S, Miyazaki Y, Sonehara K, Namba S, Honda S, Shirai Y, Yamamoto K, Kubo S, Ikari K, Harigai M, Sonomoto K, Tanaka Y.
Annals of the Rheumatic Diseases, Oct. 2023, Reviewed, No invitation
Last

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement.
Konzett Victoria, Smolen Josef S, Nash Peter, Aletaha Daniel, Winthrop Kevin, Dörner Thomas, Fleischmann Roy, Tanaka Yoshiya, Primdahl Jette, Baraliakos Xenofon, McInnes Iain B, Trauner Michael, Sattar Naveed, de Wit Maarten, Schoones Jan W, Kerschbaumer Andreas
Annals of the rheumatic diseases, Feb. 2025, Reviewed, No invitation

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
Kubo Satoshi, Miyazaki Yusuke, Nishino Takahiro, Fujita Yuya, Kono Michihiro, Kawashima Tsugumi, Ishigaki Kazuyoshi, Kusaka Katsuhide, Tanaka Hiroaki, Ueno Masanobu, Satoh-Kanda Yurie, Inoue Yoshino, Todoroki Yasuyuki, Miyagawa Ippei, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Annals of the rheumatic diseases, Oct. 2024, Reviewed, No invitation
Last

Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
Nash Peter, Kerschbaumer Andreas, Konzett Victoria, Aletaha Daniel, Dörner Thomas, Fleischmann Roy, McInnes Iain, Primdahl Jette, Sattar Naveed, Tanaka Yoshiya, Trauner Michael, Winthrop Kevin, de Wit Maarten, Askling Johan, Baraliakos Xenofon, Boehncke Wolf-Henning, Emery Paul, Gossec Laure, Isaacs John D, Krauth Maria, Lee Eun Bong, Maksymowych Walter, Pope Janet, Scholte-Voshaar Marieke, Schreiber Karen, Schreiber Stefan, Stamm Tanja, Taylor Peter C, Takeuchi Tsutomu, Tam Lai-Shan, Van den Bosch Filip, Westhovens Rene, Zeitlinger Markus, Smolen Josef S
Annals of the rheumatic diseases, Mar. 2025, Reviewed, No invitation

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement.
Konzett Victoria, Smolen Josef S, Nash Peter, Winthrop Kevin, Aletaha Daniel, Dörner Thomas, Fleischmann Roy, Tanaka Yoshiya, Primdahl Jette, Baraliakos Xenofon, McInnes Iain B, Trauner Michael, Sattar Naveed, de Wit Maarten, Schoones Jan W, Kerschbaumer Andreas
Annals of the rheumatic diseases, Feb. 2025, Reviewed, No invitation

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Vital Edward M, Merrill Joan T, Morand Eric F, Furie Richard A, Bruce Ian N, Tanaka Yoshiya, Manzi Susan, Kalunian Kenneth C, Kalyani Rubana N, Streicher Katie, Abreu Gabriel, Tummala Raj
Annals of the rheumatic diseases, Mar. 2022, Reviewed, No invitation

European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance.
Martin Aringer, Ralph Brinks, Thomas Dörner, David Daikh, Marta Mosca, Rosalind Ramsey-Goldman, Josef S Smolen, David Wofsy, Dimitrios T Boumpas, Diane L Kamen, David Jayne, R Cervera, Nathalie Costedoat-Chalumeau, Betty Diamond, Dafna D Gladman, Bevra Hahn, Falk Hiepe, Søren Jacobsen, Dinesh Khanna, Kirsten Lerstrøm, Elena Massarotti, Joseph McCune, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Matthias Schneider, Murray Urowitz, George Bertsias, Bimba F Hoyer, Nicolai Leuchten, Gabriela Schmajuk, Chiara Tani 5, Sara K Tedeschi, Zahi Touma, Branimir Anic, Florence Assan, Tak Mao Chan, Ann Elaine Clarke, Mary K Crow, László Czirják, Andrea Doria, Winfried G, Bernadett H-Kiss, Sarfaraz H, Peter M Izmirly, M J, Gábor K, X M, Ivan P, José M P-R, Juanita R-D, Íñigo R-F, Raphaèle S, Georg H S, Yoshiya Tanaka, Maria G T, Carlos V, Edward M Vital, Daniel J Wallace, Sule Yavuz, Pier L Meroni, Marvin J F, Ray Naden, Karen Costenbader, Sindhu R Johnson
Annals of the rheumatic diseases, Feb. 2021, Reviewed, No invitation

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Cohen Stanley B, van Vollenhoven Ronald F, Winthrop Kevin L, Zerbini Cristiano A F, Tanaka Yoshiya, Bessette Louis, Zhang Ying, Khan Nasser, Hendrickson Barbara, Enejosa Jeffrey V, Burmester Gerd R
Annals of the rheumatic diseases, Oct. 2020, Reviewed, No invitation

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
Kubo Satoshi, Miyazaki Yusuke, Nishino Takahiro, Fujita Yuya, Kono Michihiro, Kawashima Tsugumi, Ishigaki Kazuyoshi, Kusaka Katsuhide, Tanaka Hiroaki, Ueno Masanobu, Satoh-Kanda Yurie, Inoue Yoshino, Todoroki Yasuyuki, Miyagawa Ippei, Hanami Kentaro, Nakayamada Shingo, Tanaka Yoshiya
Annals of the rheumatic diseases, Feb. 2025, Reviewed, No invitation
Last

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
Burmester Gerd R, Gottenberg Jacques-Eric, Caporali Roberto, Winthrop Kevin L, Tanaka Yoshiya, Ekoka Omoruyi Edmund V, Rajendran Vijay, Van Hoek Paul, Van Beneden Katrien, Takeuchi Tsutomu, Westhovens René, Aletaha Daniel
Annals of the rheumatic diseases, Aug. 2024, Reviewed, No invitation

Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Katsumata Yasuhiro, Inoue Eisuke, Harigai Masayoshi, Cho Jiacai, Louthrenoo Worawit, Hoi Alberta, Golder Vera, Lau Chak Sing, Lateef Aisha, Chen Yi-Hsing, Luo Shue-Fen, Wu Yeong-Jian Jan, Hamijoyo Laniyati, Li Zhanguo, Sockalingam Sargunan, Navarra Sandra, Zamora Leonid, Hao Yanjie, Zhang Zhuoli, Chan Madelynn, Oon Shereen, Ng Kristine, Kikuchi Jun, Takeuchi Tsutomu, Goldblatt Fiona, O'Neill Sean, Tugnet Nicola, Law Annie Hui Nee, Bae Sang-Cheol, Tanaka Yoshiya, Ohkubo Naoaki, Kumar Sunil, Kandane-Rathnayake Rangi, Nikpour Mandana, Morand Eric F,
Annals of the rheumatic diseases, Jul. 2024, Reviewed, No invitation

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec Laure, Kerschbaumer Andreas, Ferreira Ricardo J O, Aletaha Daniel, Baraliakos Xenofon, Bertheussen Heidi, Boehncke Wolf-Henning, Esbensen Bente Appel, McInnes Iain B, McGonagle Dennis, Winthrop Kevin L, Balanescu Andra, Balint Peter V, Burmester Gerd R, Cañete Juan D, Claudepierre Pascal, Eder Lihi, Hetland Merete Lund, Iagnocco Annamaria, Kristensen Lars Erik, Lories Rik, Queiro Rubén, Mauro Daniele, Marzo-Ortega Helena, Mease Philip J, Nash Peter, Wagenaar Wendy, Savage Laura, Schett Georg, Shoop-Worrall Stephanie J W, Tanaka Yoshiya, Van den Bosch Filip E, van der Helm-van Mil Annette, Zabotti Alen, van der Heijde Désirée, Smolen Josef S
Annals of the rheumatic diseases, May 2024, Reviewed, No invitation

Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
Tanaka Hiroaki, Okada Yukinori, Nakayamada Shingo, Miyazaki Yusuke, Sonehara Kyuto, Namba Shinichi, Honda Suguru, Shirai Yuya, Yamamoto Kenichi, Kubo Satoshi, Ikari Katsunori, Harigai Masayoshi, Sonomoto Koshiro, Tanaka Yoshiya
Annals of the rheumatic diseases, Jan. 2024, Reviewed, No invitation
Last

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis Antonis, Kostopoulou Myrto, Andersen Jeanette, Aringer Martin, Arnaud Laurent, Bae Sang-Cheol, Boletis John, Bruce Ian N, Cervera Ricard, Doria Andrea, Dörner Thomas, Furie Richard A, Gladman Dafna D, Houssiau Frederic A, Inês Luís Sousa, Jayne David, Kouloumas Marios, Kovács László, Mok Chi Chiu, Morand Eric F, Moroni Gabriella, Mosca Marta, Mucke Johanna, Mukhtyar Chetan B, Nagy György, Navarra Sandra, Parodis Ioannis, Pego-Reigosa José M, Petri Michelle, Pons-Estel Bernardo A, Schneider Matthias, Smolen Josef S, Svenungsson Elisabet, Tanaka Yoshiya, Tektonidou Maria G, Teng Yk Onno, Tincani Angela, Vital Edward M, van Vollenhoven Ronald F, Wincup Chris, Bertsias George, Boumpas Dimitrios T
Annals of the rheumatic diseases, Oct. 2023, Reviewed, No invitation

Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka
Annals of the rheumatic diseases, May 2023, Reviewed, No invitation
Last

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja A, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin L, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger R, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy M, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poor Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Annals of the rheumatic diseases, Aug. 2022, Reviewed, No invitation
Last

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin Christopher T, Coates Laura C, McInnes Iain B, Mease Philip J, Merola Joseph F, Tanaka Yoshiya, Asahina Akihiko, Gossec Laure, Gottlieb Alice B, Warren Richard B, Ink Barbara, Bajracharya Rajan, Shende Vishvesh, Coarse Jason, Landewé Robert Bm
Annals of the rheumatic diseases, Nov. 2023, Reviewed, No invitation

Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases
Yuya Shirai, Yoshimitsu Nakanishi, Akari Suzuki, Hachirou Konaka, Rika Nishikawa, Kyuto Sonehara, Shinichi Namba, Hiroaki Tanaka, Tatsuo Masuda, Moto Yaga, Shingo Satoh, Mayuko Izumi, Yumiko Mizuno, Tatsunori Jo, Yuichi Maeda, Takuro Nii, Eri Oguro-Igashira; Biobank Japan Project; Takayuki Morisaki, Yoichiro Kamatani, Shingo Nakayamada, Chikako Nishigori, Yoshiya Tanaka, Yoshito Takeda, Kazuhiko Yamamoto, Atsushi Kumanogoh, Yukinori Okada
Annals of the rheumatic diseases, Jun. 2022, Reviewed, No invitation

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
Dörner Thomas, Tanaka Yoshiya, Dow Ernst R, Koch Alisa E, Silk Maria, Ross Terres Jorge A, Sims Jonathan T, Sun Zhe, de la Torre Inmaculada, Petri Michelle
Annals of the rheumatic diseases, May 2022, Reviewed, No invitation

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Bruce Ian N, Furie Richard A, Morand Eric F, Manzi Susan, Tanaka Yoshiya, Kalunian Kenneth C, Merrill Joan T, Puzio Patricia, Maho Emmanuelle, Kleoudis Christi, Albulescu Marius, Hultquist Micki, Tummala Raj
Annals of the rheumatic diseases, Jul. 2022, Reviewed, No invitation

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop Kevin L, Tanaka Yoshiya, Takeuchi Tsutomu, Kivitz Alan, Matzkies Franziska, Genovese Mark C, Jiang Deyuan, Chen Kun, Bartok Beatrix, Jahreis Angelika, Besuyen Robin, Burmester Gerd R, Gottenberg Jacques-Eric
Annals of the rheumatic diseases, Feb. 2022, Reviewed, No invitation

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
van Vollenhoven Ronald F, Kalunian Kenneth C, Dörner Thomas, Hahn Bevra H, Tanaka Yoshiya, Gordon Robert M, Shu Cathye, Fei Kaiyin, Gao Sheng, Seridi Loqmane, Gallagher Patrick, Lo Kim Hung, Berry Pamela, Zuraw Qing C
Annals of the rheumatic diseases, Jul. 2022, Reviewed, No invitation

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe Bernard, Kivitz Alan, Tanaka Yoshiya, van der Heijde Désirée, Simon J Abraham, Baraf Herbert S B, Kumar Uma, Matzkies Franziska, Bartok Beatrix, Ye Lei, Guo Ying, Tasset Chantal, Sundy John S, Jahreis Angelika, Genovese Mark C, Mozaffarian Neelufar, Landewé Robert B M, Bae Sang-Cheol, Keystone Edward C, Nash Peter
Annals of the rheumatic diseases, Jan. 2021, Reviewed, No invitation

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Inoue Yoshino, Fujino Yoshihisa, Tanaka Yoshiya
Annals of the rheumatic diseases, Sep. 2021, Reviewed, No invitation
Last

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash Peter, Kerschbaumer Andreas, Dörner Thomas, Dougados Maxime, Fleischmann Roy M, Geissler Klaus, McInnes Iain, Pope Janet E, van der Heijde Désirée, Stoffer-Marx Michaela, Takeuchi Tsutomu, Trauner Michael, Winthrop Kevin L, de Wit Maarten, Aletaha Daniel, Baraliakos Xenofon, Boehncke Wolf-Henning, Emery Paul, Isaacs John D, Kremer Joel, Lee Eun Bong, Maksymowych Walter P, Voshaar Marieke, Tam Lai-Shan, Tanaka Yoshiya, van den Bosch Filip, Westhovens René, Xavier Ricardo, Smolen Josef S
Annals of the rheumatic diseases, Jan. 2021, Reviewed, No invitation

Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
Tanaka Yoshiya, Oba Koji, Takeuchi Tsutomu
Annals of the rheumatic diseases, Dec. 2019, Reviewed, No invitation
Lead

Response to: 'Some concerns from Turkey' by Bilgin et al.
Kaneko Yuko, Kameda Hideto, Ikeda Kei, Ishii Tomonori, Murakami Kosaku, Takamatsu Hyota, Tanaka Yoshiya, Abe Takayuki, Takeuchi Tsutomu
Annals of the rheumatic diseases, Feb. 2020, Reviewed, No invitation

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.
Johnson SR, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M.
Annals of the rheumatic diseases, Oct. 2020, Reviewed, No invitation

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.
Tanaka Yoshiya, Oba Koji, Koike Takao, Miyasaka Nobuyuki, Mimori Tsuneyo, Takeuchi Tsutomu, Hirata Shintaro, Tanaka Eiichi, Yasuoka Hidekata, Kaneko Yuko, Murakami Kosaku, Koga Tomohiro, Nakano Kazuhisa, Amano Koichi, Ushio Kazuyasu, Atsumi Tatsuya, Inoo Masayuki, Hatta Kazuhiro, Mizuki Shinichi, Nagaoka Shouhei, Tsunoda Shinichiro, Dobashi Hiroaki, Horie Nao, Sato Norihiro
Annals of the rheumatic diseases, Oct. 2019, Reviewed, No invitation
Lead

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Yoshiya, Fautrel Bruno, Keystone Edward C, Ortmann Robert A, Xie Li, Zhu Baojin, Issa Maher, Patel Himanshu, Gaich Carol L, de Bono Stephanie, Rooney Terence P, Taylor Peter C
Annals of the rheumatic diseases, Jul. 2019, Reviewed, No invitation
Lead

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Yoshiya, Takeuchi Tsutomu, Tanaka Sakae, Kawakami Atsushi, Iwasaki Manabu, Song Yeong Wook, Chen Yi-Hsing, Wei James Cheng-Chung, Lee Sang-Heon, Rokuda Mitsuhiro, Izutsu Hiroyuki, Ushijima Satoshi, Kaneko Yuichiro, Akazawa Rio, Shiomi Teruaki, Yamada Emi
Annals of the rheumatic diseases, Oct. 2019, Reviewed, No invitation
Lead

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y,Kameda H,Ikeda K,Ishii T,Murakami K,Takamatsu H,Tanaka Y,Abe T, Takeuchi T.
Annals of the rheumatic diseases, Apr. 2018, Reviewed, No invitation

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
Kaneko Y,Kato M,Tanaka Y,Inoo M,Kobauashi-Haraoka H,Amano K,Miyata M, Murakawa Y,Yasuoka H,Hirata S,Tanaka E,Miyasaka N,Yamanaka H,Yamamoto K, Takeuchi T,and the SURPRISE study group.
Annals of the rheumatic diseases, Apr. 2018, Reviewed, No invitation

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
Ma Xiaoxue, Nakayamada Shingo, Kubo Satoshi, Sakata Kei, Yamagata Kaoru, Miyazaki Yusuke, Yoshikawa Maiko, Kitanaga Yukihiro, Zhang Mingzeng, Tanaka Yoshiya
Annals of the rheumatic diseases, Sep. 2018, Reviewed, No invitation
Last

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.
Kochi Yuta, Kamatani Yoichiro, Kondo Yuya, Suzuki Akari, Kawakami Eiryo, Hiwa Ryosuke, Momozawa Yukihide, Fujimoto Manabu, Jinnin Masatoshi, Tanaka Yoshiya, Kanda Takashi, Cooper Robert G, Chinoy Hector, Rothwell Simon, Lamb Janine A, Vencovský Jiří, Mann Heřman, Ohmura Koichiro, Myouzen Keiko, Ishigaki Kazuyoshi, Nakashima Ran, Hosono Yuji, Tsuboi Hiroto, Kawasumi Hidenaga, Iwasaki Yukiko, Kajiyama Hiroshi, Horita Tetsuya, Ogawa-Momohara Mariko, Takamura Akito, Tsunoda Shinichiro, Shimizu Jun, Fujio Keishi, Amano Hirofumi, Mimori Akio, Kawakami Atsushi, Umehara Hisanori, Takeuchi Tsutomu, Sano Hajime, Muro Yoshinao, Atsumi Tatsuya, Mimura Toshihide, Kawaguchi Yasushi, Mimori Tsuneyo, Takahashi Atsushi, Kubo Michiaki, Kohsaka Hitoshi, Sumida Takayuki, Yamamoto Kazuhiko
Annals of the rheumatic diseases, Apr. 2018, Reviewed, Null

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang Fengchun, Bae Sang-Cheol, Bass Damon, Chu Myron, Egginton Sally, Gordon David, Roth David A, Zheng Jie, Tanaka Yoshiya
Annals of the rheumatic diseases, Apr. 2018, Reviewed, Null
Last

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Yoshikazu, Isobe Mitsuaki, Takei Syuji, Tanaka Yoshiya, Ishii Tomonori, Yokota Shumpei, Nomura Akira, Yoshida Seitaro, Nishimoto Norihiro
Annals of the rheumatic diseases, Apr. 2018, Null, Null

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Yuko, Kameda Hideto, Ikeda Kei, Ishii Tomonoti, Murakami Kosaku, Takamatsu Hyota, Tanaka Yoshiya, Abe Takayuki, Takeuchi Tsutomu
Annals of the rheumatic diseases, Dec. 2018, Reviewed, No invitation

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Atsumi Tatsuya, Tanaka Yoshiya, Yamamoto Kazuhiko, Takeuchi Tsutomu, Yamanaka Hisashi, Ishiguro Naoki, Eguchi Katsumi, Watanabe Akira, Origasa Hideki, Yasuda Shinsuke, Yamanishi Yuji, Kita Yasuhiko, Matsubara Tsukasa, Iwamoto Masahiro, Shoji Toshiharu, Togo Osamu, Okada Toshiyuki, van der Heijde Désirée, Miyasaka Nobuyuki, Koike Takao
Annals of the rheumatic diseases, Aug. 2017, Null, Null

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen Stanley B, Tanaka Yoshiya, Mariette Xavier, Curtis Jeffrey R, Lee Eun Bong, Nash Peter, Winthrop Kevin L, Charles-Schoeman Christina, Thirunavukkarasu Krishan, DeMasi Ryan, Geier Jamie, Kwok Kenneth, Wang Lisy, Riese Richard, Wollenhaupt Jürgen
Annals of the rheumatic diseases, Jul. 2017, Null, Null

Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients.
Tsuboi Hiroto, Hagiwara Shinya, Asashima Hiromitsu, Takahashi Hiroyuki, Hirota Tomoya, Noma Hisashi, Umehara Hisanori, Kawakami Atsushi, Nakamura Hideki, Sano Hajime, Tsubota Kazuo, Ogawa Yoko, Takamura Etsuko, Saito Ichiro, Inoue Hiroko, Nakamura Seiji, Moriyama Masafumi, Takeuchi Tsutomu, Tanaka Yoshiya, Hirata Shintaro, Mimori Tsuneyo, Matsumoto Isao, Sumida Takayuki
Annals of the rheumatic diseases, Dec. 2017, Reviewed, Null

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone Edward C, Taylor Peter C, Tanaka Yoshiya, Gaich Carol, DeLozier Amy M, Dudek Anna, Zamora Jorge Velasco, Cobos Jose Arturo Covarrubias, Rooney Terence, Bono Stephanie de, Arora Vipin, Linetzky Bruno, Weinblatt Michael E
Annals of the rheumatic diseases, Nov. 2017, Reviewed, Null

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Schett Georg, Emery Paul, Tanaka Yoshiya, Burmester Gerd, Pisetsky David S, Naredo Esperanza, Fautrel Bruno, van Vollenhoven Ronald
Annals of the rheumatic diseases, Aug. 2016, Reviewed, Null

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo Satoshi, Nakayamada Shingo, Nakano Kazuhisa, Hirata Shintaro, Fukuyo Shunsuke, Miyagawa Ippei, Hanami Kentaro, Saito Kazuyoshi, Tanaka Yoshiya
Annals of the rheumatic diseases, Jul. 2016, Reviewed, Null
Corresponding

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi Tsutomu, Tanaka Yoshiya, Ishiguro Naoki, Yamanaka Hisashi, Yoneda Toshiyuki, Ohira Takeshi, Okubo Naoki, Genant Harry K, van der Heijde Désirée
Annals of the rheumatic diseases, Jun. 2016, Null, Null

The changing landscape of biosimilars in rheumatology.
Dörner Thomas, Strand Vibeke, Cornes Paul, Gonçalves João, Gulácsi László, Kay Jonathan, Kvien Tore K, Smolen Josef, Tanaka Yoshiya, Burmester Gerd R
Annals of the rheumatic diseases, Jun. 2016, Null, Null

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Winthrop K L, Park S-H, Gul A, Cardiel M H, Gomez-Reino J J, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H
Annals of the rheumatic diseases, Jun. 2016, Null, Null

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Takeuchi Tsutomu, Tanaka Yoshiya, Iwasaki Manabu, Ishikura Hiroaki, Saeki Satoshi, Kaneko Yuichiro
Annals of the rheumatic diseases, Jun. 2016, Null, Null

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Isenberg D A, Petri M, Kalunian K, Tanaka Y, Urowitz M B, Hoffman R W, Morgan-Cox M, Iikuni N, Silk M, Wallace D J
Annals of the rheumatic diseases, Feb. 2016, Null, Null

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Kaneko Yuko, Atsumi Tatsuya, Tanaka Yoshiya, Inoo Masayuki, Kobayashi-Haraoka Hitomi, Amano Koichi, Miyata Masayuki, Murakawa Yohko, Yasuoka Hidekata, Hirata Shintaro, Nagasawa Hayato, Tanaka Eiichi, Miyasaka Nobuyuki, Yamanaka Hisashi, Yamamoto Kazuhiko, Takeuchi Tsutomu
Annals of the rheumatic diseases, Nov. 2016, Null, Null

Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al.
Takeuchi Tsutomu, Tanaka Yoshiya, Ishiguro Naoki, Yamanaka Hisashi, Yoneda Toshiyuki, Ohira Takeshi, Okubo Naoki, Genant Harry K, van der Heijde Désirée
Annals of the rheumatic diseases, Oct. 2016, Null, Null

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi Tatsuya, Yamamoto Kazuhiko, Takeuchi Tsutomu, Yamanaka Hisashi, Ishiguro Naoki, Tanaka Yoshiya, Eguchi Katsumi, Watanabe Akira, Origasa Hideki, Yasuda Shinsuke, Yamanishi Yuji, Kita Yasuhiko, Matsubara Tsukasa, Iwamoto Masahiro, Shoji Toshiharu, Okada Toshiyuki, van der Heijde Désirée, Miyasaka Nobuyuki, Koike Takao
Annals of the rheumatic diseases, Jan. 2016, Null, Null

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Yoshiya, Hirata Shintaro, Kubo Satoshi, Fukuyo Shunsuke, Hanami Kentaro, Sawamukai Norifumi, Nakano Kazuhisa, Nakayamada Shingo, Yamaoka Kunihiro, Sawamura Fusae, Saito Kazuyoshi
Annals of the rheumatic diseases, Feb. 2015, Null, Null

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo Satoshi, Yamaoka Kunihiro, Kondo Masahiro, Yamagata Kaoru, Zhao Jidong, Iwata Shigeru, Tanaka Yoshiya
Annals of the rheumatic diseases, Dec. 2014, Null, Null

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.
Tokunaga Mikiko, Saito Kazuyoshi, Kawabata Daisuke, Imura Yoshitaka, Fujii Takao, Nakayamada Shingo, Tsujimura Shizuyo, Nawata Masao, Iwata Shigeru, Azuma Taeko, Mimori Tsuneyo, Tanaka Yoshiya
Annals of the rheumatic diseases, Apr. 2007, Null, Null

Inflammatory Cytokines and Chemokines Are Synergistically Induced in a ROS-Dependent Manner by a Co-Culture of Corneal Epithelial Cells and Neutrophil-like Cells in the Presence of Particulate Matter.
Zeng Zirui, Yoshida Yasuhiro, Wang Duo, Fujii Yuri, Shen Mengyue, Mimura Tatsuya, Tanaka Yoshiya
Antioxidants (Basel, Switzerland), Apr. 2024, Reviewed, No invitation
Last

Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death.
Nakano Kazuhisa, Saito Kazuyoshi, Mine Shinichiro, Matsushita Sho, Tanaka Yoshiya
Apoptosis : an international journal on programmed cell death, Jan. 2007, Null, Null

Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial.
Merrill Joan T, Tanaka Yoshiya, D'Cruz David, Vila-Rivera Karina, Siri Daniel, Zeng Xiaofeng, Saxena Amit, Aringer Martin, D'Silva Kristin M, Cheng Ling, Mohamed Mohamed-Eslam F, Siovitz Lucia, Bhatnagar Sumit, Gaudreau Marie-Claude, Doan Thao T, Friedman Alan
Arthritis & rheumatology (Hoboken, N.J.), Oct. 2024, Reviewed, No invitation

Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study
Kathryn Connelly , Rangi Kandane-Rathnayake , Alberta Hoi , Worawit Louthrenoo , Laniyati Hamijoyo , Shue Fen Luo , Yeong-Jian Jan Wu , Jiacai Cho , Aisha Lateef , C S Lau , Yi-Hsing Chen , Sandra Navarra , Leonid Zamora , Zhanguo Li , Yuan An , Sargunan Sockalingam , Yanjie Hao , Zhuoli Zhang , Madelynn Chan , Yasuhiro Katsumata , Masayoshi Harigai , Shereen Oon , Sang-Cheol Bae , Sean O'Neill , Kathryn A Gibson , Bmdb Basnayake , Jun Kikuchi , Tsutomu Takeuchi , Kristine Pek Ling Ng , Nicola Tugnet , Sunil Kumar , Fiona Goldblatt , Annie Law , Michael Tee , Cherica Tee , Yoshiya Tanaka , Naoaki Ohkubo , Jin Yu Tan , Chetan S Karyekar , Mandana Nikpour , Vera Golder , Eric F Morand
Arthritis & rheumatology (Hoboken, N.J.), Mar. 2023, Reviewed, No invitation

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian Kenneth C, Furie Richard, Morand Eric F, Bruce Ian N, Manzi Susan, Tanaka Yoshiya, Winthrop Kevin, Hupka Ihor, Zhang Lijin Jinny, Werther Shanti, Abreu Gabriel, Hultquist Micki, Tummala Raj, Lindholm Catharina, Al-Mossawi Hussein
Arthritis & rheumatology (Hoboken, N.J.), Feb. 2023, Reviewed, No invitation

Synovial Tissue Heterogeneity in Japanese Patients With Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach.
Nakajima Sotaro, Tsuchiya Haruka, Ota Mineto, Ogawa Megumi, Yamada Saeko, Yoshida Ryochi, Maeda Junko, Shirai Harumi, Kasai Taro, Hirose Jun, Ninagawa Keita, Fujieda Yuichiro, Iwasaki Takeshi, Aizaki Yoshimi, Kajiyama Hiroshi, Matsushita Masakazu, Kawakami Eiryo, Tamura Naoto, Mimura Toshihide, Ohmura Koichiro, Morinobu Akio, Atsumi Tatsuya, Tanaka Yoshiya, Takeuchi Tsutomu, Tanaka Sakae, Okamura Tomohisa, Fujio Keishi
Arthritis & rheumatology (Hoboken, N.J.), Dec. 2023, Reviewed, No invitation

Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial)
Tsutomu Takeuchi, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Yoshiya Tanaka
Arthritis & rheumatology (Hoboken, N.J.), Nov. 2022, Reviewed, No invitation
Last

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Tanaka Yoshiya, Takeuchi Tsutomu, Yamanaka Hisashi, Nanki Toshihiro, Umehara Hisanori, Yasuda Nobuyuki, Tago Fumitoshi, Kitahara Yasumi, Kawakubo Makoto, Torii Kentaro, Hojo Seiichiro, Kawano Tetsu, Imai Toshio
Arthritis & rheumatology (Hoboken, N.J.), Apr. 2021, Reviewed, No invitation
Lead

Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus.
Hao He, Nakayamada Shingo, Yamagata Kaoru, Ohkubo Naoaki, Iwata Shigeru, Inoue Yoshino, Zhang Mingzeng, Zhang Tong, Kanda Satoh Yurie, Shan Yu, Otsuka Takashi, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jan. 2021, Reviewed, No invitation
Last

Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase enhancer of zeste homolog 2.
Zhang Mingzeng, Iwata Shigeru, Hajime Maiko, Ohkubo Naoaki, Todoroki Yasuyuki, Miyata Hiroko, Ueno Masanobu, Hao He, Zhang Tong, Fan Jie, Nakayamada Shingo, Yamagata Kaoru, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jan. 2020, Reviewed, No invitation
Last

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Tanaka Yoshiya, McInnes Iain B, Taylor Peter C, Byers Nicole L, Chen Lei, de Bono Stephanie, Issa Maher, Macias William L, Rogai Veronica, Rooney Terence P, Schlichting Douglas E, Zuckerman Steven H, Emery Paul
Arthritis & rheumatology (Hoboken, N.J.), Dec. 2018, Reviewed, No invitation
Lead

Relapsing Polychondritis Diagnosed by Fusion Images of Gallium-67 Uptake on Computed Tomography and Single-Photon-Emission Computed Tomography.
Nakano Kazuhisa, Aritomi Takafumi, Ohkubo Naoaki, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Dec. 2017, Reviewed, Null
Last

Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients.
Kubo Satoshi, Nakayamada Shingo, Yoshikawa Maiko, Miyazaki Yusuke, Sakata Kei, Nakano Kazuhisa, Hanami Kentaro, Iwata Shigeru, Miyagawa Ippei, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jun. 2017, Reviewed, No invitation
Last

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Winthrop Kevin L, Curtis Jeffrey R, Lindsey Stephen, Tanaka Yoshiya, Yamaoka Kunihiro, Valdez Hernan, Hirose Tomohiro, Nduaka Chudy I, Wang Lisy, Mendelsohn Alan M, Fan Haiyun, Chen Connie, Bananis Eustratios
Arthritis & rheumatology (Hoboken, N.J.), Oct. 2017, Reviewed, Null

Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells.
Kondo Masahiro, Yamaoka Kunihiro, Sakata Kei, Sonomoto Koshiro, Lin Lin, Nakano Kazuhisa, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), May 2015, Null, Null
Corresponding

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
Iwata Shigeru, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Yunoue Naoki, Wang Sheau-Pey, Yoshikawa Maiko, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis & rheumatology (Hoboken, N.J.), Jan. 2015, Null, Null

Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages.
Trimova Gulzhan, Yamagata Kaoru, Iwata Shigeru, Hirata Shintaro, Zhang Tong, Uemura Fumi, Satoh Minoru, Biln Norma, Nakayamada Shingo, Maksymowych Walter P, Tanaka Yoshiya
Arthritis Research and Therapy, Feb. 2020, Reviewed, No invitation
Last

Tofacitinib plus methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes through 24 months.
Tanaka Yoshiya
Arthritis Rheum, Apr. 2019, Reviewed, No invitation

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.
Arthritis Rheumatol, Sep. 2019, Reviewed, No invitation

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis.
Tanaka Y,McInnes IB,Taylor PC,Byers NNL,Chen L,de Bono S,Issa M,Macias WL, Rogai V,Rooney TP,Schlichting DE,Zuckerman SH,Emery P.
Arthritis and rheumatism, Apr. 2018, Reviewed, No invitation
Lead

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima Keisuke, Yamaoka Kunihiro, Kubo Satoshi, Nakano Kazuhisa, Iwata Shigeru, Saito Kazuyoshi, Ohishi Masanobu, Miyahara Hisaaki, Tanaka Shinya, Ishii Koji, Yoshimatsu Hironobu, Tanaka Yoshiya
Arthritis and rheumatism, Jun. 2012, Null, Null

Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway.
Sonomoto Koshiro, Yamaoka Kunihiro, Oshita Koichi, Fukuyo Shunsuke, Zhang Xiangmei, Nakano Kazuhisa, Okada Yosuke, Tanaka Yoshiya
Arthritis and rheumatism, Oct. 2012, Null, Null
Corresponding

Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production.
Oshita Koichi, Yamaoka Kunihiro, Udagawa Nobuyuki, Fukuyo Shunsuke, Sonomoto Koshiro, Maeshima Keisuke, Kurihara Ryuji, Nakano Kazuhisa, Saito Kazuyoshi, Okada Yosuke, Chiba Kenji, Tanaka Yoshiya
Arthritis and rheumatism, Jun. 2011, Null, Null
Corresponding

Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus.
Nakayamada Shingo, Saito Kazuyoshi, Nakano Kazuhisa, Tanaka Yoshiya
Arthritis and rheumatism, May 2007, Null, Null

Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.
Tsujimura Shizuyo, Saito Kazuyoshi, Nakayamada Shingo, Nakano Kazuhisa, Tanaka Yoshiya
Arthritis and rheumatism, Jun. 2005, Null, Null

Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts.
Nakano Kazuhisa, Okada Yosuke, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis and rheumatism, Aug. 2004, Null, Null

Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region.
Tanaka Yoshiya, O'Neill Sean, Li Mengtao, Tsai I-Ching, Yang Ya-Wen
Arthritis care & research, Feb. 2021, Reviewed, No invitation
Lead

Accelerated Type VII collagen turnover in systemic sclerosis patients, reflected by serological neo-epitope fragment biomarkers.
He Yi, Sand Jannie M B, Kubo Satoshi, Ohkubo Naoaki, Miyazaki Yusuke, Karsdal Morten, Tanaka Yoshiya, Bay-Jensen Anne-Christine
Arthritis research & therapy, Mar. 2025, Reviewed, No invitation

Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry.
Ochi Sae, Sonomoto Koshiro, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Jul. 2024, Reviewed, No invitation
Last

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas W J Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Chun Wu, Sean E Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski, Roy Fleischmann
Arthritis research & therapy, Apr. 2023, Reviewed, No invitation

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato , Saeko Uchida, Yoshiya Tanaka
Arthritis research & therapy, Apr. 2023, Reviewed, No invitation
Last

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.
Miyagawa Ippei, Nakayamada Shingo, Ueno Masanobu, Miyazaki Yusuke, Iwata Shigeru, Kubo Satoshi, Sonomoto Koshiro, Anan Junpei, Ohkubo Naoaki, Inoue Yoshino, Tanaka Yoshiya
Arthritis research & therapy, Apr. 2022, Reviewed, No invitation
Last

'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
Kandane-Rathnayake Rangi, Louthrenoo Worawit, Hoi Alberta, Luo Shue-Fen, Wu Yeong-Jian J, Chen Yi-Hsing, Cho Jiacai, Lateef Aisha, Hamijoyo Laniyati, Navarra Sandra V, Zamora Leonid, Sockalingam Sargunan, An Yuan, Li Zhanguo, Katsumata Yasuhiro, Harigai Masayoshi, Hao Yanjie, Zhang Zhuoli, Kikuchi Jun, Takeuchi Tsutomu, Basnayake B M D B, Chan Madelynn, Ng Kristine Pek Ling, Tugnet Nicola, Kumar Sunil, Oon Shereen, Goldblatt Fiona, O'Neill Sean, Gibson Kathryn A, Ohkubo Naoaki, Tanaka Yoshiya, Bae Sang-Cheol, Lau Chak Sing, Nikpour Mandana, Golder Vera, Morand Eric F,
Arthritis research & therapy, Mar. 2022, Reviewed, No invitation

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Ochi Sae, Sonomoto Koshiro, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Mar. 2022, Reviewed, No invitation
Corresponding

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes.
Ueno Masanobu, Miyagawa Ippei, Miyazaki Yusuke, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Oct. 2022, Reviewed, No invitation
Last

Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression.
Kawabe Akio, Yamagata Kaoru, Kato Shigeaki, Nakano Kazuhisa, Sakata Kei, Tsukada Yu-Ichi, Ohmura Koichiro, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Sep. 2022, Reviewed, No invitation
Last

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
Masanobu Ueno, Ippei Miyagawa, Takafumi Aritomi, Koichi Kimura, Shigeru Iwata, Kentaro Hanami, Syunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Shingo Nakayamada, Yoshiya Tanaka
Arthritis research & therapy, Jun. 2022, Reviewed, No invitation
Last

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
Kameda Hideto, Takeuchi Tsutomu, Yamaoka Kunihiro, Oribe Motohiro, Kawano Mitsuhiro, Yokoyama Masayuki, Pangan Aileen L, Konishi Yuko, Meerwein Sebastian, Tanaka Yoshiya
Arthritis research & therapy, Jan. 2021, Reviewed, No invitation
Last

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
Ueno Masanobu, Miyagawa Ippei, Nakano Kazuhisa, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Miyazaki Yusuke, Kawabe Akio, Yoshinari Hiroko, Nakayamada Shingo, Tanaka Yoshiya
Arthritis research & therapy, Mar. 2021, Reviewed, No invitation
Last

Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus.
Hao He, Nakayamada Shingo, Ohkubo Naoaki, Yamagata Kaoru, Zhang Mingzeng, Shan Yu, Iwata Shigeru, Zhang Tong, Tanaka Yoshiya
Arthritis research & therapy, Dec. 2021, Reviewed, No invitation
Last

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Emery Paul, Durez Patrick, Hueber Axel J, de la Torre Inmaculada, Larsson Esbjörn, Holzkämper Thorsten, Tanaka Yoshiya
Arthritis research & therapy, Jan. 2021, Reviewed, No invitation
Last

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Tanaka Yoshiya, Takeuchi Tsutomu, Izutsu Hiroyuki, Kaneko Yuichiro, Kato Daisuke, Fukuda Musashi, Rokuda Mitsuhiro, Schultz Neil M
Arthritis research & therapy, Aug. 2021, Reviewed, No invitation
Lead

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Miyagawa Ippei, Yamaguchi Ayako, Kawabe Akio, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2021, Reviewed, No invitation
Last

Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.
Sugihara Takahiko, Hasegawa Hitoshi, Uchida Haruhito A, Yoshifuji Hajime, Watanabe Yoshiko, Amiya Eisuke, Maejima Yasuhiro, Konishi Masanori, Murakawa Yohko, Ogawa Noriyoshi, Furuta Shunsuke, Katsumata Yasuhiro, Komagata Yoshinori, Naniwa Taio, Okazaki Takahiro, Tanaka Yoshiya, Takeuchi Tsutomu, Nakaoka Yoshikazu, Arimura Yoshihiro, Harigai Masayoshi, Isobe Mitsuaki,
Arthritis research & therapy, Apr. 2020, Reviewed, No invitation

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi Tsutomu, Tanaka Yoshiya, Tanaka Sakae, Kawakami Atsushi, Song Yeong-Wook, Chen Yi-Hsing, Rokuda Mitsuhiro, Izutsu Hiroyuki, Ushijima Satoshi, Kaneko Yuichiro, Nakashima Yoshihiro, Shiomi Teruaki, Yamada Emi
Arthritis research & therapy, Mar. 2020, Reviewed, No invitation

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study.
Ochi Sae, Saito Kazuyoshi, Mizoguchi Fumitaka, Kato Shigeaki, Tanaka Yoshiya
Arthritis research & therapy, Mar. 2020, Reviewed, No invitation
Last

ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Takeuchi Tsutomu, Tanaka Yoshiya, Erdman Jay, Kaneko Yuichiro, Saito Masako, Higashitani Chieri, Smulders Ronald, Lademacher Christopher
Arthritis research & therapy, Oct. 2020, Reviewed, No invitation

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Ishikawa Yuichi, Yoshikawa Maiko, Sakata Kei, Iwata Shigeru, Miyagawa Ippei, Nakano Kazuhisa, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2020, Reviewed, No invitation
Last

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Kawabe Akio, Nakano Kazuhisa, Kubo Satoshi, Asakawa Takeshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2020, Reviewed, No invitation
Last

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
Emery Paul, Tanaka Yoshiya, Cardillo Tracy, Schlichting Douglas, Rooney Terence, Beattie Scott, Helt Cameron, Smolen Josef S
Arthritis research & therapy, May 2020, Reviewed, No invitation

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Yoshiya, Wada Kazuteru, Takahashi Yoshinori, Hagino Owen, van Hoogstraten Hubert, Graham Neil M H, Kameda Hideto
Arthritis research & therapy, Apr. 2019, Reviewed, No invitation
Lead

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Yoshiya, Wada Kazuteru, Takahashi Yoshinori, Hagino Owen, van Hoogstraten Hubert, Graham Neil M H, Kameda Hideto
Arthritis research & therapy, Mar. 2019, Reviewed, No invitation
Lead, Corresponding

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Yoshiya, Smolen Josef S, Jones Heather, Szumski Annette, Marshall Lisa, Emery Paul
Arthritis research & therapy, Jul. 2019, Reviewed, No invitation
Lead

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
Miyagawa Ippei, Nakano Kazuhisa, Iwata Shigeru, Nakayamada Shingo, Saito Kazuyoshi, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Kawabe Akio, Miyazaki Yusuke, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2019, Reviewed, No invitation
Last, Corresponding

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients.
Takeuchi T,Yamanaka H,Harigai M,Tamamura R,Kato Y,Ukyo Y,Nakano T,Hsu B,Tanaka Y.
Arthritis research & therapy, Apr. 2018, Reviewed, No invitation

Relevance of IFN-γ in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
Ishikawa Y,Iwata S,Hanami K,Nawata A,Zhang M,Yamagata K,Hirata S,Sakata K, Todoroki Y,Nakano K,Nakayamada S,Satoh M,Tanaka Y.
Arthritis research & therapy, Apr. 2018, Reviewed, No invitation
Corresponding

Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
Ishikawa Yuichi, Iwata Shigeru, Hanami Kentaro, Nawata Aya, Zhang Mingzeng, Yamagata Kaoru, Hirata Shintaro, Sakata Kei, Todoroki Yasuyuki, Nakano Kazuhisa, Nakayamada Shingo, Satoh Minoru, Tanaka Yoshiya
Arthritis research & therapy, Oct. 2018, Reviewed, No invitation
Last, Corresponding

Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
Tanaka Yoshiya, Kameda Hideto, Saito Kazuyoshi, Kaneko Yuko, Tanaka Eiichi, Yasuda Shinsuke, Tamura Naoto, Fujio Keishi, Fujii Takao, Kojima Toshihisa, Anzai Tatsuhiko, Hamada Chikuma, Fujino Yoshihisa, Matsuda Shinya, Kohsaka Hitoshi
Arthritis research & therapy, Jul. 2018, Reviewed, No invitation

Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC Study.
Tanaka Y,Kameda H,Saito K,Kaneko Y,Tanaka E,Yasuda S,Tamura N,Fujio K,Fujii T,Kojima T,Anzai T,Hamada C,Fujino Y,Matsuda S,Kohsaka H.
Arthritis research & therapy, Apr. 2018, Reviewed, No invitation
Lead

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
Tanaka Yoshiya, Yamanaka Hisashi, Ishiguro Naoki, Miyasaka Nobuyuki, Kawana Katsuyoshi, Kimura Junko, Agata Naoki, Takeuchi Tsutomu
Arthritis research & therapy, Mar. 2017, Reviewed, Null
Lead

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka Hisashi, Tanaka Yoshiya, Takeuchi Tsutomu, Sugiyama Naonobu, Yuasa Hirotoshi, Toyoizumi Shigeyuki, Morishima Yosuke, Hirose Tomohiro, Zwillich Samuel
Arthritis research & therapy, Jan. 2016, Reviewed, Null

Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study.
Torimoto Keiichi, Okada Yosuke, Tanaka Yoshiya, Matsuoka Atsuko, Hirota Yushi, Ogawa Wataru, Saisho Yoshifumi, Kurihara Isao, Itoh Hiroshi, Inada Shinya, Koga Masafumi
BMC cancer, Feb. 2019, Reviewed, No invitation

Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan.
Hase Ryota, Suzuki Daisuke, de Luise Cynthia, Chen Haoqian, Nonnenmacher Edward, Higuchi Takakazu, Katayama Kayoko, Kinjo Mitsuyo, Jinno Sadao, Morishima Toshitaka, Sugiyama Naonobu, Tanaka Yoshiya, Setoguchi Soko
BMC infectious diseases, Oct. 2023, Reviewed, No invitation
Last

Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study.
Nawata Masao, Someya Kazuki, Funada Masashi, Fujita Yuya, Nagayasu Atsushi, Saito Kazuyoshi, Tanaka Yoshiya
BMC rheumatology, Nov. 2021, Null, Null
Last

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Yap Christina, Solovyeva Olga, de Bono Johann, Rekowski Jan, Patel Dhrusti, Jaki Thomas, Mander Adrian, Evans Thomas R Jeffry, Peck Richard, Hayward Kathryn S, Hopewell Sally, Ursino Moreno, Rantell Khadija Rerhou, Calvert Melanie, Lee Shing, Kightley Andrew, Ashby Deborah, Chan An-Wen, Garrett-Mayer Elizabeth, Isaacs John D, Golub Robert, Kholmanskikh Olga, Richards Dawn, Boix Oliver, Matcham James, Seymour Lesley, Ivy S Percy, Marshall Lynley V, Hommais Antoine, Liu Rong, Tanaka Yoshiya, Berlin Jordan, Espinasse Aude, Dimairo Munyaradzi, Weir Christopher J
BMJ (Clinical research ed.), Oct. 2023, Reviewed, No invitation

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Yap Christina, Rekowski Jan, Ursino Moreno, Solovyeva Olga, Patel Dhrusti, Dimairo Munyaradzi, Weir Christopher J, Chan An-Wen, Jaki Thomas, Mander Adrian, Evans Thomas R Jeffry, Peck Richard, Hayward Kathryn S, Calvert Melanie, Rantell Khadija Rerhou, Lee Shing, Kightley Andrew, Hopewell Sally, Ashby Deborah, Garrett-Mayer Elizabeth, Isaacs John, Golub Robert, Kholmanskikh Olga, Richards Dawn P, Boix Oliver, Matcham James, Seymour Lesley, Ivy S Percy, Marshall Lynley V, Hommais Antoine, Liu Rong, Tanaka Yoshiya, Berlin Jordan, Espinasse Aude, de Bono Johann
BMJ (Clinical research ed.), Oct. 2023, Reviewed, No invitation

Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population.
Kawahara Tetsuya, Suzuki Gen, Mizuno Shoichi, Inazu Tetsuya, Kasagi Fumiyoshi, Kawahara Chie, Okada Yosuke, Tanaka Yoshiya
BMJ (Clinical research ed.), May 2022, Reviewed, No invitation
Last

Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study.
Kawahara Tetsuya, Suzuki Gen, Inazu Tetsuya, Mizuno Shoichi, Kasagi Fumiyoshi, Okada Yosuke, Tanaka Yoshiya
BMJ open, Jul. 2016, Null, Null
Corresponding

Systemic lupus erythematosus
Tanaka Yoshiya
Best practice & research. Clinical rheumatology, Jan. 2023, Reviewed, No invitation
Lead

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Tanaka Yoshiya
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, Oct. 2016, Null, Null
Corresponding

Histamine inhibits differentiation of skin fibroblasts into myofibroblasts.
Lin Lin, Yamagata Kaoru, Nakayamada Shingo, Sawamukai Norifumi, Yamaoka Kunihiro, Sakata Kei, Nakano Kazuhisa, Tanaka Yoshiya
Biochemical and biophysical research communications, Jul. 2015, Null, Null

Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus.
Nakayamada Shingo, Tanaka Yoshiya
Biomolecules, Jun. 2023, Reviewed, No invitation
Last

Constitutive activation of LIL-Stat in adult T-cell leukemia cells.
Tsukada J, Toda Y, Misago M, Tanaka Y, Auron P E, Eto S
Blood, Apr. 2000, Reviewed, No invitation

Dopamine D2-like receptor signaling suppresses human osteoclastogenesis.
Hanami Kentaro, Nakano Kazuhisa, Saito Kazuyoshi, Okada Yosuke, Yamaoka Kunihiro, Kubo Satoshi, Kondo Masahiro, Tanaka Yoshiya
Bone, Sep. 2013, Null, Null

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability.
Narisawa Manabu, Kubo Satoshi, Okada Yosuke, Yamagata Kaoru, Nakayamada Shingo, Sakata Kei, Yamaoka Kunihiro, Tanaka Yoshiya
Bone, Jan. 2021, Reviewed, No invitation
Last

Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.
Tanaka Kenichi, Yamagata Kaoru, Kubo Satoshi, Nakayamada Shingo, Sakata Kei, Matsui Takanori, Yamagishi Sho-Ichi, Okada Yosuke, Tanaka Yoshiya
Bone, Aug. 2019, Reviewed, No invitation
Last, Corresponding

IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.
Kurozumi Akira, Nakano Kazuhisa, Yamagata Kaoru, Okada Yosuke, Nakayamada Shingo, Tanaka Yoshiya
Bone, Apr. 2019, Reviewed, No invitation
Last, Corresponding

Neuropsychiatric Systemic Lupus Erythematosus.
Tanaka Yoshiya
Brain and nerve = Shinkei kenkyu no shinpo, May 2019, Reviewed, No invitation
Lead

Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report.
Nawata Aya, Nakamura Ayane, Taba Masanao, Kosaka Shumpei, Kawabe Akio, Miyata Hiroko, Matsuki Yasumasa, Tanaka Yoshiya, Hisaoka Masanori
CEN case reports, May 2021, Reviewed, No invitation

Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.
Fujita Yuya, Nawata Masao, Nagayasu Atsushi, Someya Kazuki, Saito Kazuyoshi, Tanaka Yoshiya
Case reports in rheumatology, Jul. 2019, Reviewed, No invitation
Last, Corresponding

High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production
Sonomoto Koshiro, Song Rui, Eriksson Daniel, Hahn Anne M, Meng Xianyi, Lyu Pang, Cao Shan, Liu Ning, Taudte R Verena, Wirtz Stefan, Tanaka Yoshiya, Winkler Thomas H, Schett Georg, Soulat Didert, Bozec Aline.
Cell Reports, Jul. 2023, Reviewed, No invitation

Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder.
Yata Tomohiro, Sato Go, Ogawa Kotaro, Naito Tatsuhiko, Sonehara Kyuto, Saiki Ryunosuke, Edahiro Ryuya, Namba Shinichi, Watanabe Mitsuru, Shirai Yuya, Yamamoto Kenichi, NamKoong Ho, Nakanishi Tomoko, Yamamoto Yuji, Hosokawa Akiko, Yamamoto Mamoru, , , , Oguro-Igashira Eri, Nii Takuro, Maeda Yuichi, Nakajima Kimiko, Nishikawa Rika, Tanaka Hiroaki, Nakayamada Shingo, Matsuda Koichi, Nishigori Chikako, Sano Shigetoshi, Kinoshita Makoto, Koike Ryuji, Kimura Akinori, Imoto Seiya, Miyano Satoru, Fukunaga Koichi, Mihara Masahito, Shimizu Yuko, Kawachi Izumi, Miyamoto Katsuichi, Tanaka Yoshiya, Kumanogoh Atsushi, Niino Masaaki, Nakatsuji Yuji, Ogawa Seishi, Matsushita Takuya, Kira Jun-Ichi, Mochizuki Hideki, Isobe Noriko, Okuno Tatsusada, Okada Yukinori
Cell genomics, Feb. 2025, Reviewed, No invitation

Clinical Characteristics and Treatment Outcomes of Patients With Newly Diagnosed Takayasu Arteritis in Japan During the First 2 Years of Treatment　- A Nationwide Retrospective Cohort Study.
Uchida HA, Nakaoka Y, Sugihara T, Yoshifuji H, Maejima Y, Watanabe Y, Nagafuchi H, Okazaki T, Komagata Y, Tanaka Y, Amiya E, Atsumi T, Tanemoto K, Takeuchi T, Naniwa T, Komatsuda A, Dobashi H, Amano K, Ogawa N, Murakawa Y, Hasegawa H, Hayashi T, Arimura Y, Isobe M, Harigai M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)
Circulation Journal, Apr. 2025, Reviewed, No invitation

Abatacept therapy reduces CD28+CXCR5+ follicular helper like T cells in patients with rheumatoid arthritis.
Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.
Clin Exp Rheumatol, 2017, Reviewed, Null
Last

Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance.
Okabe Y, Aoki T, Terasawa T, Kinoshita S, Nakayamada S, Tanaka Y, Korogi Y
Clinical Imaging, May 2019, Reviewed, Null

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus
Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S.
Clinical Immunology, Jan. 2018, Not reviewed, Null
Lead

A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations
Reia Hashimoto, Asuka Katsuki, Yuya Fujita, Atsuko Ikenouchi, Yoshiya Tanaka, Reiji Yoshimura
Clinical Neuropsychopharmacology and Therapeutics, Feb. 2020, Reviewed, No invitation

Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus.
Ishii Akina, Nakayamada Shingo, Ohkubo Naoaki, Miyazaki Yusuke, Iwata Shigeru, Annan Junpei, Hashimoto Naohiro, Sakata Kei, Tanaka Yoshiya
Clinical and experimental rheumatology, Apr. 2025, Reviewed, No invitation
Last

Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry.
Ochi Sae, Mizoguchi Fumitaka, Nakano Kazuhisa, Tanaka Yoshiya
Clinical and experimental rheumatology, Dec. 2021, Reviewed, No invitation
Last

Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.
Tanaka Yoshiya, Takahashi Toshiya, Van Hoogstraten Hubert, Praestgaard Amy, Kato Naoto, Kameda Hideto
Clinical and experimental rheumatology, Oct. 2022, Reviewed, No invitation
Lead

Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.
Winthrop Kevin L, Tanaka Yoshiya, Lee Eun Bong, Wollenhaupt Jürgen, Al Enizi Ahmad, Azevedo Valderilio F, Curtis Jeffrey R
Clinical and experimental rheumatology, Jan. 2021, Reviewed, No invitation

Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis.
Yamagata Kaoru, Nakayamada Shingo, Zhang Tong, Zhang Xiangmei, Tanaka Yoshiya
Clinical and experimental rheumatology, Oct. 2019, Reviewed, No invitation
Last, Corresponding

Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
Gudmann Natasja Stæhr, Hirata Shintaro, Karsdal Morten Asser, Kubo Satoshi, Bay-Jensen Anne-Christine, Tanaka Yoshiya
Clinical and experimental rheumatology, Apr. 2018, Reviewed, Null
Last

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Kubo Satoshi, Nakano Kazuhisa, Nakayamada Shingo, Hirata Shintaro, Fukuyo Shunsuke, Sawamukai Norifumi, Saito Kazuyoshi, Tanaka Yoshiya
Clinical and experimental rheumatology, 2016, Null, Null
Corresponding

[Efficacy of tacrolimus for joint destruction in rheumatoid arthritis].
Tanaka Yoshiya, Suzuki Katsunori, Saito Kazuyoshi
Clinical calcium, Apr. 2007, Null, Null
Lead

Thin-section chest CT findings in polymyalgia rheumatica: a comparison between with and without rheumatoid arthritis.
Kinoshita Shunsuke, Aoki Takatoshi, Takahashi Hiroyuki, Oki Hodaka, Hayashida Yoshiko, Saito Kazuyoshi, Tanaka Yoshiya, Korogi Yukunori
Clinical imaging, Jun. 2016, Reviewed, No invitation

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.
Yoshikawa Maiko, Nakayamada Shingo, Kubo Satoshi, Nawata Aya, Kitanaga Yukihiro, Iwata Shigeru, Sakata Kei, Ma Xiaoxue, Wang Sheau Pey, Nakano Kazuhisa, Saito Kazuyoshi, Tanaka Yoshiya
Clinical immunology (Orlando, Fla.), Mar. 2019, Reviewed, No invitation
Last, Corresponding

Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.
Torigoe Masataka, Sakata Kei, Ishii Akina, Iwata Shigeru, Nakayamada Shingo, Tanaka Yoshiya
Clinical immunology (Orlando, Fla.), Oct. 2018, Reviewed, No invitation
Last